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Background and Significance:  
 Prostate cancer (PCa) is the most common non-cutaneous tumor in American 
men, and the second leading cause of cancer-related deaths. PCa-related deaths can 
be attributed to heterogeneous tumors containing metastatic and therapy-resistant 
cancer cells. Cancer stem cells (CSC) are an important contributor to this tumor 
heterogeneity, which are present in primary tumors and become enriched in castration-
resistant PCa (CRPC). Our lab has demonstrated that the prostate cancer stem cells 
(PCSCs) are enriched in the phenotypically undifferentiated PCa cell population that 
lacks the expression of differentiation marker prostate-specific antigen (PSA). Our work 
has also demonstrated that PCa cells manifest significant plasticity such that 
phenotypically differentiated PSA+ PCa cells can be reprogrammed to the castration-
resistant, stem-like state by chronic castration or overexpression of the stemness factor 
NANOG. Therefore, my overarching hypothesis is that PSA-/lo cells possess intrinsic 
molecular and epigenetic features that regulate their aggressiveness and 
stemness and contribute to tumor progression and therapy resistance, and that 
these properties can be gained through epigenetic reprogramming of more 
differentiated PSA+ PCa cell population. Throughout my Ph.D. thesis research, I 
	 ix	
employed an integrative bioinformatics approach to test this hypothesis with the 
following Specific Aims. 
 
Specific Aim 1. Determine the intrinsic transcriptomic and epigenetic identities of 
PSA-/lo and PSA+ PCa cells using an integrative bioinformatics approach 
(Chpater 3) 
 Previous work demonstrated that the PSA-/lo cell population pre-exists in 
untreated patient tumors, becomes enriched in CRPCs, and is negatively associated 
patient overall survival. My hypothesis herein is that PSA-/lo cells possess unique intrinsic 
transcriptomic and epigenetic features that causally regulate their stemness and 
aggressiveness. To test this hypothesis, we purified PSA-/lo and PSA+ cell populations 
from untreated PCa cell culture models and performed deep RNA-Seq and H3K4me3 
and H3K27me3 ChIP-Seq analyses. I have performed integrative bioinformatics 
analyses on these newly generated large-scale data, and the results reveal an 
interesting neurogenesis program in PSA-/lo PCa cells that is linked to their unique 
histone-association profiles.  
 
Specific Aim 2. Use integrative bioinformatics approaches to elucidate how 
NANOG drives epigenetic reprogramming in PSA+ PCa cells (Chapter 4) 
 CSCs are well known to contribute to tumor heterogeneity.  However, it is still 
poorly understood what factors drive the formation of CSCs in tumor development and 
progression. There are a number of ways that a more differentiated cancer cell may 
undergo reprogramming to become a CSC, including genetic deletions and therapy 
induced reprogramming.  We have previously shown that the ES cell pluripotency factor 
NANOG is required for CSC properties and that inducible NANOG expression in bulk 
AR+PSA+ LNCaP cells can reprogram them to a castration-resistant stem-like state. 
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Here in this project, we followed up on this latter observation and performed both 
NANOG ChIP-Seq and RNA-Seq experiments in LNCaP cells expressing an inducible 
NANOG transgene. Our integrative bioinformatics-based analyses of the datasets 
reveals, surprisingly, that NANOG reprograms LNCaP cells not through reactivating the 
endogenous SOX2/OCT4/NANOG pluripotency network but instead via dynamically 
repressing and engaging the AR/FOXA1 signaling axis as well as MYC.  
 
Specific Aim 3. Use integrative bioinformatics approaches to elucidate molecular 
mechanisms underlying treatment-induced CRPC reprogramming (Chapter 5)  
 Previously studies from our lab indicate that long-term castration of (AR+)PSA+ 
PCa cells in vitro and in vivo gradually ‘reprograms’ these cells and androgen-dependent 
tumors into androgen-independent cultures/tumors. In this project, we modeled CRPC 
development in the LNCaP and LAPC9 tumor systems and performed deep RNA-Seq 
experiments. Integrative bioinformatics analyses of the newly generated data revealed 
gene expression changes both common and unique to the two models. Importantly, my 
analysis helps pinpoint BCL-2 as a critical driver and therapeutic target in both models of 
CRPC.  
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CHAPTER ONE 
Background and Introduction  
 The overarching goal of my Ph.D. thesis research is to employ various 
bioinformatics and related approaches and tools to help understand large datasets 
derived from experimental prostate cancer (PCa) models and clinical samples. 
Specifically, by analyzing these large –omics datasets, I aim to help my (1) cancer 
biology colleagues to generate testable hypotheses. In this starting chapter of my 
Ph.D. thesis, I shall first introduce a few general cancer biology concepts followed by 
brief discussions of PCa biology and treatment. I shall conclude this chapter by 
presenting my overall hypothesis.   
 
1.1  Tumor cell heterogeneity and its clinical relevance 
 Cellular heterogeneity is an omnipresent phenomenon in solid tumor masses. 
Intratumoral heterogeneity describes the co-existence of distinct cancer cell 
subpopulations within a malignancy. The phenotypic and functional diversity of cell 
populations can be attributed to both genetic and non-genetic factors (2). Genetic 
influence on phenotypic diversity is driven by cancer cell intrinsic genomic instability 
that in combination with cell proliferation gives rise to clonal variants of the original 
neoplastic cell (3). On the other hand, non-genetic sources include distinct alterations 
in the epigenetic landscape and transcriptome, both of which may be partly 
attributable to the evolutionary gauntlet of the harsh tumor microenvironment. The 
epigenetic landscape, i.e., chromatin modifications, principally including DNA 
methylation, histone methylation and histone acetylation, often underlies cancer cell 
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phenotypic instability, permanently or transiently, by impacting expression of 
transcription factors (TF) and gene regulatory networks governing gene expression 
programs (4). Considering that the evolution of malignant neoplasms is fundamental to 
disease progression and the emergence of therapeutic resistance, a comprehensive 
understanding of the molecular circuitry underlying tumor cell heterogeneity and its 
relationship to the tumor microenvironment and epigenetic landscape is imperative (5). 
 Tumor cell heterogeneity provides the fuel for the development of clinically 
advanced cancer including metastatic and therapy-resistant diseases. For instance, 
the degree of tumor heterogeneity has been shown to negatively correlate with overall 
survival in ovarian cancer (6), lung cancer (7), and acute myeloid leukemia (AML) (8), 
as well as worse prognosis in breast cancer (9). The reciprocal correlation between 
tumor cell heterogeneity and cancer patient prognosis may implicate numerous 
dynamic populations driving tumor evolution and disease progression. 
 Highly tumorigenic and stem-like cancer cells termed cancer stem cells (CSCs) 
have been implicated as engines driving tumor heterogeneity and manifestation of 
aggressive cancer cell phenotypes including invasion, metastasis and therapy 
resistance (10). Phenotypically distinct from their more differentiated and non-
tumorigenic counterparts, a higher frequency of CSCs - characterized by a broad 
spectrum of tissue and tumor type-specific markers - has been shown to correlate with 
poor clinical outcome in glioblastoma (11), breast cancer (12), pancreatic cancer (13), 
among other tumors. Tumorigenic CD44+CD24-/lo breast CSCs implicated in invasion 
and metastasis (14, 15) were used to derive a 186-gene invasiveness signature to 
predict overall and metastasis-free survival of breast cancer patients as well as predict 
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poor clinical outcomes of patients afflicted with other types of cancer such as brain, 
lung, and prostate (16). Regardless of the presence of defined “cancer stem cells”, 
malignant cell plasticity, i.e., cancer cell ‘de-differentiation’ or phenotype switching, 
has been implicated in the evolution of patient tumor cells, such as the emergence of 
chemotherapy-resistant cells in triple-negative breast cancer or TNBC (17), and, in 
melanoma (18).  
 In light of the emerging importance of tumor cell heterogeneity and plasticity in 
the reprogramming of cancer cells to lethal therapy-resistant and metastatic disease, 
crucial outstanding questions include: what are the distinct molecular circuitries 
underlying such malignant cancer cells and how can we use that knowledge to target 
those cells in the clinic?  
 
1.2  Generation of tumor cell heterogeneity: Clonal evolution and CSCs  
 Clonal evolution is a process of clonal expansion, diversification and selection, 
following the rules of Darwinian evolution (19) (Figure 1-1). The CSC model proposes 
a hierarchal organization of cancer cells in a tumor clone, with CSCs undergoing 
different levels of differentiation (maturation) thus generating intra-clonal cellular 
heterogeneity (Figure 1-1). CSCs are defined as unique cancer cells possessing 
certain biological properties of normal stem cells (SC) such as the capacities of self-
renewal and phenotypic/functional differentiation, manifested as the abilities for tumor 
initiation, long-term clonal propagation, and anchorage independence (20). Among a 
wide variety of cell surface markers, CD24, CD44, CD133, CD166 and ALDH have 
been routinely applied to select for, assess and characterize CSCs from multiple solid 
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tumors including breast, prostate, colon, brain and many others (21, 22). The “gold 
standard” assay to demonstrate definitive CSC traits of prospectively purified 
candidate CSC populations is tumor regeneration upon transplantation. For example, 
primary human colorectal cancer specimens contain relatively rare CD133+ cells that, 
when xenografted in limiting numbers into immunocompromised recipient mice, 
generated tumors comprised of both rare CD133+ and a majority of CD133- cells, 
whereas CD133- cells lacked similar tumor-regenerating capabilities (23). Similar 
recapitulation of heterogeneous tumor cell subpopulations has been observed in 
CD133+ ovarian CSC-derived xenograft tumors (23, 24). Conversely, expression of 
the prostate differentiation marker prostate specific antigen (PSA) can distinguish PCa 
cells with reduced tumorigenic potential relative to more primitive PSA-/lo cells and, 
importantly, xenografted PSA-/lo PCa cells can give rise to heterogeneous tumors 
harboring both PSA-/lo and PSA+ cells (25). These general phenomena have also been 
observed upon transplantation of stem versus non-stem cells derived from other 
cancers, including those in the brain (26), breast (27), colon (23, 28, 29), ovary (30), 
and pancreas (31, 32). However, CSCs are not a static entity - rather, the CSC 
population may yet be heterogeneous containing subsets of tumorigenic cells and 
CSC themselves, just like normal SCs, may possess significant plasticity (33) (Figure 
1-1). Furthermore, not all CSC subsets may possess sustaining tumorigenic potential. 
 
1.2.1 Cell-of-origin of cancer  
 The cancer cell-of-origin is defined as the normal cell in which the first cancer 
driver mutation occurs and that is responsible for tumor initiation but may not 
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necessarily be identical to CSCs (Figure 1-1). Whereas the cell-of-origin is responsible 
for the initiation of tumorigenesis, the CSC is responsible for driving tumor growth and 
long-term tumor maintenance and disease progression. The cancer cell-of-origin may 
arise from mutations in tissue SCs; alternatively, the cancer cell-of-origin may be more 
mature progenitor cells, or even differentiated cells that have undergone de-
differentiation and re-acquired self-renewal properties (34). Cancer cell longevity 
supports the accumulation of additional oncogenic mutations that gradually confer the 
hallmarks of cancer (35), thereby facilitating the expansion of tumorigenic populations.  
 
1.2.2 Self-renewal 
 Self-renewal refers to a mode of cell division that generates at least one 
daughter cell with long-term repopulating potential and multipotency (36). Self-
renewing divisions may be asymmetric giving rise to one SC and one lineage-
restricted progeny, or symmetric yielding two equipotent SCs or two differentiated 
daughter cells. During normal organogenesis, asymmetric cell division (ACD) is 
fundamental for generating the myriad of functional cells in a tissue or organ. Tumors, 
like abnormally developed organs, harbor a spectrum of phenotypically and 
histologically distinct cancer cells ranging from renewing stem-like cells to more 
mature and differentiated cells (Figure 1-2A) (20). Although aberrantly differentiated or 
present in skewed ratios relative to normal tissues, pre-existent stem-like cancer cells 
displaying high self-renewal and differentiation potential (often corresponding with a 
lack of terminal differentiation markers) have been found to be tumorigenic upon 
transplantation. For example, limiting numbers of self-renewing CD133+ human colon 
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cancer-initiating cells recapitulated the parental tumor phenotype upon transplantation, 
forming heterogeneous tumors composed of relatively rare CD133+ and a prevalence 
of CD133- tumor cells; CD133+ cells could also uniquely reform secondary and tertiary 
tumors upon serial transplantation (23). Similarly, a single self-renewing CD34−p75− 
murine melanoma cell reestablished a heterogeneous tumor mass upon 
transplantation whereas CD34+p75− cells were tumorigenic but not capable of 
reestablishing tumor heterogeneity (37). Thus, self-renewal is a cardinal property of 
CSCs to generate cellular heterogeneity observed in tumors.  
 CSCs may acquire self-renewal property by “hijacking” normal SC self-renewal 
signaling mechanisms, such as WNT/β-catenin, Sonic Hedgehog (SHH) and Notch 
(38). For example, the WNT/β-catenin signaling has been implicated in the 
maintenance of normal and cancer stem cell self-renewal. In mouse embryonic SCs 
(ESCs), paracrine and autocrine WNT signaling promotes self-renewal preventing 
differentiation to (less primitive) epiblast stem cells (39). Furthermore, inhibition of the 
β-catenin negative regulator glycogen synthase kinase-3 (GSK3) stabilizes β-catenin 
(40), which, in turn, interacts with and inhibits Tcf3 repression of the ESC pluripotency 
network Oct3/4, Sox2, and Nanog (41); alternatively, β-catenin may independently 
interact with Oct4 to regulate the SC properties in ESCs (42). In the cancer context, 
aberrant Wnt signaling has been implicated in a wide variety of malignancies, 
including breast, colon, skin, and brain cancers, as well as leukemia (43-45). Stem-like 
colorectal cancer cells display higher Wnt activity, and hepatocyte growth factor (HGF) 
has been shown to activate β-catenin activity and promote the CSC phenotype (46). 
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WNT also sustains breast CSCs, induces infiltration, and augments metastatic 
colonization (47).  
 TFs regulating normal SC self-renewal have also been implicated in cancer. 
For example, ectopic expression of the pluripotency and reprogramming factor Oct4 in 
a doxycycline-inducible transgenic mouse model induces rapid hyperplasia and 
dysplasia in the skin and colon by expansion of progenitor cells and blocking their 
differentiation (48). These studies illustrate that CSCs may deregulate normal SC self-
renewal signaling networks to drive malignant transformation and maintain tumor 
growth (43). 
 
1.2.3 Plasticity and evolution 
 Cellular plasticity is the ability of cells to reversibly change the directions of their 
development, by dedifferentiation, transdifferentiation, and reprogramming to adapt to 
a unique microenvironment (Figure 1-2B). Cell plasticity is tightly constrained and 
rarely occurs in fully differentiated somatic cells under normal homeostatic conditions 
but may be important for regeneration of damaged tissues and organs (Figure 1-2A). 
Dedifferentiation is a restoration process of reverting terminally specialized cells back 
to a more primitive state, whereas transdifferentiation is a process of breaking the 
lineage barrier and reverting terminally specialized cells into an alternative lineage. In 
normal cells, transdifferentiation can be a two-step process: cell dedifferentiation 
followed by reactivation of another differentiation program. Experimentally, both 
dedifferentiation and transdifferentiation can be reprogrammed via epigenetic 
mechanisms. In vitro, cell reprogramming can be engineered via exogenous growth 
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factors and directed expression of TFs specifying cell fate. For example, 
overexpression of a cocktail of TFs, OCT3/4, SOX2, KLF4, and c-MYC (OSKM), is 
sufficient to reprogram mouse fibroblasts to a pluripotent state generating so-called 
induced pluripotent stem (iPS) cells (Figure 1-3) (49). Reprogramming of differentiated 
cells to iPS cells requires transcriptome and chromatin changes to erase the lineage-
specific program, followed by increased expression of genes crucial to reestablish and 
maintain pluripotency, then by changes in the epigenetic landscape to lock the cells in 
the reprogrammed state (Figure 1-3) (50). This breakthrough study (51) and many 
following studies reveal that critical TFs orchestrate dynamic reorganization of the 
epigenome and intimately interplay with the transcriptome during cell reprogramming 
(52). 
 Cancer cells in general, due to their unstable genome and more ‘fluid’ 
epigenome, display higher plasticity than their normal, differentiated counterparts. 
CSCs also possess significant plasticity to adapt to changes during disease 
progression. For example, the CD133+CD144+ CSC subpopulation derived from 
patient glioblastoma is endowed with characteristics similar to endothelial progenitors 
with expression of vascular endothelial-cadherin (53, 54). Under drug perturbation, 
CSCs and non-CSCs are inter-convertible, such as stem-like ABCG2+ and more 
differentiated ABCG2- cells in breast cancer and PCa, and stem-like CD44+ and more 
differentiated CD44- cells in PCa (55, 56). Besides treatment, other elements in the 
tumor microenvironment, such as inflammatory molecules (e.g., TNF-α and reactive 
oxygen species) and hypoxia, can also promote cancer cell dedifferentiation together 
with increased expression of stemness genes and CSC properties (57). The 
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acquisition of epithelial-mesenchymal transition (EMT), a phenotype often correlated 
with CSCs, facilitates cancer progression, especially invasion and metastasis (58). 
Furthermore, EMT-related TFs such as Zeb1 have been implicated as a driving force 
of cellular plasticity and metabolic changes by globally switching the cancer cell gene 
expression profiles and promoting metastasis in pancreatic cancer (59). Thus, 
specifically targeting emerging and evolving CSCs is essential to successfully treat 
patients in the clinic. 
 In Chapters 4 and 5, I shall present examples of PCa cell plasticity induced by 
a ‘stemness’ gene NANOG and by therapeutic treatment, castration, respectively.  
 
1.2.4 Therapeutic targeting of CSCs 
 Clinical studies indicate that the percentage of CD44+CD24- breast CSCs in 
patient tumors after neoadjuvant chemotherapy is increased (60) and CSC-like 
molecular features have been detected in the transcriptome of breast tumors following 
endocrine therapy or chemotherapy as compared to treatment-naïve tumors (61). 
Additionally, a drug screen targeting mesenchymally transdifferentiated CSCs 
revealed a novel compound (salinomycin) with a select toxicity for CSCs that could 
potentially be combined with standard chemotherapy (paclitaxel) to benefit patient 
prognosis in breast cancer (62). Targeting CSCs may also be applied to treat PCa, 
particularly castration-resistant PCa (CRPC). For example, Wnt/β-catenin signaling 
regulates expression of the stem cell marker CD44 and pharmacological inhibition of 
Wnt in combination with the conventional chemodrug docetaxel synergistically inhibits 
CRPC xenograft growth, presumably by targeting both CSCs and non-CSCs, 
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respectively (63). Inhibition of the SHH self-renewal pathway by siRNAs directly 
against pathway components has also been shown to reduce tumorigenic potential 
and metastasis in multiple cancer types in xenograft models (64, 65). Such evidence 
offers a new therapeutic strategy that combination of agents aimed at both CSC and 
non-CSC may produce synergistic anticancer efficacy. Encouragingly, various 
experimental therapeutics and therapeutic strategies targeting different aspects of 
CSC properties to selectively eradicate CSCs have entered or are being translated 
into clinical trials (66). 
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Figure 1-1. Clonal evolution and cancer stem cells (adapted from (67) Kreso, A., and J. E. 
Dick. 2014. Evolution of the cancer stem cell model. Cell stem cell 14: 275-291). 
In clonal evolution, the founder tumor cell can give rise to subclones that have gained novel 
mutations (or epigenetic changes) imparting an oncogenic evolutionary advantage to 
particular cell subsets making up the heterogeneous tumor mass. Dynamic CSC 
subpopulations may emerge during tumor evolution accounting for subclonal cellular 
heterogeneity over time.  
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Figure 1-2. Cell plasticity in cancer (adapted from (20) Tang, D. G. 2012. Understanding 
cancer stem cell heterogeneity and plasticity. Cell research 22: 457-472). 
In untreated tumors, CSCs may self-renew and generate lineage-restricted progenitor cells 
that then give rise to (phenotypically) differentiated tumor cells. Only very rarely can the 
differentiated tumor cell ‘spontaneously’ dedifferentiate to regain CSC properties (back arrow). 
On the other hand, CSCs may manifest intrinsic plasticity, such as glioblastoma multiforme 
(GBM) CSCs transdifferentiating into endothelial cells (EC) to promote tumor development. 
During tumor progression, environmental stresses (e.g., inflammation, EMT, hypoxia etc) may 
facilitate non-CSC dedifferentiation to CSCs. Experimental perturbations and therapeutic 
treatments also contribute to dedifferentiation of non-CSCs. 
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Figure 1-3.  Fibroblast reprogramming via iPS cell factors (adapted from (50) Sancho-
Martinez, I., and J. C. Izpisua Belmonte. 2013. Stem cells: Surf the waves of reprogramming. 
Nature 493: 310-311). 
Adult fibroblasts and mouse embryonic fibroblasts subject to forced dedifferentiation and 
acquisition of ESC traits by engineered expression of the OSKM (Oct4, Sox2, Klf4 and c-Myc) 
TFs. In the early phase of reprogramming, differentiated cells undergo transcriptome and 
chromatin landscape changes, which may be driven by c-Myc to trigger mesenchymal 
epithelial transition (MET) and erase cell identity, such as differentiation markers. The 
intermediate phase, regulated by Oct4 and Sox2, leads to partially reprogrammed cells giving 
rise to a heterogeneous dynamic cell population. In the late phase of reprogramming, Klf4 
promotes partially reprogrammed cells to gradually express endogenous genes involved in re-
establishing pluripotency and to alter DNA methylation to ‘seal’ the cell in reprogrammed 
state.  
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 1.3  Epigenetics 
 A recent study investigated the chemoresistance evolution in TNBC treated 
with neoadjuvant chemotherapy by integrative single-cell DNA- and RNA- sequencing 
(17). The results revealed that chemoresistance-associated mutations existed in pre-
treatment tumors and mutation frequencies of post-treatment tumors were either 
unchanged or decreased. However, transcriptome profiles were reprogrammed by 
acquiring new chemoresistant transcriptional changes and converged on a few 
common pathways related to extracellular matrix degradation, CDH1 targets, hypoxia, 
EMT, and angiogenesis (17). These observations provide direct evidence that 
mechanisms other than genetic alterations critically underlie adaptive phenotype 
emergence.  
 Canonical non-genetic factors regulating developmental processes are 
epigenetic regulatory mechanisms, which include DNA methylation, crosstalk of 
histone posttranslational modifications, incorporation of histone variants, chromatin 
remodelers managing chromatin structure, and non-coding RNAs that modulate and 
fine-tune gene expression (reviewed in (68)). These machineries play versatile roles in 
cell fate decision-making processes (Figure 1-4).  
 
1.3.1 Chromatin landscape affects transcriptome and cell fate 
 Chromatin is relatively more accessible in ES cells than in terminally 
differentiated cells and is subject to dynamic changes during cell differentiation (68). In 
ES cells, pluripotency genes are transcriptionally active with enrichment of active 
marks on enhancer (e.g., H3K4me1, H3K27ac, and histone acetyltransferase p300), 
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promoter (H3K4me3), and gene body (H3K36me3) regions, as well as less inhibitory 
marks on heterochromatin (e.g., H3K9me2, H3K9me3, and HP1) and lower levels of 
methylated DNA (5’-methyl cytosine). On the other hand, lineage-restricted genes are 
considered “poised” for expression manifested by the presence of bivalent (both 
transcriptionally activating and repressing) marks on enhancer (H3K4me1, p300, and 
H3K27ac) and promoter (H3K4me3 and H3K27me3) regions and low level of 
H3K27me3 on intergenic regions (68). In differentiated cells, pluripotency genes are 
turned off by removing active histone marks on enhancers, promoters, and gene 
bodies as well as the addition of suppressive marks (H3K9me2 and HP1) and heavy 
DNA methylation on promoters and heterochromatin. Lineage genes are 
correspondingly activated by H3K4me1, H3K27ac, and p300 on enhancers, H3K4me3 
on promoters, and H3K36me3 on gene bodies (68).  
 Histone modifications are more than simply markers of the gene transcription 
state - they not only adjust chromatin accessibility and recruitment or removal of 
effector proteins regulating transcription, DNA replication, and/or DNA repair (69) but 
also delineate a unique cellular identity (68). For example, ES cells possess bivalent 
chromatin domains, which contain both H3K4me3 and H3K27me3 marks, regulated 
by trithorax group and polycomb group, respectively (70-72). The development genes 
enriched with bivalent marks on promoters are poised for exquisite and rapid response 
of gene expression. In contrast, those genes that lose bivalency preserve the cell in 
differentiated fate (73). The other way around, chromatin remodelers affecting histone 
modifications may help in the establishment of cell identity. For example, the ATP-
dependent chromatin remodeler, Tip60-p400, co-localizes with H3K4me3 around the 
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gene transcription start site (TSS), and, RNAi-mediated knockdown of Tip60-p400 in 
mouse ES cells causes upregulation of genes responsible for early differentiation (74). 
Interestingly, this study also suggests that knocking down the pluripotency TF Nanog 
reduces p400 binding to target genes thus impacting gene expression in ES cells (74). 
These studies, together, demonstrate that epigenetic regulatory mechanisms that alter 
the chromatin landscape and the TFs cross talk with chromatin remodelers to 
coordinately regulate cell fate decisions. 
   
1.3.2 TFs and cell state 
 TFs such as Oct4, Sox2, and Nanog are crucial in maintaining pluripotency and 
self-renewal (75, 76). Introducing the OSKM factors can reprogram fibroblasts into iPS 
cells (Figure 1-3). Oct4 is critical to maintain ESCs in a pluripotent state and keep their 
stem-cell identity (48). Functional studies using cultured ESCs demonstrate that 
overexpressing Nanog promotes ESC self-renewal; conversely, targeted disruption of 
Nanog in mouse embryos causes endoderm-like cell differentiation and Nanog-null 
embryos fail to form a pluripotent inner cell mass. (77). In more lineage-restricted cells 
later in development, and, in homeostasis in the adult, a panoply of tissue-specific 
master TFs regulate gene expression programs via occupancy of super-enhancers 
dictating and maintaining cell specification (78).  
 Among the TFs involved in either developmental programming (cell 
differentiation) or induced reprogramming, the so-called ‘pioneering’ TFs can uniquely 
access closed chromatin and further recruit other TFs, cofactors, chromatin-modifiers 
or modelers to activate target gene expression. During iPS cell reprogramming, Sox2 
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occupies chromatin first followed by Oct4, which, together, assemble an 
enhanceosome to launch the reprogramming process to a pluripotent state (79). 
Pioneering TFs are also indispensable for development, such as Forkhead box protein 
A1 (FoxA1), a member of the winged-helix FoxA family crucial for organ development 
and a key mediator of postnatal development and homeostasis of epithelial tissues 
(80). For example, FoxA1 can bind heterochromatin, and recruit chromatin remodelers 
and other TFs to remodel the chromatin landscape and transcriptionally activate target 
genes, such as Muc2 (involved in the differentiation of goblet cells in the gut 
epithelium (81)) and alb1 (involved in liver development (82)). Additionally, FoxA1 is 
known to alter the activity of nuclear hormone receptors estrogen receptor (ER) and 
androgen receptor (AR), thus regulating breast and prostate development, 
respectively (80, 83). Of interest, FoxA1 has also been implicated in breast and 
prostate cancer development (80, 83). 
 
1.3.3 Oncogenic reprogramming 
 In cancer development, oncogenic transformation mirroring cellular 
reprogramming suggests that pluripotency and self-renewal TFs may play critical roles 
in the emergence of various malevolent properties, including tumorigenicity, 
clonogenic growth, invasion, metastasis, and therapeutic resistance. Master TF-
mediated reprogramming in cancer cells may thus drive the formation and plasticity of 
CSCs (84). For instance, inducing NANOG expression in a wide variety of cancer cell 
types (e.g., breast, prostate, liver and ovary) promotes cell reprogramming with 
expression of stem cell markers, (e.g., CD44 and CD133) and increased tumor-
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initiating capacity (85-93). In our lab, loss- and gain-of-function studies have 
demonstrated that NANOG loss inhibits sphere formation, clonal growth, and tumor 
development in several tumor systems (87) whereas NANOG overexpression 
enhances CSC phenotypes and functional reprogramming including CRPC 
development (93). Suppressing NANOG specifically in PSA-/lo prostate CSCs inhibits 
xenograft tumor regeneration in castrated hosts (25). In addition to NANOG, other 
pluripotency molecules including SOX2 and OCT4 have also been implicated in 
regulating CSC properties and tumor development (94). 
 Deregulated epigenetic mechanisms have also been implicated in 
tumorigenesis. Hypermethylation of CpG islands and global DNA hypomethylation are 
commonly observed in the cancer epigenome (95). DNA hypomethylation at repeat 
sequence or retrotransponsons result in gene instability by increasing chromosomal 
rearrangement and gene translocation events and DNA hypomethylation activate 
oncogenes, such as RAS and IGF2 (due to loss of imprinting), potentially contributing 
to cancer development and disease progression (96). Finally, epigenetic switching is 
altered in cancer cells such that developmental genes silenced by H3K27me3 in ES 
cells and only activated during cell development may be switched from a flexible 
repressive polycomb mark to stable DNA methylation that permanently silences these 
genes. Therefore, precisely regulating epigenetic machinery is critical for normal cell 
differentiation and organ development, and aberrant regulation of these pivotal control 
mechanisms may drive oncogenic reprogramming including cancer initiation and 
malignant progression. 
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 In Chapter 4, I shall discuss LNCaP cell reprogramming by inducible 
expression of NANOG, a process that resembles oncogenic reprogramming. 
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Figure 1-4. CSCs induced by genetic lesions, epigenetic alterations, and oncogenic 
reprogramming (adapted from (97) Wainwright, E. N., and P. Scaffidi. 2017. Epigenetics and 
Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity. Trends in cancer 
3: 372-386). 
Normal SCs or committed cells can be transformed to CSCs by genetic lesions, epigenetic 
alterations, and oncogenic reprogramming, which disrupt the normally tight control of cell 
identity, plasticity, and self-renewal. The ‘reprogrammed’ CSCs may acquire self-renewal 
properties and manifest increased plasticity. 
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1.4   Prostate and PCa 
 The prostate is a muscular, androgen-regulated and androgen-dependent 
secretory gland of the male reproductive system involved in producing seminal fluids. 
The prostate is composed of three distinct cell types, luminal cells, basal cells, and 
neuroendocrine (NE) cells. Luminal and basal cells are structured into two stratified 
epithelial layers, with the luminal layer facing the lumen and the basal layer adjacent 
to the basement membrane with interspersed NE cells. Luminal cells, the 
differentiated, androgen-dependent secretory cells of the gland, express abundant AR, 
PSA, and the cytokeratins CK8 and CK18. Basal cells, on the other hand, express 
p63, CK5, and CK14, and low levels of AR. NE cells are rare and express 
chromogranin A, synaptophysin, and serotonin, but do not express AR. 
 
1.4.1 Prostate development and prostate stem cells (PSCs) 
 The prostate is of endodermal origin, arising from the urogenital sinus 
epithelium upon stimulation by AR-expressing, ectodermally derived urogenital sinus 
mesenchyme (98). In humans, branching morphogenesis primarily occurs 
embryonically whereas in mouse the process mainly occurs postnatally, with prostate 
growth and maturation occurring upon pubescence stimulated by rising androgen 
levels (98). Prostate morphogenesis and homeostasis are initiated and maintained by 
steroid hormones that regulate prostate development especially androgens. The 
androgen receptor, AR, is a steroid hormone dependent nuclear TF and plays a 
pivotal role in prostate development (99). AR binding to 5α-dihydrotestosterone (DHT), 
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a metabolite of testosterone, causes a conformational change in the receptor, leading 
to the formation of an AR dimer that then translocates into the nucleus. Dimeric AR 
binds to androgen response elements (AREs) on AR-target genes, triggering 
downstream gene expression such as PSA and transmembrane protease serine 2 
(TMPRSS2) driving normal male sexual development and differentiation. Autocrine 
and paracrine growth and differentiation factors under mesenchymal AR control 
induce epithelial cell proliferation and differentiation, whereas epithelial AR regulates 
mesenchymal cell differentiation and basal cell proliferation (100).  
 In addition to AR, several other TFs also help coordinate prostate 
organogenesis. For instance, FOXA1 is expressed in the developing prostate 
epithelium and regulates cell maturation and ductal morphogenesis. FOXA1 physically 
interacts with AR and a FOXA1 responsive element is critical for PSA expression, 
which indicates functional maturation of luminal epithelial cells (101). Of note, the roles 
of FoxA1 in epithelial differentiation and maturation can be both AR-dependent and 
independent (100). Similarly, the homeobox domain TF Nkx3.1 is expressed in 
budding tips of the urogenital sinus epithelium during fate determination and 
maintained continuously during branching morphogenesis and throughout life, 
indicating that this TF is crucial for both prostate morphogenesis and homeostasis. 
Other signaling pathways and molecules such as Notch, SHH, FGF-10, TGFβ, and 
WNT also spatially and temporally regulate prostate gland development. 
 Unlike the mammary gland that undergoes cyclic changes in sync with 
menstrual cycles and in response to pregnancy, the adult prostate is a relatively 
dormant organ with slow cell turnovers. However, experimentally castrating the rodent 
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prostate will induce dramatic organ atrophy and re-supplementation of androgens 
restores organ growth to the original size (102), suggesting the presence of PSCs that 
can survive androgen deprivation and regenerate the entire organ. Tissue 
recombination studies using fractionated cells suggested that a subset of rare basal 
cells (CK5+CK14+CK8+CK18+CK19+GSTpi+p63+) might be tripotent and able to 
generate basal, luminal, and NE cells (98), Similarly, human PSCs have been 
prospectively isolated by virtue of their high expression of α2β1+ integrin and CD133+, 
with FACS purified α2β1+CD133+ basal cells displaying higher capacities forming 
colonies in vitro and prostatic glandular structures in vivo (103). More recently, lineage 
tracing studies in mice have definitely identified a subset of basal cells as the primitive 
PSCs being able to generate terminally differentiated basal cells, luminal cells and NE 
cells (104). In the adult prostate, however, both basal and luminal cell compartments 
seem to be largely self-sustained by lineage-restricted progenitor cells (105).  
 
1.4.2 PCa cell of origin and prostate CSCs (PCSCs) 
 The majority of human PCa present as adenocarcinomas with an AR+PSA+ 
luminal phenotype, making most oncologists believe that the cell of origin of human 
PCa is the luminal cell. However, tissue recombination (ex vivo) assays using basal 
vs. luminal (stem/progenitor) cells that express activated oncogenes suggested basal 
cells as the preferred cell of origin for PCa. For example, transplantation experiments, 
using tissue recombinants containing AKT-transduced murine prostate epithelial cells 
combined with rat embryonic UGS mesenchyme and transplanted into 
immunocompromised mice, demonstrate that activation of AKT in Sca1hi basal cells 
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but not luminal cells was sufficient for PCa initiation (106, 107). Similarly, human 
prostate-derived primary basal cells transduced to express activated AKT, ERG, and 
AR gave rise to adenocarcinomas with histological features reminiscent of human 
tumors whereas similarly transduced luminal cells were ineffective in forming tumors 
(107).  
 On the other hand, in contrast to the results obtained from these 
transplantation-based experiments using manipulated human prostate cells, lineage-
tracing studies in genetic mouse models have arrived at opposite conclusions, i.e., 
luminal cells (or cells in the luminal cell compartment) actually represent the preferred 
cell of origin for PCa. For instance, conditional deletion of Pten in luminal cells induced 
luminal-type of adenocarcinomas (108-110). Indeed, Pten deletion in K8+ luminal cells 
generated adenocarcinomas with shorter latency and higher incidence than Pten 
deletion in K5+ basal cells (111). Thus, PCa derived from transformed luminal cells 
appears to be more aggressive (than basal cell-derived tumors) and harbors a 
molecular signature associated with worse prognosis in PCa patients (111).  
 Recent RNA-Seq studies using purified human prostate basal and luminal 
epithelial cells (112, 113), 2D luminal progenitor cell cultures (114), and 3D organoid 
cultures (115) have reconciled the above-discussed discrepancies observed in 
transplantation vs. lineage tracing studies with respect to the PCa cell-of-origin. The 
consensus from these new studies is that both basal and luminal cells can be 
tumorigenically transformed and, depending on the transforming events, the two cell 
types may give rise to different histological subtypes of PCa. Specifically, transformed 
luminal cells or luminal progenitor cells generate mostly adenocarcinomas whereas 
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transformed basal cells preferentially generate basal cell and squamous type of 
carcinomas.  
 Regardless of the potential cell of origin of PCa, work from our lab and many 
others’ has provided strong evidence for the presence and clinical relevance of 
PCSCs, which have been prospectively identified, purified and characterized from a 
variety of human PCa cell lines, xenografts and patient tumor samples. Our early 
study revealed that the multi-drug resistant side population (SP) from the LAPC9 
xenograft model manifested 500-fold higher tumorigenicity than the non-SP or bulk 
LACP9 cells (55). Subsequently, we demonstrated that PCa cells expressing high 
levels of cell surface CD44 are enriched in clonogenic, tumorigenic and metastatic 
stem/progenitor cells (56). In a separate study, we showed that PCa cell holoclones 
could regenerate all three types of clones in culture (i.e., holoclones, meroclones, and 
paraclones), and, importantly, harbored self-renewing PCSCs that could long-term 
propagate xenograft tumors (116). Combinatorial markers have also been employed 
to enrich PCa stem/progenitor cells. For example, CD44+α2β1hiCD133+ cells from 
human primary PCa have been reported to possess high proliferative, self-renewal, 
and differentiation capacities (117). Similarly, in cell line and xenograft models, 
CD44+CD133+ PC3 and DU145 cells have been shown to be more tumorigenic than 
marker-negative cells (118). Likewise, CD44+α2β1hiCD133+ DU145 cells (119) and 
CD44+CD24+ LNCaP (120) cells express higher levels of certain stemness genes 
(e.g., Oct4, BMI1, β-catenin) and display higher clonogenic and tumorigenic potential 
than CD44+α2β1loCD133- DU145 and CD44+CD24- LNCaP cells, respectively. 
Interestingly, docetaxel-resistant DU145 and 22RV1 cells have been shown to lack 
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differentiation markers (e.g., CK19, CK18, HLA-I antigen, PSA and AR), display high 
tumor-initiating capacity, and overexpress some stemness genes such as NOTCH2 
(121).  
 Relying on PSA as one of the most prostate-specific differentiation markers and 
by developing a lentiviral-based tracking system using the PSA promoter (PSAP) to 
drive the expression of GFP or dsRed, our lab has demonstrated PCSCs in the PSA-/lo 
PCa cell population, which preferentially express some stem cell-associated genes, 
are relatively quiescent (slow cycling), can undergo ACD generating differentiated 
PSA+/hi daughter cells, and possess long-term tumor-propagating capabilities in 
castrated hosts (25). Of clinical relevance, the PSA-/lo PCa cells are intrinsically 
resistant to androgen deprivation therapy (ADT) and become enriched upon castration 
(25). Interestingly, castration of bulk AR+PSA+ PCa cells (e.g., LNCaP) in vitro leads to 
the generation of homogenous population of PSA-/lo cells that become completely 
refractory to antiandrogens such as enzalutamide (122). It should be noted that true 
PCSCs in the PSA-/lo PCa cell population, assessed by their abilities to undergo ACD, 
are generally rare, ranging from 3-18% depending on models (25). Moreover, the 
PSA-/lo PCa cell pool is yet heterogeneous containing subsets of tumorigenic cells 
(123) (Figure 1-5). For instance, we have recently demonstrated that a subset of PSA-
/lo cells marked by the ALDHhiCD44+α2β1+ phenotype [also called triple marker+ (TM+)] 
are highly castration-resistant and can initiate and long-term propagate CRPC upon 
serial transplantations in castrated NSG mice (124). Altogether, these studies (25, 
122-124) establish the PSA-/lo PCa cells as a clinically relevant cell population highly 
enriched in PCSCs that fulfill the most stringent defining criteria of CSCs. These 
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studies also establish the PSA-/lo PCa cell population as a therapeutic target in treating 
PCa and CRPC.  
 In Chapter 3, we further define the transcriptomic features and several histone 
mark profiles in PSA-/lo PCa cells. 
 
1.4.3 PCa treatment 
 AR is not only important for normal prostate development. It is frequently 
overexpressed and/or mutated in treatment-failed PCa and the vast majority of early 
stage prostate tumors are androgen-dependent (99). Due to AR’s role in PCa, the 
first-line treatment for PCa patients in the clinic is ADT. ADT includes different types of 
hormonal interventions, including bilateral orchiectomy, gonadotropin-releasing 
hormone (GnRH) antagonist, GnRH agonist, anti-androgens (e.g., bicalutamide and 
enzalutamide), adrenal androgen suppression (abiraterone) and combined androgen 
blockade (Figure 1-6). ADT, as a standard therapeutic strategy, is used to treat 
advanced PCa patients (i.e., those who are ineligible for surgical resection due to 
high-grade tumors and/or the presence of metastasis) and patients who experience 
biochemical recurrence (i.e., rising serum PSA levels after primary therapy) (125, 
126). ADT regimens, such as GnRH, bicalutamide, enzalutamide, or abiraterone, 
effectively shrink primary tumors and decrease the serum PSA levels, at least initially 
(Figure 1-6) (127-129). Enzalutamide is a novel second-generation AR antagonist and 
functions via obstructing nuclear localization and chromatin binding of AR (130). 
Although enzalutamide increases patient overall survival by 4.8 months in clinical trials 
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for metastatic CRPC patients, enzalutamide-resistant disease occurs in < 2 years and 
progression is inevitably terminal (128, 129, 131).  
 Clinically, PCa patients are put on androgen blockade and/or antiandrogen 
treatment for many months and years until treatment failure, evidenced by rising 
serum PSA levels and radiographic progression. Such long-term treatment is 
frequently called chronic and persistent castration. In the laboratory setting, PCa cells 
are often acutely treated with various ADT protocols for hours to 1-2 days, which will 
not model the persistent castration in the clinic. In our lab, we modeled the clinical 
treatment by continuously exposing LNCaP PCa cells to castration regimens (dextran-
stripped serum (CDSS), enzalutaminde, and CDSS with bicalutamide) and 
longitudinally tracked the dynamic changes in LNCaP cell subpopulations for up to 21 
months (122). Under such ‘chronic castration’ conditions, we found that PCa cells 
underwent dynamic and cyclic molecular changes (122). 
 The therapeutic target of ADT and enzalutamide is AR. AR expression is 
heterogeneous in both primary tumors and CRPC, and changes dynamically overtime 
during tumor progression and treatment (132-134). In CRPC, AR expression is highly 
variable and not correlated with grade and stage (123, 135-138). Mechanisms that 
underlie development of resistance to AR-targeting therapies may include AR 
amplification increasing its sensitivity to its agonists, AR mutation leading to its 
activation by alternative hormone ligands (e.g., glucocorticoids), constitutively 
activated AR (ligand independent), upregulation of AR-independent pathways 
provoking downstream gene expression bypassing AR, atypical activation of AR by 
post-translational modifications, and aberrant expression and activity of AR co-factors 
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(99, 139). Of interest, AR regulates a distinct transcription program in androgen-
independent PCa (compared to in hormone-naïve tumors), with distinct target genes 
such as cell cycle related UBE2C (140). Relevant to our work, castration enriches the 
undifferentiated PSA-/lo cell population with CSC properties (25, 123). Moreover, lower 
PSA mRNA levels in high-grade tumors are correlated with worse biochemical 
recurrence (BCR)-free and overall survival (123). Thus, the inherently castration-
resistant PCSCs, whether pre-existent in untreated primary tumors or enriched in 
treatment-failed tumors, represent a clinically relevant therapeutic targets that require 
novel therapeutic strategies.   
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Figure 1-5. A hypothetical model of tumorigenic heterogeneity of human PCa cells 
(adapted from (123) Liu, X., X. Chen, K. Rycaj, H. P. Chao, Q. Deng, C. Jeter, C. Liu, S. 
Honorio, H. Li, T. Davis, M. Suraneni, B. Laffin, J. Qin, Q. Li, T. Yang, P. Whitney, J. Shen, J. 
Huang, and D. G. Tang. 2015. Systematic dissection of phenotypic, functional, and 
tumorigenic heterogeneity of human prostate cancer cells. Oncotarget 6: 23959-23986). 
The PSA-/lo stem/progenitor cells pre-exist in untreated primary tumors. The PSA-/lo population 
is heterogeneous containing subsets of tumorigenic cells that express a spectrum of surface 
markers (e.g., CD44 and CD133), phenotypes (e.g., ALDHhi and side population (SP)) and 
stemness-promoting factors (e.g., NANOG). The PSA-/lo PCa cell is relatively quiescent 
(bottom panel) and can undergo asymmetric self-renewing cell divisions (arrow) generating 
both PSA-/lo and more differentiated, less tumorigenic PSA+ progeny (top). In experimental 
models, PSA-/lo cells possess long-term tumor-propagating activities and can preferentially 
survive castration. Also, the minor PSA-/lo population in primary PCa frequently becomes the 
predominant cell population in androgen-independent xenografts and clinical CRPC. NANOG 
has been shown to positively regulate certain CSC subsets (e.g., CD44+ cells) in the PSA-/lo 
cell population.  
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Figure 1-6. Schema of current clinical treatment for advanced and metastatic PCa. 
Shown is a clinical treatment course of PCa patients by longitudinal tracking of serum PSA 
levels after patients are first treated by prostatectomy and/or radiation. The first-line hormonal 
therapy GnRH analogs with or without short-term AR antagonist are given when post-
treatment serum PSA levels rise. The treatment is effective for about a year and the PSA 
levels rise again as recurrence of primary CRPC. The second-line castration regimen aims to 
suppress both AR function by AR antagonist and adrenal androgen production by abiraterone. 
The secondary CRPC appears after shorter intervals.  
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1.5   Bioinformatics  
 Bioinformatics, the application of computer algorithms to globally assess high-
volume biological datasets, can be employed to help illuminate features of the subject 
being investigated. To dissect molecular characteristics and cell subtypes, analyses 
typically focus on the transcriptome but may also include the genome, metabolome, 
proteome, cistrome (Chromatin Immunoprecipitation Sequencing, ChIP-Seq), and 
epigenome (chromatin modifications) along with biochemical and molecular biology 
investigations. Recent advances in RNA-Sequencing (RNA-Seq) have provided 
researchers a powerful and revolutionary method to globally identify and quantify 
transcripts in particular cell subsets (or even single cells) to connect molecular 
phenotypes and biological properties (141). We have been applying transcriptome 
profiling to interrogate tumor cell heterogeneity and the molecular and functional 
underpinnings of CSC such as chemodrug or castration resistance (142). In Chapter 
2, I shall describe in detail several major bioinformatics approaches and pipelines I 
have adopted in conducting my Ph.D. thesis research. Below I provide a very brief 
description of these approaches and pipelines. 
 RNA-Seq is a methodology of identification and quantification of relative 
transcript abundance between samples. Transcriptome profiles can be deciphered by 
comparison to known gene ontology (functional classifications) using bioinformatics 
tools, such as Ingenuity Pathway Analysis (IPA) and Genomic Regions Enrichment of 
Annotations Tool (GREAT). IPA interprets transcriptome profiles based on 
comprehensive knowledge of gene biological functions, canonical pathways and 
protein networks from published literature. GREAT similarly applies functional 
	 33	
categorization of TF-occupied cis-regulatory regions incorporating biological 
knowledge from public ontologies (143). In contrast, Gene Set Enrichment Analysis 
(GSEA) provides statistical modeling for evaluating concordance and distinctions in 
transcript profiles marking a particular biological state based on comparisons with 
previously published transcriptomes and gene signatures (144). Public gene 
expression profile databases, such as The Cancer Genome Atlas (TCGA), Oncomine 
and Gene Expression Omnibus (GEO) comprise patient transcriptional profiles, 
facilitating the discoveries of clinical relevance. TCGA collects high-quality and 
sufficient sample size for statistical interrogations. Oncomine contains various sample 
types, including normal tissues, primary tumors, metastases, and recurrent tumors, 
often associated with patient diagnosis or disease status. GEO is a repository with 
thousands of transcriptome datasets from many different studies and containing 
technical information such as experimental conditions, cell types, etc. In my studies I 
have utilized these bioinformatics tools widely to help decipher the biological meaning 
buried in the cancer cell transcriptomes and dissect tumor cell heterogeneity. 
 
1.5.1 Transcriptome analysis used in dissecting cancer cell heterogeneity and in 
de-convoluting tumor complexity 
 Annotation of transcriptomic profiles help delineate cancer cell heterogeneity 
and predict prognosis in cancer types, such as acute myeloid leukemia (145), 
colorectal cancer (146), and glioma (147). For example, a recent study (148) applied 
multi-dimensional scaling analysis to dissect single-cell RNA-Seq from 430 cells in 
primary glioblastomas and showed that each individual tumor contains a spectrum of 
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cell populations with gene expression profiles of four glioblastoma subtypes, 
proneural, neural, classical and mesenchymal. Also, RNA-Seq analysis of single cells 
from each individual tumor revealed a gradient of association with a glioblastoma stem 
cell (GSC) stemness signature derived from differentially expressed gene (DEG) 
profiles of cultured stem-like cells (cultured spheroids that were enriched in GSCs) 
and serum differentiated neural-like cells (148). Thus, the transcriptome profiles 
represent and decrypt various molecular phenotypes of cancer cell subpopulations, 
including CSCs that co-exist in a given patient tumor. 
 Transcriptome profiling assists translating molecular knowledge to clinical 
relevance, including diagnosis, prognosis, and prediction, and facilitate designing and 
tailoring the therapeutic strategies. A recent study investigated the transcriptome 
profiles of hematopoietic stem cells versus leukemia stem cells to discover a 
commonly shared transcriptional program associated with canonical stem cell 
functions, including ABCB1, MEIS1, ERG, HLF, and MECOM (145). Strikingly, these 
stemness gene signatures also successfully predicted patient survival. Another recent 
study compared transcriptome changes in TNBC before and after neoadjuvant 
chemotherapy and uncovered two chemoresistance gene signatures (AKT1 signaling 
and hypoxia) associated with poor patient survival (17). These studies suggest that 
the patient transcriptomic profile can ‘divulge’ transcriptional reprogramming by 
therapies. 
 Whole-genome, whole-exome, and transcriptome analyses have been studied 
in association with clinical significance providing unbiased insights into cancer 
molecular mechanisms and revealing novel therapeutic targets in diverse cancers 
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(141, 149). Ultimately, such molecular dissections may lead to the discovery of new 
prognostic biomarkers and therapeutic strategies for personalized medicine in the 
clinic.  
 
1.6  Hypothesis 
 Tumor cell heterogeneity and plasticity represent critical features of most 
clinical tumors and important mechanisms of therapy resistance. PCa is a highly 
heterogeneous malignancy that contains many phenotypically and functionally distinct 
cell subpopulations, which also dynamically change during tumor progression and in 
response to treatments. Our work has demonstrated that the phenotypically 
undifferentiated PSA-/lo PCa cell population harbors authentic PCSCs that are 
intrinsically resistant to castration and antiandrogens (25). Our work has also 
demonstrated that PCa cells manifest significant plasticity such that phenotypically 
differentiated PSA+ PCa cells can be reprogrammed to the castration-resistant, stem-
like state by chronic castration (150) or overexpression of the stemness factor 
NANOG (151). These observations lead to my overarching hypothesis that PCSCs 
possess intrinsic molecular and epigenetic features that help regulate their 
aggressiveness and stemness and contribute to tumor progression and therapy 
resistance, and that these CSC properties can be gained through epigenetic 
reprogramming of more differentiated cancer cells. Dissecting their transcriptome 
profiles will provide novel insights on disease progression and designing novel 
therapeutic strategies. 
 To test this hypothesis and to execute my overall Ph.D. research plan, I applied 
bioinformatics approaches to analyzing the -omics data in 3 experimental systems. 
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First, I helped analyze the RNA-Seq and histone modification ChIP-Seq data in highly 
purified PSA-/lo vs. PSA+ PCa cell subpopulations, aiming to elucidate the intrinsic 
transcriptomic and epigenetic differences between the PCSC and non-CSC 
subpopulations (Chapter 3). This part of the work has not been published but we are 
in the process of preparing the manuscript. Second, I helped analyze both 
transcriptomic and ChIP-Seq data in NANOG-induced LNCaP cell reprograming, 
representing one aspect of cancer cell plasticity caused by stemness gene 
overexpression (Chapter 4). This part of my work was published during the course of 
my Ph.D. thesis research (151). Finally, I helped analyze RNA-Seq data in our models 
of treatment-induced PCa cell plasticity (Chapter 5). This work was recently published 
in Nat. Commun (152). 
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CHAPTER TWO 
Materials and Methods 
2.1  Databases 
The Cancer Genome Atlas (TCGA) 
 The Cancer Genome Atlas (TCGA) (https://www.cancer.gov, 
https://portal.gdc.cancer.gov) has characterized multi-dimensional data types in 33 
cancer types with hundreds of samples in each cancer type and 10 rare cancer types. 
The data types include DNA sequencing (e.g., whole exome sequencing, whole 
genome sequencing), miRNA sequencing (miRNA and isoform), mRNA sequencing 
(exon, gene, splice junctions, and isoform), total RNA sequencing (exon, gene, splice 
junctions, and isoform), array-based DNA methylation, and protein expression. TCGA 
database has also collected comprehensive clinical information, diagnostic image, and 
pathology reports. For prostate cancer (PCa), a total of 498 Prostate adenocarcinoma 
(PRAD) samples are available in TCGA, including 45 cases with GS6 (Gleason Score 
6; Gleason Score is a pathology grading system the describes the overall degree of 
tumor differentiation and malignancy, the higher GS the less differentiated the tumoe), 
246 with GS7, 62 with GS8, 131 with GS9 and 3 with GS10. There are also 52 pairs of 
matched PCa and benign/normal prostate tissues. 
 The TCGA is not only a database but also has extended online data analysis 
platforms, such as cBioPortal (http://www.cbioportal.org) and FireBrowse 
(http://firebrowse.org). To further analyze the detailed phenotypic features, the level 3 
PRAD RNA-Seq and clinical data were downloaded in 2015. The transcription profile 
table was generated by merging all the *rsem.genes.normalized_results data with 
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FILE_SAMPLE_MAP.txt to get the TCGA barcodes and further determining the 
sample types. Of note, there are only 10 PCa patients expired in TCGA. 
OncomineTM 
 OncomineTM (Oncomine) (https://www.oncomine.com) is an online data-mining 
and visualization platform with database repository collecting 729 microarray datasets. 
The unique advantages of Oncomine are microarray platform integration and dataset 
diversification. For microarray platform integration, Oncomine standardizes processing, 
normalizing, and analyzing all datasets by unifying the analytical methods of cross-
platform normalization and meta-analysis, which allow for gene centric analysis. For 
dataset diversification, Oncomine acquires datasets with various study designs and 
clinical information, which leads to different available analysis types, like cancer 
versus normal tissue, high-grade versus low-grade cancer, recurrent versus primary 
cancer, metastatic versus primary cancer, and different cancer subtypes. Also, 
Oncomine offers various analysis methods, like differential expression analysis, co-
expression analysis, meta-analysis, and cancer outlier profile analysis. Differential 
expression analysis is the crux of Oncomine resource and applies Student's t test to 
determine the difference of two classes and Pearson's correlation to determine the 
difference of multiple ordinal classes. Co-expression analysis helps identify 
synchronous gene expression patterns, and it applies average linkage hierarchical 
clustering to identify sets of co-expressed genes. Meta-analysis is an extended 
function of differential expression analysis and the program orders the individual 
genes by the median rank across all selected datasets. The meta-analysis can be 
carried out with more than one gene, which is called concept analysis. Cancer outlier 
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profile analysis is used to identify potential oncogenes differentially expressed in a 
subset of samples due to the cancer heterogeneity. More importantly, the processed 
expression data and clinical information is available to download from Oncomine for 
detailed analysis. For PCa, there are 61 datasets with 3,820 samples including 18 
datasets with cancer versus normal analysis (16 mRNA and 2 DNA), 16 datasets with 
metastasis versus primary analysis (13 mRNA and 3 DNA), 10 datasets with 
recurrence analysis, 22 datasets with grade type analysis, and 11 datasets with stage 
type analysis, and 5 datasets with survival analysis. Detailed information is organized 
in table 2-1. 
Gene Expression Omnibus (GEO) (153) 
 Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo) is a public 
high-throughput functional genomics data repository, which archives both raw data 
and processed data from array and sequence platforms and associated descriptive 
metadata. The data in GEO follow the standard guidelines of Minimum Information 
About a Microarray Experiment (MIAME) (154) and Minimum Information about a 
high-throughput SEQuencing Experiment (MINSEQE) from Functional Genomics Data 
Society (http://www.fged.org), which in turn facilitate establishment of databases that 
could be interpreted and replicated for users. GEO was designed for high-throughput 
expression data but now is collecting data from studies on genome methylation, 
genome binding/occupancy, genome variation/copy number, chromosome 
conformation, and protein profiling. Moreover, GEO offers web-based tools and 
strategies for data analysis and visualization (GEO Profiles and Genome Data Viewer), 
advanced interactive analysis tool (GEO2R), and download tools. The most updated 
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statistics of GEO datasets is 108,705 series records with 2,819,723 samples in total 
and 1,428 series records with 20,609 samples in PCa. To simplify the processing of 
the datasets used in our studies, all the raw data of each dataset from GEO were 
manually downloaded. The information of all the datasets used in my studies was in 
table 2-2. 
 
2.2  RNA-Seq analysis 
 RNA-Seq has replaced microarrays as the current ‘standard’ laboratory 
technique to routinely analyze global gene expression. Basic steps in an RNA-Seq 
experiment are presented in a flowchart (Figure 2-1A) and mainly consist of:  
Library Preparation and Sequencing Platform: RNA-Seq libraries in our studies 
were constructed generally by using TruSeq Stranded mRNA following manufacturer’s 
instructions (Illumina). The libraries were sequenced using 2x75 bases paired-end 
protocol on Illumina HiSeq 2000 instrument. In total, 28-39 million pairs of reads were 
generated per sample. Each pair of reads represents a cDNA fragment from the 
library.  
Mapping: The total reads were mapped to mouse genome (mm10) or human genome 
(hg18, hg 19 or hg38) by TopHat (version 2.0.10). The TopHat prerequisite software 
tools included Bowtie2 (version 2.1.0), samtools (version 0.1.18), and Python (version 
2.7.10). Both the expected inner distance and the standard deviation were set as 50 
bp.  
Differential Expression: The number of fragments mapped to each known gene from 
GENCODE Release M4 or 21 (https://www.gencodegenes.org/) was quantified using 
htseq-count from HTSeq package (version 0.6.1) (155). To avoid the transcriptional 
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noise, genes with fewer than 10 fragments in all the samples were removed before 
differential expression analysis. The differential expression between conditions was 
statistically assessed by R/Bioconductor package edgeR (version 3.0.8) (156) or 
DESeq (version 1.14.0) (157). Genes with false discovery rate (FDR) ≤ 0.05 and 
length > 200 bp were called as differentially expressed.  
Sample Clustering: Hierarchical clustering of samples was performed using the cpm 
(count per million fragments) values of all the genes by hclust function in R. Euclidean 
distance and complete clustering method were used. 
Pairwise Correlation: Pearson’s correlation coefficient was computed by cor function 
in R using the cpm values with the top 5% most abundant genes across all the 
samples removed.  
Principal Component Analysis (PCA): The function in stats package prcomp in R 
was applied. The cpm values for each gene across all the samples were centered to 
zero and scaled to have unit variance before the analysis took place.  
Gene Landscape Profile: For the fragments that have both ends mapped, the first 
reads were kept. Together with the reads from the fragments that have only one end 
mapped, every read was extended to its 3' end by 200 bp in exon regions. For each 
read, a weight of 1/n was assigned, where n is the number of positions the read was 
mapped to. The sum of weights for all the reads that cover each genomic position was 
rescaled to normalize the total number of fragments to 1M and averaged over 10 bp 
resolution. The normalized values of each single gene were displayed using web-
based University of California, Santa Cruz (UCSC) genome browser 
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(https://genome.ucsc.edu) or local Integrative Genomics Viewer (IGV, 
http://software.broadinstitute.org/software/igv/).  
Functional Annotations: Ingenuity Pathway Analysis (IPA, 
https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/) is based 
on Ingenuity Knowledge Base and serves to uncover and interpret the underlying 
meanings of the experimental context. The DEGs (Differentially Expressed Genes) 
were uploaded for Core analysis with Fisher’s exact test to test the statistical 
significance of gene function and pathway enrichment. Canonical pathway analysis 
and upstream regulator analysis were applied in this study to predict the pathways 
changed based on gene expression changes and to predict the regulators causing 
changes in gene expression, respectively (Figure 2-1B). GSEA 
(http://software.broadinstitute.org/gsea/index.jsp, (144)) is a computational method to 
examine the statistic concordance of functionally unknown gene expression change 
profile and prior defined gene sets with biological information. It helps to interpret the 
genome-wide expression change profile and is linked to known biological functions 
and phenotypes (Figure 2-1C). To examine the gene signature enrichment, the 
normalized counts estimated by edge R (156) or DESeq (157) of all genes and 
replicates were included to compare to the known biological phenotypes as 
customized gene sets. To examine the GO term enrichment, only the DEGs were 
ranked and included to interrogate gene signatures in Molecular Signature Database 
(MSigDB, http://software.broadinstitute.org/gsea/msigdb/index.jsp, version6.0) of 
GSEA (Figure 2-1D). For the statistical test in GSEA, the permutation type was set as 
"gene_set" and all the other parameters were set as default. 
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Figure 2-1. RNA-Seq analysis pipeline and gene annotation analysis 
A. RNA-Seq pipeline. The RNA-Seq pipeline was developed by Next-Generation Sequencing 
core of MDACC at Science Park. TopHat and htseq-count were applied for read mapping 
and read counting, respectively. Both edgeR and DESeq were employed to identify the 
DEGs. Next, gene ontology analysis (Ingenuity® Pathway Analysis, IPA and gene set 
enrichment analysis, GSEA) is performed to assist gene annotation or interpretation of 
expression profiles into biological functions. Potential clinical significance of gene 
expression changes is investigated via data-mining in public databases, such as 
Oncomine, TCGA, and GEO. 
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B. An example of canonical pathway analysis by IPA. IPA identifies particular signaling 
pathways enriched in input DEGs. The height of the bar indicates -log10 p-value of 
enrichment for each pathway. 
C. An example of GSEA plot. GSEA is designed to statistically test the concordance between 
expression change profile and the previously defined gene sets. The gene set is the one 
with defined biological phenotype (e.g., after and before ADT from Rajan dataset), and the 
expression change profile is the whole-DEG profile to be tested (e.g., CRPC and AD tumor 
lines derived from LAPC9). The results reveal that gene expression changes in LAPC9 
CRPC (over AD tumors) are significantly associated with the gene expression changes of 
patient tumors after ADT (compared to the same patient tumors before ADT). 
	 45	
2.3  2D global GO enrichment analysis 
 The enrichment scores (ES) against all GO gene sets in Molecular Signatures 
Database (MSigDB) were computed by GSEA using the whole-transcriptome profile 
from each experiment. Then enrichment scores of the GO categories that were 
enriched in both experiments are presented as a scatter plot in gray dots (Figure 2-2A). 
The red dots indicate the GO term associated with particular GO terms (e.g., 
neuron/neuronal development and SC development).  
 
2.4  DEG profile comparison 
 The log2 fold changes of all genes in the two experimental conditions are 
plotted as the gray dots in the scatter plot (Figure 2-2B). The red dots represent the 
genes of interest GO categories. For example, here we marked all the neurogenesis 
genes in red (Figure 2-2B). The violin plots displayed on the margins of the scatter plot 
are the distributions of log2 change values of the genes highlighted in red. Scatter 
plots and violin plots were drawn by ggplot2 and grid packages in R. 
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Figure 2-2. 2D global GO analysis and DEG profile comparison 
A. 2D global GO analysis. The gray dots indicate all the GO terms enriched in both 
experimental conditons (i.e., LNCaP PSA-/lo and Rajan after ADT, Table 2-2), and the red 
dots are the GO terms associated with specific biological functions. The numbers on the 
figures show the number of specific terms (in red; i.e., neurogenesis related GO terms), 
the number of total GO terms (in black), and their ratios in each quadrant.  
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B. DEG profile comparison. The gray dots indicate the log2 fold change of each gene in the 
two experiments, and the red dots mark the interested genes. The violin plots on top and 
right panels are the distribution of log2 fold change values for the red dots. 
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2.5  Survival analysis 
Single gene survival analysis 
 Survival analysis was performed and Kaplan-Meier survival plot was generated 
using the survfit function in R package survival. In brief, the normalized gene 
expression values of each individual gene from patient samples were imported with 
both survival time and survival status from Oncomine. The patient samples were 
ranked according to the gene expression. Each of the ranked samples from the first 
quartile to the third quartile was taken as the cutoff to assign the samples into high or 
low expression group and the one with the smallest p-value was chosen as the final 
cutoff.  
Gene signature survival analysis 
 There were four PCa datasets (Nakagawa, Setlur, Taylor, and Yu) with overall 
survival information and six PCa datasets (Barwick, Glinsky, Holzbeierlein, Lapointe, 
Nakagawa, and Taylor) with biochemical recurrence (BCR) survival information in 
Oncomine. Among these datasets, Barwick and Nakagawa had very limited number of 
genes (487 genes), and Glinsky, Holzbeierlein, Lapointe, and Yu had relatively limited 
number of patients (79, 54, 112, 112 patients, respectively). The remaining datasets 
were Setlur with 363 samples and Taylor with 140 samples, and were used in our 
gene signature survival analysis. The gene signature survival analysis was conducted 
in two steps. First, the gene signatures were selected by meta-analysis comparison 
between primary and metastatic tumors in Oncomine. All the candidate genes with 
overall median rank < 2000 and p-value < 0.05 were included in the gene signature. 
Second, the largest cohort (Setlur) was used as the training set for the program to 
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decide the parameters of the predictor to assign the samples into binary risk classes 
(high or low risk). To create a predictor to classify subjects, the numeric score was 
computed by pairwise, ridge, LASSO linear regression using LMC package in R. The 
risk coefficients (i.e., the weight for each gene) were estimated by the pairwise linear 
coefficient (158). To define a threshold to separate high and low risk group, the 
optimized risk coefficients were determined as the ones with the best discrimination 
power computed by ROC (measured by AUC, Area under Curve of the combined 
predictor) in the training set. The Taylor dataset was used as an independent testing 
set to further examine the model. 
 
2.6  In-house gene function tool 
AmiGO (159) and in-house non-redundant GO analysis tool 
 AmiGO2 (http://amigo.geneontology.org/amigo) is one of the web-based tools 
under Gene Ontology Consortium (GOC) (http://www.geneontology.org). AmiGO2 has 
two parts: client software tools and data backend. The client interface is mainly written 
in JavaScript and scripting language, Perl, is applied to handle synchronous 
operations. Because of the increasing complexity of GO terms and improving 
efficiency of data queries, AmiGO2 has been moved from MySQL database backend 
to Solr search platform.  
 GO analysis sometimes is more complicated due to the redundancy of GO 
terms and different structure of GO interdependency. There are a few programs that 
are designed to reduce the redundancy (160) but can only minimize the redundant 
terms. To tailor a GO database for our research goal, we applied literature-based 
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manual curation to classify gene functions into non-redundant functional categories. 
To assist establishing the non-redundant GO database (Figure 2-3A-D) and data 
visualization (Figure 2-3E), I wrote a small program with graphical user interface (GUI) 
in Java. Because our definition of non-redundant GO is that one gene can only be 
signed into one category and user can decide categories, I applied HashMap to store 
the genes as keys and GO terms as values and ArrayList of HashMap to store the GO 
terms as keys and multiple genes as values. The program has two major functions. 
First, it can take user’s input to establish the database. Second, it can make an inquiry 
of single gene or gene list and output the inquiry result of single gene or the pie chart 
of the gene list. Also, the program can connect to MySQL database of AmiGO by 
Object/Relational Map (ORM), Hibernate. In the future, the program will be updated to 
connect to Solr by SolrJ because of the update in AmiGO2 system. 
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Figure 2-3. Non-redundant GO database tool 
A. Java icon. Double click the JAVA icon to start the program 
B and D. Inquiry GUI. The GO file function allows user to upload the GO annotation file. The 
GUI also includes two inquiry features for single gene searching and whole gene list 
searching. 
C and E. The result windows. C is the result of single gene and D is the result of a gene list, 
showing as the pie chart and percentage of genes assigned in each categories.  
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CHAPTER THREE 
Bioinformatics analyses reveal intrinsic transcriptomic and 
epigenetic differences in PSA-/lo and PSA+ PCa cells 
3.1 Introduction  
 Prostate specific antigen (PSA) is a 34 KDa glycoprotein enzyme belonging to 
the kallikrein (KLK) gene family. A secretory component of prostatic seminal fluid, the 
role of PSA in prostate adenocarcinoma is obscure, although PSA is a known PCa 
biomarker. Immunohistochemistry studies have provided evidence that the degree of 
the patient’s prostate tumor differentiation is positively correlated with the expression 
levels of PSA protein in PCa cells (161), and undifferentiated PCa cells express low or 
undetectable PSA (PSA-/lo). In clinical specimens, PSA-/lo cells appear rarely in early-
stage tumors but become more abundant in late-stage and locally advanced PCa and 
become the predominant cell population in treatment-failed castration-resistant PCa or 
CRPC (25, 123). Of clinical significance, PCa patients with tumors harboring more 
than 50% (phenotypically differentiated) PSA+ cells survive longer (138, 162), and 
higher intra-tumoral PSA (KLK3) mRNA levels have been shown to predict better 
patient survival (123).  
 Like most cancers, PCa exhibits significant heterogeneities in cellular 
morphologies and histopathological structures manifested as a mixture of multiple 
tumor foci displaying various degrees of differentiation (25, 134). Intriguingly, even 
seemingly ‘homogeneous’ PCa cell lines still exhibit heterogeneous subpopulations. 
For example, our previous study demonstrated ~2-6% of PSA-/lo cells that pre-exist in 
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unperturbed LNCaP human PCa cultures, and the percentage of PSA-/lo cells 
markedly increases in response to castration treatments (25, 123). Interestingly, 
despite PSA being a known AR-regulated target gene, discordant expression of AR 
and PSA has been observed in patient tumors and xenografts, discernable as 
AR+PSA+, AR+PSA-, AR-PSA+, and AR-PSA- phenotypes (123).  
 Through a spectrum of in vitro biological and in vivo tumor regeneration assays, 
we have observed that a fraction of the cells in the PSA-/lo cell population possesses 
properties attributable to normal stem cells (SCs) and cancer stem cells (CSCs), 
including the ability to undergo asymmetric renewing cell division to generate both 
PSA-/lo and PSA+ cells, preferential expression of SC genes, relative dormancy, and 
long-term tumor-propagating capacity (25). The PSA-/lo cell population is androgen-
independent and refractory to androgen-deprivation therapy (ADT), and harbors highly 
tumorigenic CRPC cells (123). These functional studies (25, 123) suggest that PSA-/lo 
cells not only have CSC properties but may also be drivers of CRPC, and thus may 
represent therapeutic targets to treat CRPC. 
 In both SCs and CSCs, bivalent chromatin regulates cell-fate specification and 
self-renewal capacity (163). Bivalency describes simultaneous presence of the active 
(H3K4me3) and repressive (H3K27me3) histone occupancy of the gene promoters. 
Genes associated with the bivalent histone marks and a lack of DNA methylation on 
CpG island in their promoters are thought to be ‘poised’ to regulate cell differentiation 
(73, 164, 165). Cancer cells in general and CSCs in particular may acquire a certain 
degree of plasticity by disrupting the “double-lock” mechanism that silences the gene 
via both DNA methylation and histone modifications, which together establishes an 
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epigenetic barrier to prevent normal differentiated cells from moving back to the 
undifferentiated state (166). Plasticity of cancer cells has been surmised to contribute 
to tumor cell heterogeneity in breast (163, 167), colon (168, 169), and brain (170-172) 
cancers by generating cells with a range of phenotypic differentiation states and 
distinct clonal subsets. Transient changes in the epigenetic landscape have also been 
linked to therapy resistance in CSCs, such as the reversible acquisition of a drug-
tolerant CSC subset via IGF-1R signaling and an altered chromatin state that requires 
the KDM5/Jarid1A histone demethylase (173). That these drug-tolerant ‘persistors’ are 
sensitive to the histone deacetylase inhibitor trichostatin A and an IGF-1R inhibitor 
(173) provides the proof of principle that subsets of CSCs may be targetable by 
epigenetic modulations.  
 
3.2 Hypothesis  
 Previous work in our lab has demonstrated that the PSA-/lo cell population pre-
exits in untreated patient tumors, becomes enriched in CRPC, and is negatively 
associated with patient overall survival (25, 123). Of clinical importance, the PSA-/lo 
cell population possesses CSC properties, including long-term tumor propagating 
capacity and the ability to regenerate and propagate CRPC in androgen-ablated 
hosts. The study has also revealed bivalent histone associations in the promoters of 
several select SC genes preferentially in the PSA-/lo cell population (123). Unknown is 
whether the PSA-/lo cell population is governed by regulation of several specific SC 
genes or whether the entire transcriptome is distinct from lineage-related but more 
differentiated PSA+ cells. Therefore, my hypothesis herein is that PSA-/lo cells possess 
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unique intrinsic transcriptomic and epigenetic features that causally regulate their 
stemness and aggressiveness. To test this hypothesis, we purified PSA-/lo and PSA+ 
cell populations from untreated LNCaP cell cultures and performed RNA-Seq and 
H3K4me3 and H3K27me3 ChIP-Seq experiments. Also, I have performed integrative 
bioinformatics analysis to further dissect the transcriptome profile of PSA-/lo cell 
population and its potential association with bivalently marked promoters.  
 
3.3 Materials and Methods 
Biological model 
 The lentiviral vector construct with a green fluorescent protein (GFP) reporter 
driven by the PSA promoter was packaged into lentiviral particles produced in 293FT 
packaging cells (Figure 3-1A). Regularly cultured bulk LNCaP cells were infected with 
the lentivirus harboring the reporter plasmid (Figure 3-1B). The infected cells were 
purified by flow cytometry into GFP+ (PSA+) and GFP-/lo (PSA-/lo) subsets 48-72 hours 
after infection (Figure 3-1C). 
RNA extraction, RNA-Seq, and RNA-Seq analysis 
 Total RNA was extracted from purified PSA+ and PSA-/lo LNCaP cells. RNA-
Seq library was prepared using the TruSeq Stranded Total RNA Library Preparation 
Kit with Ribo-Zero (#20020599, Illumina) following manufacturer’s protocol, and 50 bp 
pair-end sequencing was performed on an Illumina HiSeq2000 system.  
ChIP-Seq  
 PSA+ and PSA-/lo LNCaP cells were sorted and 100,000 purified cells were 
pooled together (from multiple sorts, as needed) for each ChIP assay. ChIP-Seq was 
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performed using antibodies specific for H3K4me3 (04-745, Millipore) and H3K27me3 
(07-449, Millipore). ChIP-Seq libraries were generated using NEBNext ChIP-Seq 
Library Prep Master Mix following the manufacturer’s protocol (New England Biolabs), 
and single-end 38 bp sequencing was performed on an Illumina HiSeq2000 system.  
Bioinformatics analysis 
 For RNA-Seq, the reads were aligned to human genome (hg19) by TopHat 
(version 2.0.3) with parameter “-r 50 --mate-std-dev 50 --library-type fr-unstranded -G”. The 
transcript assembly was performed by using cufflink (version 2.0.1) with input bam file 
from TopHat and parameters “-u -g gene.gtf”. In total, there were around 88M-92M 
reads with 80% mapping rates. Then, the cuffdiff was performed to test DEG analysis 
with parameters “--library-type fr-firststrand”, resulting in 1,075 genes upregulated in 
PSA-/lo cells and 285 genes upregulated in PSA+ cells with cutoff fold change ≥ 2.  
 Gene ontology (GO) analysis was performed by manually assigning the genes 
into non-redundant functional categories with the assistance of an in-house java 
program. This graphical user interface (GUI) program helped establish the non-
redundant GO database by virtue of an extension function to search for GO terms of 
genes in AmiGO, an online gene ontology database ((174), 
http://amigo.geneontology.org/amigo) and facilitate data visualization. Global 2D GO 
analysis was applied by Molecular Signatures Database (MSigDB) of GSEA to 
perform unbiased whole-transcriptome analysis in comparison with primary prostate 
tumor (TCGA) dataset or with ADT failed prostate tumor (Rajan_after_ADT) dataset 
(175). GSEA was also applied for exploring the associated biological phenotypes. 
Whole-transcriptome profile analyses were also performed to compare the PSA-/lo cell 
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profile and TCGA dataset or the Rajan_after_ADT dataset. Also, the data used for 
gene expression heatmaps and survival analysis were from Oncomine. The details of 
GO and data-mining analyses were described in Chapter 2. 
 For ChIP-Seq analysis, raw reads were aligned to the hg19 genome assembly 
using BWA (version 0.6.2) with sub-command “aln” and default parameters. There 
were a total of 40-48M reads and 81%-84% mapping rate for H3K4me3 and 41-51M 
and 77%-79% mapping rate for H3K27me3. Only tags that uniquely mapped to the 
genome were used for further analysis. ChIP-Seq peaks were identified using MACS 
(version 1.3.7.1). The scanning window size was set for 1,000 bp and the cutoff of was 
1e-5. The background was the input DNA controls from PSA-/lo and PSA+ cells. To 
summarize, in the promoter region (defined as ±1kb from transcription start site (TSS)), 
21,089 and 20,347 H3K4me3 peaks and 24,411 and 25,352 H3K27me3 peaks were 
identified from PSA-/lo and PSA+ chromatin, respectively. For heatmap distribution, the 
peaks were centered by middle of the peak with a range of ±5kb. Whole regions were 
divided into 250 bins, and the average reads per kilobase transcript per million reads 
(RPKM) were calculated in each bin and plotted by heatmap.2 function in R. GO 
analysis was performed using GREAT (version 2.0, 
http://great.stanford.edu/public/html/). 
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Figure 3-1. Strategy to purify and characterize subpopulations of LNCaP cells on the 
basis of PSA expression (adapted from (25) Qin, J., X. Liu, B. Laffin, X. Chen, G. Choy, C. 
R. Jeter, T. Calhoun-Davis, H. Li, G. S. Palapattu, S. Pang, K. Lin, J. Huang, I. Ivanov, W. Li, 
M. V. Suraneni, and D. G. Tang. 2012. The PSA(-/lo) prostate cancer cell population harbors 
self-renewing long-term tumor-propagating cells that resist castration. Cell stem cell 10: 556-
569). 
A. The PSAP-GFP lentivector reporter used in this study. GA. gag gene; eGFP, 
enhanced green fluorescence protein; LTR, long-terminal repeat; PSAP, prostate 
specific antigen promoter; RRE, Rev responsive element; SD, splice donor. 
B. Representative fluorescence images of LNCaP cells transduced with the PSAP-GFP 
reporter and immunostained for PSA in both PSA+ and PSA-/lo cells, showing that the 
PSA reporter system accurately reports PSA expression in cells.  
C. Schema of flow-based purification of PSA+ and PSA-/lo LNCaP cells and molecular 
analysis by RNA-Seq and ChIP-Seq. LNCaP cells with strong PSA expression (i.e., 
the top 10% of the GFP+/bright population) and with low or no PSA expression (i.e., the 
bottom 2-6% of GFP-/lo cells) were collected by flow cytometry and the transcriptome 
assessed by RNA-Seq and the epigenetic landscape by H3K4me3 and H3K27me3 
ChIP-Seq. 
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3.4 Results 
 To understand the potential biological differences between the PSA+ and PSA-
/lo cell populations, I performed manually curated non-redundant gene ontology (GO) 
analysis to assign each DEG into the most relevant gene category with the assistance 
of an in-house program developed specifically for GO annotation (25). Analysis of the 
DEG profiles revealed significant upregulation of genes involved in 
development/stemness, epigenetic regulation, DNA damage response and genome 
stability, detoxification and stress responses, extracellular matrix and cell-cell 
communications, as well as neural and neuronal development/functions in the PSA-/lo 
cell subset. In contrast, genes that participate in metabolic processes, signal 
transduction, and cellular differentiation and many AR target genes, were enriched in 
the PSA+ cell population (Figure 3-2A). GSEA suggested that the transcriptome profile 
of PSA-/lo cells, but not PSA+ cells, was associated with normal SCs and CRPC 
(Figure 3-2B). These unique DEG profiles in PSA-/lo and PSA+ cell subpopulations 
portend that, despite their identical genetic background, the two cell subpopulations 
likely possess distinct biological functions. 
 Unbiased global GO enrichment analysis demonstrated that the PSA-/lo LNCaP 
cells had more GO terms (gray dots) with a positive enrichment score (the ratio of GO 
terms in the 1st and the 2nd quadrant to those in the 3rd and the 4th quadrant: 
2,604:1,367 (1.91; left panel) and 2,611:1,325 (1.97; right panel)) (Figure 3-2C). On 
the other hand, fewer GO terms with a positive enrichment score were observed in 
primary patient samples (the ratio GO terms in the 1st and the 4th quadrant to the 2nd 
and the 3rd quadrant: 1,267:2,701). On the other hand, patient CRPC displayed an 
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enrichment pattern more similar to that derived from PSA-/lo cells, with more GO terms 
with a positive enrichment score than primary patient tumors (the ratio of GO terms in 
the 1st and the 4th quadrant to the 2nd and the 3rd quadrant: 1,639:2,297). These 
observations may indicate highly active transcriptome programs in CSCs and 
relatively ‘inert’ transcriptomes in primary PCa. Intriguingly, very much like the AR-
PSA- normal human prostate basal/stem cells that preferentially express a 
neurogenesis ‘program’ (112), the PSA-/lo LNCaP cells also preferentially expressed 
neurogenesis (i.e., neural and neuronal development/function) genes (Figure 3-2C; 
red dots). The data is consistent with results from our non-redundant GO manual 
curation (Figure 3-2A) showing enrichment of neurogenesis genes in PSA-/lo cells. 
When comparing global GO enrichment patterns of DEGs between PSA-/lo cells 
versus patient primary tumor or patient CRPC, neural and neuronal 
development/function terms (red dots) preferentially showed in quadrant 1 in 
comparison of PSA-/lo cells versus CRPC (Figure 3-2C), meaning that the 
neurogenesis GO terms are enriched in both PSA-/lo LNCaP cells and patient CRPC 
samples, but not primary tumors. 
 To establish potential clinical relevance and biological meaning of neurogenesis 
gene enrichment, the global transcriptome (i.e., all genes) in PSA-/lo LNCaP cells was 
analyzed by scatter plots and compared to the transcriptome profiles of patient 
primary and CRPC samples. The overall transcriptomes were evenly distributed, and 
the neurogenesis genes were mostly upregulated in PSA-/lo LNCaP cells and CRPC 
(quadrant 1 in right panel) but not in primary patient tumors (left panel) (Figure 3-3A). 
Moreover, the Oncomine Concept analysis revealed that the expression levels of 
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many neurogenesis genes were increased in primary patient tumors over normal 
tissues and in metastatic tumors compared to primary tumors (Figure 3-3B). Strikingly, 
Kaplan-Meir survival analysis showed that the mRNA expression levels of several 
neurogenesis genes (e.g., NRXN1 and CHRM3) correlated with poor patient survival 
(Figure 3-3C). These results, collectively, demonstrate that the neurogenesis gene 
expression profile, preferentially expressed in PSA-/lo PCa cells, is associated with 
clinical manifestations of CRPC, and advanced and metastatic PCa, and predicts 
worse patient survival. 
 Because the PSA-/lo and PSA+ PCa cells are lineage-related (25) and some SC 
gene promoters are enriched in bivalent (dual activating and repressive) histone 
modifications (123), the global active (H3K4me3) and suppressive (H3K27me3) 
histone marks on promoter regions in the two cell subpopulations were investigated by 
ChIP-Seq. There were 2,088 peaks associated with 1,528 genes preferentially marked 
by H3K4me3 from analysis of PSA-/lo cell chromatin and 1,346 H3K4me3 peaks 
associated with 1,194 genes called from analysis of PSA+ cell chromatin. The majority 
of peaks (19,001 peaks associated with 12,993 genes) were commonly marked by 
H3K4me3 in both cell populations (Figure 3-4A), with 33.7% peaks from the promoter 
region, 7.5% in coding exons, 28.3% in introns, and 30.4% located at distal intergenic 
regions (Figure 3-4B). The heatmap revealed notably more differential H3K4me3 
signal in comparison of the peaks preferentially enriched in PSA-/lo chromatin (peaks 
called only in PSA-/lo cells), whereas the ChIP-Seq peak intensity preferentially 
enriched in PSA+ cells only differed modestly (Figure 3-4D). GO analysis revealed that 
the gene functions associated with activate histone marks in PSA-/lo cells were related 
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to cell development, cell migration, and neuron migration, whereas gene functions 
associated with active histone marks in PSA+ cells corresponded to cell differentiation, 
cell fate specification, and hormone stimulation (Figure 3-4C).  
 The suppressive histone mark, H3K27me3, was enriched in 1,010 peaks 
associated with 604 genes in PSA-/lo cells and 1,951 peaks (1,103 genes) in PSA+ 
cells (Figure 3-4E). The majority of peaks (23,401 peaks associated with 5,702 genes) 
were commonly marked by H3K4me3 in both cell populations (Figure 3-4E), with 9.1% 
of the repressive H3K27me3 peaks were localized to promoter regions, 6.6% on 
coding exons, 26.9% on introns, and 57.4% were located in distal intergenic regions 
(Figure 3-4F). Biological annotation of the genes marked by suppressive histone 
modification in PSA-/lo cells revealed their association with GO terms such as 
programmed cell death, steroid biosynthesis and metabolism, and cell adhesion. On 
the other hand, biological functions associated with stem cell development, Notch 
pathway and neuronal maturation were detected more prominently in H3K27me3-
associated genes in PSA+ cells (Figure 3-4G). The heatmap revealed notably more 
differential H3K27me3 signal in comparison of the peaks preferentially enriched in 
PSA+ chromatin (Figure 3-4H). Thus, PSA-/lo and PSA+ cells purified from the same 
untreated bulk LNCaP culture manifest quite different epigenetic landscapes reflecting 
their distinct transcriptome profiles. 
 Bivalent domains, particularly those associated with promoters of 
developmental genes, are a pivotal feature of embryonic SCs (176). A previous study 
from our lab demonstrated that several development-associated genes, including 
NKX3.1, FGF5, BCL-2, and CDH2, have bivalent histone modifications preferentially 
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in PSA-/lo cells (123). Here, we examined the genome-wide bivalency association 
within the ± 1 Kb of TSS in PSA-/lo vs. PSA+ LNCaP cells. The majority (96%) of TSS 
marked by H3K4me3 on gene promoters in PSA-/lo cells were also marked with 
H3K4me3 in PSA+ cells, and roughly 75% of TSS marked by H3K27me3 in PSA-/lo 
cells were also marked with H3K27me3 in PSA+ cells. However, only 44% of the 
bivalent TSS in PSA-/lo cells maintained their bivalency in PSA+ cells, with 19% losing 
their H3K27 repressive mark (i.e., H3K4me3 only), 35% losing their H3K4me3 
activating mark (H3K27me3 only), and 2% losing both activating and repressive 
histone modifications (unmarked) (Figure 3-5A). In total, there were 1,126 bivalent 
marked TSS in PSA-/lo cells and 894 in PSA+ cells. Transition of chromatin status, i.e., 
loss of bivalent domains in PSA+ cells may indicate that PSA+ cells specifically 
activate and repress certain genes during differentiation from PSA-/lo cells (Figure 3-
5A). To determine the effect of repressive and activating chromatin changes on 
transcription, transcript levels for gene promoters with transition of bivalent domains 
were evaluated. The mRNA levels of genes with bivalent domains on their TSS in 
PSA-/lo cells slightly increased in PSA+ cells with H3K4me3 only and slightly 
decreased if the mark transitioned to H3K27me3 only (Figure 3-5B). However, the 
comparisons are not statistically significant, which might be because the baseline 
expression levels of genes are widely variable or because the PSA-/lo subpopulation is 
yet heterogeneous (123). 
 Next, we made efforts to correlate preferential neurogenesis gene expression in 
PSA-/lo LNCaP cells with certain histone mark association. The most highly enriched 
neurogenesis transcripts in PSA-/lo cells include NRXN1, and its interacting protein, 
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NLGN1. NRXN1 belongs to neurexin cell-surface receptor family and NLGN1 belongs 
to neuroligin family. Neuroligins bind to neurexins to form CTGF+-dependent 
neurexin/neuroligin complexes at synapses in the central nervous system, which are 
essential for neurotransmission (177). The neuroligins expressed on dendritic cells 
and neurexin expressed on axons trigger the formation of synaptic contacts and 
presynaptic and postsynaptic differentiation, respectively (177). In gastric cancer, 
patient tumors with TP53 mutations co-occurring with mutations in NRXN1 are 
predicted by the drug-gene association tool, Connectivity Map (CMAP), to have 
different drug response to chemotherapy and molecular and clinical profiles versus 
TP53 mutation alone, suggesting a unique role for NRXN1 in cancer (178). Another 
neurogenesis gene highly expressed in PSA-/lo LNCaP cells is CHRM3, one of the 
muscarinic cholinergic receptors belonging to a larger family of G protein-coupled 
receptors normally expressed in smooth muscle cells, endocrine and exocrine glands, 
lungs, pancreas and brain (179). CHRM3 has been reported to preferentially couple 
with Gq, predominantly activating phospholipase C (PLC) and assisting in the 
mobilization of intracellular CTGF+ stores subsequently activating protein kinase C 
(PKC) (179). CHRM3 has also been implicated in PKC-independent pathways, such 
as activation of PI3K and MAP kinase pathways, possibly underlying CHRM3-
mediated cancer phenotypes such as cell proliferation and migration in a variety of 
cancers, including prostate (179, 180). Of importance, CHRM3 is upregulated in 
human CRPC cell lines, and overexpression of CHRM3 augments PC3-AR+ xenograft 
tumor growth in castrated hosts via AKT activation (180). 
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 In contrast to the differentiation marker gene KLK3 (encoding PSA), which 
displayed strong H3K4me3 enrichment, low levels of H3K27me3 and higher PSA 
expression in PSA+ cells compared to those in PSA-/lo cells (Figure 3-5C), NRXN1 and 
CHRM3, which were preferentially expressed in PSA-/lo cells, exhibited high H3K4me3 
enrichment at the promoter particularly in PSA-/lo cells. The H3K27me3 mark was 
present on NRXN1 and CHRM3 promoters and gene bodies in both PSA-/lo and PSA+ 
cells (Figure 3-5D). Interestingly, although the NRXN1 mRNA level was significantly 
higher in PSA-/lo cells compared to PSA+ cells, its overall expression level was low (the 
intensity scale was only 0.41 and FPKM was 0.32). Nevertheless, NRXN1 
transcription was greatly reduced in PSA+ cells (FPKM was 0.0048). Taken together, 
these results imply that bivalent domains on NRXN1 and CHRM3 in undifferentiated 
PSA-/lo cells might poise the genes for low expression in PSA-/lo cells that is further 
suppressed in PSA+ cells, with removal of the activating H3K4me3 mark (Figure 3-
5D). Overall, PSA-/lo cells possess more genes with bivalent domains on promoter 
regions and low levels of expression, and the majority of these genes change their 
chromatin status to activated or suppressed states in more differentiated PSA+ cells. 
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Figure 3-2. Functional annotation of the transcriptome profiles in PSA-/lo and PSA+ 
LNCaP cell subpopulations. 
A. PSA-/lo and PSA+ LNCaP cells express functionally distinct genes. Non-redundant 
gene annotations of DEGs from PSA-/lo and PSA+ cells. Each DEG (fold change ≥ 2) 
was manually curated into a single functional gene category using the in-house non-
redundant GO analysis tools.  
B. The transcriptome profile of PSA-/lo cells tends to be positively associated with 
transcriptome profiles of normal human prostate basal cells (Zhang; (112)), patient 
CRPC post ADT (Rajan; (175)), and castration-selected LNCaP AI cells (Wang; 
(181)), whereas the transcriptome of PSA+ cells displays the reciprocal pattern and is 
associated with transcriptome profiles of normal differentiated (AR+PSA+) prostate 
luminal cells, AD patient tumors, and AD LNCaP cells, respectively. The DEGs of 
PSA-/lo and PSA+ cells were compared to transcriptome profiles of various known 
biological phenotypes by GSEA. 
C. Global gene annotation of PSA-/lo cell transcriptome with enrichment of neural and 
neuronal development/function more similar to transcript profiles from patient CRPC 
(Rajan dataset) than those of primary tumors (TCGA dataset). Analysis was 
performed with all the GO gene sets in GSEA and NES (normalized enrichment 
scores) are displayed in scatter plots. The gray dots represent all the GO terms in 
GO gene sets and red dots the neurogenesis genes. The transcriptome profiles in 
PSA-/lo cells and patient CRPC, but not primary PCa, show positive enrichment of a 
neurogenesis gene signature. 
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Figure 3-3. Clinical relevance of neurogenesis genes enriched in the PSA-/lo 
subpopulation. 
A. Global transcriptome plot shows that neurogenesis (i.e., neural and neuronal 
development/function) genes are enriched in PSA-/lo LNCaP cells and patient CRPC 
relative to primary (AD) tumors. The gray dots represent individual mRNAs from the 
transcriptome profiles of PSA-/lo cells and primary patient tumors in TCGA (left panel) or 
PSA-/lo cells and patient CRPC (right panel) with neuronal development/function 
associated genes highlighted in red. 
B. The Oncomine concept analysis was performed with cutoff at median rank < 6,000 and p-
value < 0.05. The results show the upregulated neurogenesis genes when comparing 
primary tumors versus normal tissue (left) and when comparing metastases over primary 
tumors (right). 
C. The expression of individual neurogenesis genes correlates with poor patient survival. 
The indicated neurogenesis genes upregulated in PSA-/lo LNCaP cells were used to 
stratify patients into high and low expressers; patient survival information was obtained 
from Oncomine datasets. Data presented were statistically significant with p-value cutoff 
< 0.05. 
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Figure 3-4.  Functional annotation of histone binding profiles in PSA-/lo and PSA+ LNCaP 
cell subpopulations. 
A-D. GO annotation by GREAT (Gene Region Enrichment Annotation Tool) of the genes 
marked by H3K4me3 on promoters in both LNCaP cell subpopulations. A. The Venn 
diagram presents the total numbers of peaks called and the degree of overlap between 
PSA-/lo and PSA+ LNCaP cells. There are 19,001 H3K4me3 peaks (12,993 genes) 
commonly detected in both cell populations, 2,088 peaks (1,528 genes) and 1,346 
peaks (1,194 genes) preferentially appeared in PSA-/lo and PSA+ cells, respectively. B. 
Genomic distribution of H3K4me3 occupancy. Promoter region is defined as ±3 Kb from 
the TSS and distal intergenic region includes < -3Kb from TSS and outside the 
transcription end site (TES). C. GO analyses, performed by GREAT with GO terms and 
Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathways, revealed 
distinct categories of gene enrichment in the two cell subpopulations. D. Heatmaps of 
the H3K4me3 peaks (±5 Kb) preferentially enriched in PSA-/lo cells (top) or in PSA+ cells 
(bottom). 
E-H. GO annotation by GREAT of the genes marked by H3K27me3 on promoters in both 
LNCaP cell subpopulations. E. In total, there are 23,401 peaks associated with 5,702 
genes in both cell populations, and 1,010 peaks (604 genes) and 1,951 peaks (1103 
genes) called in PSA-/lo and PSA+ cells, respectively. F. Genomic distribution of 
H3K4me3 occupancy. G. Differential H3K27me3 marked genes reveal divergent 
biological functions and phenotypes in GO analysis. H. Heatmaps showing the 
preferentially enriched H3K27me3 peaks in the two cell subpopulations. 
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Figure 3-5. Chromatin state transitions in the two LNCaP cell subpopulations and their 
associated gene expression profiles. 
A. Histone modification shift in comparison of peak type frequency between PSA-/lo and 
PSA+ cells. The sizes of the top circles represent the numbers of peak regions with 
H3K4me3, H3K27me3, both, or neither on promoter regions (± 1Kb from TSS) in PSA-/lo 
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cells. The lower circles are the pie charts indicating the percentages of promoter regions 
that have changed status in PSA+ cells. Blue indicates active (H3K4me3), red bivalent 
(both H3K4me3 and H3K27me3), green suppressive (H3K27me3), and purple neither 
mark. 
B. Gene expression corresponding to chromatin status transition derived from profiling 
PSA-/lo cells versus PSA+ cells. All genes with bivalently marked TSS in PSA-/lo cells with 
FPKM > 0.2 were separated into two groups according to a change to activating 
(H3K4me3) or suppressive (H3K27me3) histone status on promoters in PSA+ cells. Box 
plots show average transcript abundance in PSA-/lo and PSA+ cells for genes with the 
indicated chromatin mark transition.   
C-D. Histone and mRNA landscapes of the indicated representative genes. Shown are UCSC 
tracks from H3K4me3, H3K27me3, and RNA-Seq landscape. Green peaks represent 
tracks of PSA+ cells, and red peaks the tracks of PSA-/lo cells. 
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3.5 Discussion  
 In general, cultured cancer cell lines are considered to be relatively 
homogeneous in comparison to highly heterogeneous patient tumors. Nevertheless, 
distinct LNCaP subsets can be distinguished on the basis of the expression of the 
differentiation marker PSA. PSA-/lo and PSA+ subpopulations co-exist in the untreated 
cultures, and their gene expression profiles reveal molecular distinctions reflecting 
their biological features (Figure 3-2A). The bulk cells display a spectrum of 
intermediated cells with various PSA expression levels. Here, I focus on comparing 
the intrinsic differences of transcriptome differences and histone modifications 
between lineage-related cell subpopulations with top 6-10% (PSA+) and lowest 2-3% 
(PSA-/lo) PSA expression. This strategy aims to simply our understanding of the PCa 
cells at the two extreme spectra – i.e., the most differentiated (PSA+/hi) and the least 
differentiated (PSA-/lo) without considering the continuum in between. It should be 
noted that the current study is conducted in a single PCa cell system, LNCaP. 
However, the PSA-/lo cell population is highly clinical relevant. Firstly, PSA-/lo cells pre-
exist in untreated patient tumors and become enriched in advanced tumors and the 
predominant cell population in CRPC (123). Secondly, higher PSA mRNA level is 
associated with better overall patient survival. Thirdly, biological relevance of the PSA-
/lo population has been corroborated in multiple cancer models, including the LAPC4, 
LAPC9, and LNCaP as well as patient derived PSA-/lo cells (124). Therefore, although 
my current study focused on one cell model, I believe that data presented here and 
conclusions drawn should be applicable to PCa in the clinic. 
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 Analysis of unperturbed PSA-/lo cell transcriptomes uncovers unique SC, 
development, epigenetic regulator, extracellular matrix, and cell-cell communication 
enriched gene-expression profiles. In contrast, the PSA+ cell transcriptome is enriched 
in genes related to metabolic processes, signal transduction, differentiation, AR 
target/responsive, and cell cycle.  Also, the gene expression profile of PSA-/lo cells is 
highly associated with the transcriptome of stem-like normal prostate basal cells and 
treatment-failed CRPC (Figure 3-2B). These results are consistent with the biological 
phenotypes discovered previously in which PSA-/lo cells are found to be 
undifferentiated, stem-like cells, whereas PSA+ cells were found to be more 
differentiated and functional prostate cell types (25). These DEG profiles further 
support the unique capabilities of PSA-/lo PCa cells to survive androgen deprivation 
and drive CRPC progression and implicate these cells as potential therapeutic targets 
in the clinic. 
 The bivalent domains on the promoters of development genes poise them for 
timely responses to differentiation signals (176). Promoter bivalency also regulates 
cellular plasticity and phenotypic flexibility via modulating expression of genes 
involved in EMT signaling pathways, such as WNT and TGFβ (182). PSA-/lo cells 
appear to have more genes associated with bivalent domains along with upreguation 
of some epigenetic modifiers (e.g., ARID2, JMJDIC, KDM5A, KDM6A, KDM6B, 
SETD2, SETD5, TET1, and TET3), which might suggest that not only bivalency but 
also other epigenetic mechanisms may be in operation to sustain CSC properties of 
the PSA-/lo cells. Also, genes important to stemness and EMT are upregulated in PSA-
/lo DEG profiles (e.g., WNT5A and TGFβ, MMP7) (Figure 3-2A). Together, the results 
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suggest that lineage-related PSA-/lo and PSA+ cells possess distinct epigenetic 
landscapes, which are crucial for cell identities.  
 PSA-/lo cells are enriched in genes normally associated with neural and 
neuronal development/function. Intriguingly, such neurogenesis genes are also 
preferentially expressed in AR-PSA- normal prostate basal/stem cells and have been 
linked to cell plasticity and adverse clinical features of PCa (Figure 3-2B) (112). 
Detailed examination of the PSA-/lo transcriptome profile shows that at least some of 
these genes, like NRXN1 and CHRM3, are poised with bivalent marks with a loss of 
H3K4me3 at the TSS in more differentiated PSA+ cells (Figure 3-5D). Therefore, we 
reason that NRXN1 and CHRM3 may function as stem cell factors and regulate CSC 
properties of PSA-/lo cells. In support of this hypothesis, our pilot functional studies 
show that siRNA- or shRNA-mediated knockdown of NRXN1 expression or CHRM3 
reduced the colony- and sphere-forming properties of PSA-/lo or bulk LNCaP cells in 
vitro (Figure 3-6A-C; data not shown). Importantly, knocking down NRXN1 in LAPC9 
xenografts using shRNA lentiviral vectors inhibited tumorigenesis, as indicated by 
reduced tumor incidence and tumor weight upon transplantation of limiting cell 
numbers into immunocompromised hosts (Figure 3-6D). Interestingly, suppressing 
CHRM3 expression appeared to also inhibit PSA-/lo cell invasion and migration abilities 
(Figure 3-6E). 
 Of clinical relevance, CHRM3 has been implicated in CRPC (180) and the 
neurogenesis gene signature is highly enriched in patient CRPC transcriptome profiles 
(Figure 3-2C and 3-3A). In further support, we have observed that expression of 
NRXN1 and CHRM3 is upregulated in not only PSA-/lo LNCaP cells but also LNCaP 
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cells selected after chronic castration in vitro (Figure 3-6F). Moreover, expression of 
these genes adversely correlates with patient survival (Figure 3-3C). Although it 
remains to be determined whether the entire cohort of neurogenesis genes or a 
‘neurogenesis gene signature’ could predict patient survival, our data has linked a few 
highly expressed neurogenesis genes, individually, to the poor patient survival (Figure 
3-3C). In the re-analyzed Rajan dataset comparing patient samples before and after 
ADT, NRXN1 mRNA expression showed around 2.9 times higher with p-value < 0.012 
after ADT (compared to before ADT), but, surprisingly, CHRM3 was actually 
downregulated 4.3 times in patient tumors after ADT. This latter observation is 
inconsistent with an earlier report (180) and the reason underlying this inconsistency 
remains unclear. 
 In summary, our data has shown that the expression levels of many individual 
neurogenesis genes are adversely associated with patient survival. Concept analysis 
from Oncomine also reveals that many genes are highly upregulated in prostate 
tumors compared to normal and in metastases compared to primary tumors. 
Moreover, previous studies have demonstrated that the neurogenesis gene profiles 
expressed in the normal human prostate basal/stem cells have been linked to 
aggressive PCa (112, 183). All such evidence suggests the clinical relevance of 
neurogenesis genes on the whole. Of interest, the ‘default differentiation path in 
normal stem cells, when cultured under inappropriate conditions, is the neural 
differentiation. This indicates that the neural differentiation program is built in the 
intrinsic stem cell-associated differentiation program (112, 184). Also, neural stem and 
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progenitor cells are well known to be very ‘aggressive’ and are highly migratory and 
invasive undergoing EMT during development (112, 183).  
 To conclude, the CSC-enriched PSA-/lo PCa cell subpopulation exhibits intrinsic 
transcriptomic and epigenomic differences compared with lineage-related PSA+ 
differentiated PCa cells. The PSA-/lo CSC subset possesses SC properties discernible 
in both its transcriptome profiles (this study) and biological functions (25), and may 
serve as a cell-of-origin for CRPC (124). It is tempting to speculate that the 
neurogenesis genes enriched in PSA-/lo cells may be causally related to NEPC 
(neuroendocrine PCa) phenotype although the PSA-/lo cells purified from multiple PCa 
models and patient tumors lack the expression of mature NEPC markers such as 
chromogrannin A and synaptophysin (25, 123). Regardless, these interrogations 
demonstrate the molecular divergence of prostate CSCs and non-CSCs, potentially 
shedding light on CSC-targeting therapeutics to eradicate PCa, especially CRPC. 
Considering that the PSA-/lo cells pre-exist in the primary tumors (25, 123), 
combinatorial therapies targeting both CSCs (with novel CSC-directed therapies) and 
non-CSCs (e.g., using enzalutamide to target differentiated AR+PSA+ PCa cells) for 
early-stage PCa patients may prove to be valuable in the clinic. 
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Figure 3-6. Characterization of NRXN1 and CHRM3 biological functions (performed by 
Dr. Xin Liu and Dr. Kiera Rycaj) 
A-C. Knockdown down the expression of NRXN1 and CHRM3 inhibits the CSC properties of 
PSA-/lo cells. (A) The results display images of clongenic assay of siRNA repressing 
NRXN1 (versus non-silencing control (NS)) in both PSA-/lo cells and PSA+ cells. (B) The 
results are sphere formation assay and its quantification data of PSA-/lo cells and PSA+ 
cells with siRNA of NRXN1 or NS. (C) The results show sphere formation assay upon 
knocking down CHRM3 in PSA-/lo cells. # indicated p-value < 0.05 and ** is p-value < 0.01 
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D. Knockdown of NRXN1 inhibits tumorigenesis. The tumor incidence and tumor weights were 
measured at 38 days after xenografting 5K or 50K LAPC9 cells transduced with 
nonsilencing control shRNA or NRXN1 shRNA prior to subcutaneous transplantation into 
immunocompromised hosts. 
E. Knocking down CHRM3 inhibits PSA-/lo cells migration and invasion. Transwell assays were 
performed without or with matrigel for migration and invasion assays, respectively. Crystal 
violet stained cells on the bottom side of well were counted. 
F.  Expression of NRXN1 and CHRM3 in PSA-/lo, PSA+, and long-term castrated LNCaP cells. 
Quantitative RT-PCR was applied to detect the mRNA expression in PSA-/lo, PSA+, and 
MDV3100 treated LNCaP cells. LNCaP cells were treated in MDV3100 containing medium 
longer than a year to select the long-term castration resistant LNCaP cells. 
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CHAPTER FOUR 
Bioinformatics analyses reveal unexpected molecular 
mechanisms underlying NANOG-induced PCa cell 
reprogramming 
4.1 Introduction 
 Self-renewal is a critical biological property for normal adult SCs, embryonic 
stem cells (ESCs), induced pluripotent stem cell (iPSCs), and CSCs. Nanog is a 
transcription factor involved in the self-renewal of ESCs by working coordinately with 
other stemness genes, including octamer-binding transcription factor 4 (OCT4) and 
the sex-determining region Y HMG-box2 (SOX2) (77, 185).  The main role of Nanog is 
to maintain the ESCs in a stable undifferentiated state and establish the pluripotent 
ground state in the inner cell mass. NANOG is expressed in epiblast ES cells and 
undetectable in most of the somatic cells in normal adult organs, except in germ cells. 
Nanog, collaborating with other pluripotency transcription factors, is also critical in 
iPSCs reprogramming to facilitate adult somatic cells to regain the SC properties 
(186). The primary function of Nanog on iPSC reprogramming is transition of pre-
iPSCs to fully induced ground state iPSCs but not during early stages of iPSC 
generation (187). Mechanistically, Nanog directly interacts with methylcytosine 
hydroxylase TET1/2, which globally demethylates 5’-mC to generate 5’- 
hydroxymethylcytosine (5hmC), resulting iPSC generation (188). 
 The NANOG expressed in ESCs, i.e., NANOG1, is encoded by the gene 
located on chromosome 12p13 (189). There are many retrotransposed NANOG 
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‘homologs’ in the human genome (189). These retrogene variants (pseudogenes) of 
NANOG, i.e., NANOGP2 to NANOGP11, are encoded by genes located on 
chromosome 12, 2, 6, 7, 9, 10, 14, 15, X, and X, respectively. NANOGP5 shows 85% 
homology to NANOG, whereas all other variants have more than 90% similarity. The 
human NANOGP8 (NP8) can encode full-length NANOG protein of 305 amino acid, 
whereas NANOGP2, P4, P5, P9, P10 are presumed to generate truncated protein 
products due to the presence of premature stop codons in the coding sequence (190, 
191). NP8 is highly similar to NANOG with five nucleotide substitutions, only 1 of 
which, nucleotide 795, encodes a putative amino acid change at Q253H (87). 
 Although NANOG is not expressed in the majority of normal somatic cells, 
NANOG expression has been reported in many cancer types, including breast (192), 
bladder (193), ovary (194), and prostate (195) cancers. Interestingly, NP8, instead of 
NANOG1, has been reported to be the predominant NANOG ‘isoform’ expressed in 
somatic cancer cells, although in some cancers NANOG mRNA might potentially arise 
from the NANOG1 locus (196). Functionally, NANOG in cancer cells has been 
implicated in regulation of migration and metastasis (197-200), apoptosis and cell 
cycle (201-204), angiogenesis (205, 206), multidrug resistance (89, 207), and CSC 
self-renewal (208).  
 Work from our laboratory has demonstrated that NP8 mRNA and NANOG 
protein are expressed in PCa (87, 93). Interestingly, NANOG positivity is negatively 
correlated with AR expression in patient PCa cells in vivo and enriched in CD44hi PCa 
stem/progenitor cells, which are frequently AR-/lo (87). Knocking down NANOG inhibits 
tumor development in xenograft models, and suppresses clonal and clonogenic 
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growth of PCa cell lines and primary human PCa cells in vitro (87). On the other hand, 
overexpressing NANOG and NP8 increases expression of CSC-associated molecules, 
CD133 and CD44, and decreases differentiation molecules, AR and PSA (93). These 
results indicate that NANOG promotes CSC phenotypes and NANOG-expressing cells 
might serve as cell-of-origin of these cancers. Furthermore, NANOG and NP8 
overexpression facilitates the development of ADT resistance by stimulating 
survivability of LNCaP cells in experimental androgen deprivation conditions and, 
importantly, enhance the clonogenic ability and tumor regeneration of LNCaP cells in 
androgen-deprived host (93). Inducible overexpression of NANOG promotes 
acquisition of CSC properties and resistance to castration in PCa cells (93), and 
knocking down NANOG inhibits tumor regeneration of the PSA-/lo LAPC9 PCa cells in 
castrated host (25). In this experimental setting, NANOG promotes the expression of 
pro-survival, pro-proliferation, anti-apoptosis, pro-migration, and detoxification genes, 
including ABCG2, CD133, IGFBP-5, BCL-2, CXCR4, and ALDH1A1 (93). These 
functional studies (87) (93) suggest that the endogenously expressed ‘master’ 
transcription factor, NANOG, seems to be critical for tumorigenic properties of 
(prostate) cancer cells. More importantly, our studies with inducible NANOG in PCa 
cells (93) suggest that overexpression of NANOG alone appears to be sufficient to 
reprogram androgen-sensitive (androgen-dependent, AD) PCa cells to the androgen-
independent (AI; castration-resistant) state that also acquires a variety of phenotypic 
and functional CSC properties (93). In this project, we made efforts to define the 
mechanisms underlying the NANOG-induced reprogramming of AD LNCaP cells to 
the AI LNCaP cells manifesting castration resistance and CSC characteristics. 
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4.2 Hypothesis  
 To a degree, the process of NANOG-induced reprogramming of LNCaP cells, 
within 2-3 weeks (93), into the castration-resistant state that has also acquired certain 
CSC properties resembles somatic cell reprogramming by OSKM factors (Oct4, Sox2, 
KLF4, and Myc) to generate the iPSCs. Therefore, our initial hypothesis is that 
NANOG may reprogram PCa cells via reactivating the pluripotency network to engage 
endogenous stemness factors such as Oct4 and SOX2 as in iPSC reprogramming. On 
the other hand, we are mindful that LNCaP cells, unlike normal ‘differentiated’ somatic 
cells such as fibroblasts, are metastatic cancer cells that already possess some stem 
cell properties such as longevity (at the population level). Therefore, we alternatively 
hypothesize that NANOG-induced LNCaP cell reprogramming may not necessarily 
involve reactivation of the pluripotency network and pluripotency factors but instead 
may engage PCa-specific lineage regulators. In this project, we test these hypotheses 
by performing NANOG ChIP-Seq experiments combined with time-resolved RNA-Seq 
analyses and some biological validations. I helped annotate and interpret the newly 
generated ChIP-Seq and RNA-Seq data sets, and the results tested our hypotheses 
and led to some new testable hypotheses. 
 
4.3 Materials and Methods 
Biological models 
 Inducible NANOG expression in LNCaP cells was established using a binary 
Tet-on system, in which the CMV promoter drives TetR expression and TRE drives 
the expression of NANOG1 or NP8  (Figure 4-1; (93)). In principle, the transgene 
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(NANOG1 or NP8) is turned on by addition of doxycycline (DOX) in the culture 
medium for various time intervals. LNCaP-NANOG1 or LNCaP-NP8 cells were 
cultured in normal serum-containing medium, i.e., AD condition, or in medium 
containing charcoal dextran-stripped serum (CDSS), i.e., the AI condition. As 
illustrated in Figure 4-1, samples were harvested at different time points for analysis. 
For RNA-Seq experiments, the LNCaP-NP8 cells cultured in the presence of DOX 
were collected at both early (i.e., 5 days in AD conditions and 7 days in AI conditions) 
and late (i.e., 12 days in AD conditions and 22 days in AI conditions) time points. For 
RNA-Seq in LNCaP-NANOG1 cells, we only used the DOX-induced cells for 5 days in 
the AD conditions. For ChIP-Seq experiments, samples with NANOG1 or NP8 
induction for 5 days in AD condition were studied (Figure 4-1). 
RNA-Seq 
 Total RNA was extracted using the RNeasy RNA purification kit (Oiagen, 
Valencia, CA, USA) and contaminating DNA was removed by on-column DNase 
digestion. One hundred nanogram of RNA was used to synthesize complementary 
DNA libraries using NuGEN’s Ovation RNA-Seq System. The libraries were 
sequenced by 2x75 bases paired-end on HiSeq 2000 instrument (Illumina, San Diego, 
CA).  
ChIP-Seq 
 Before DNA extraction, cells were fixed in formaldehyde and lysed. Genomic 
DNA was then extracted and sheared by sonication, captured by anti-NANOG 
antibody (H-155, cat# sc-33759; Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
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and pulled down by protein-A beads. The libraries were sequenced by 36 bases 
single-end on HiSeq 2000 instrument (Illumina, San Diego, CA). 
Bioinformatics analysis 
 For RNA-Seq, 26-36 million pairs of read from paired end sequencing were 
produced per sample, of which 76-91% of reads were mapped to the reference human 
genome sequence (hg18) downloaded from UCSC. The program TopHat (version 
2.0.7) (209), which implements Bowtie (version 2.0.6), was employed for mapping 
(210). RNA sequence fragments (or read counts) were enumerated by htseq-count 
from HTSeq package (version 0.5.3p9) (155), and genes with fewer than 10 fragments 
in all the samples were removed for DEG analysis. A total of > 14,000 genes that 
remained and DEGs were called using edgeR (version 3.0.8) (156) and a threshold 
cutoff of p-value < 0.05 and fold change (FC) > 1.5.  
 We performed comprehensive unsupervised hierarchical clustering and 
generated heatmaps using the DEGs in all experimental groups (Figure 4-1). The log2 
ratios of each comparison were calculated by rescaling sum of the squares of each 
gene as 1.0. The unsupervised hierarchical clustering was computed by hclust 
function in R with Euclidean distance and ward clustering method, and the heatmap 
was plotted by heatmap.2 function in R. 
 Detailed procedures for GSEA, Oncomine analysis, IPA, and survival analysis 
based on gene signatures were discussed in Chapter 2. In short, transcriptome-
associated biological phenotype was determined by GSEA by interrogating multiple 
PCa datasets, including those in cell lines (e.g., LNCaP), xenografts (e.g., LAPC9), 
normal human prostate basal vs. luminal cells, and different patient samples. The 
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Oncomine ‘Concept analysis’ was performed to discover the gene expression patterns 
in 16 PCa datasets with tumor-to-normal comparison and 13 datasets with metastasis-
to-primary tumor comparison. For IPA, the ‘Upstream Regulator’ analysis was 
conducted with input of the DEGs filtered by cutoff at p-value < 0.05 and FC > 1.5.  
For gene signature-based survival analysis, we used the genes that passed p-value < 
0.05 and median rank < 2000 in meta-analysis of comparison between primary versus 
metastasis in Concept Analysis. The genes that passed the statistical threshold and 
were shared in the datasets with survival information were selected as the signatures. 
The signatures were derived from each unsupervised cluster from previous analysis 
and contained 33 genes from clusters 1 and 3 and 58 genes from cluster 5 (see 
Results below). The predictor to classify subjects was computed by pairwise, ridge, 
LASSO linear regression using LMC package in R. The risk coefficients were 
estimated by the pairwise linear coefficient [107]. The optimized risk coefficient with 
the best discrimination power measured by Area under Curve of the combined 
predictor was applied in the training set to define a threshold for high and low risk 
group separation. The largest cohort (Setlur) (211) was the training set and the Taylor 
dataset (212) was the testing set. 
 For ChIP-Seq, we obtained 22-26 million reads per sample, of which 87-90% 
were mapped to human reference genome (hg18) and 66-70% were uniquely mapped. 
To quantify the peak density, only uniquely mapped reads were counted. Also, only 
one copy of the reads was kept for all the reads mapped to the same genomic location. 
The peaks were called using model-based analysis of ChIP-Seq (MACS) 1.3.7.1 (213). 
The scanning window size was set at 300 bp and the cutoff p-value was set at 1e-5. 
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Differential peaks were identified by comparison between with and without DOX and 
subjected to NANOG and NP8 immunoprecipitation after the background peak 
subtraction. The background was the peak captured by IgG and NANOG in pLVX 
vector only with DOX treatment. In total, we obtained 14,331 NANOG1 and 14,449 
NP8 peaks, of which 1,342 NANOG1 and 1,313 NP8 peaks were located in the 
promoter region defined as −5 kb to +0.5 kb from transcription start site (TSS). 
 The distribution heatmap was generated by centering the peaks on NP8 with a 
range of upstream and downstream 10 kb. Whole regions were divided into 250 bins, 
and the average reads per kilobase transcript per million reads (RPKM) were 
calculated in each bin and plotted by heatmap.2 function in R. The presentation order 
was sorted by intensity of NP8 peaks and the classification of co-occupancy of nuclear 
factors, including three factors (NP8/FOXA1/AR), two factors (NP8/FOXA1 or 
NP8/AR), and one factor (NP8 only). The enriched motifs of 100 bp flanking the 
summit of top 800 peaks in NANOG and NP8 binding region were identified by 
MEME-ChIP (151) and compared to known motifs by TOMTOM in MEME Suite 
(version 4.9.0). 
 Of note, both RNA-Seq and ChIP-Seq data were analyzed by collaboration with 
Dr. Yue Lu and her bioinformatics team of Next Generation Sequencing (NGS) core at 
Science Park. 
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Figure 4-1. Experimental schema (adapted from (151) Jeter, C. R., B. Liu, Y. Lu, H. P. 
Chao, D. Zhang, X. Liu, X. Chen, Q. Li, K. Rycaj, T. Calhoun-Davis, L. Yan, Q. Hu, J. Wang, 
J. Shen, S. Liu, and D. G. Tang. 2016. NANOG reprograms prostate cancer cells to castration 
resistance via dynamically repressing and engaging the AR/FOXA1 signaling axis. Cell 
discovery 2: 16041).  
The inducible NANOG1 or NP8 expression was controlled by the binary Tet-ON system, 
which overexpresses target genes via the tetracycline response element (TRE) after 
administration of doxycycline (DOX). The pLVX vector only was the control group. For ChIP-
Seq, samples were collected at day 5 after DOX induction. For RNA-Seq, samples were 
harvested at two different time points for both AD and AI conditions. 
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4.4 Results 
 The main goal of this project is to understand how NANOG reprograms the bulk 
AD LNCaP cells to the AI, stem cell-like state (93). Practically, through transcriptome 
and ChIP-Seq analyses, we hope to test the two alternative, although not necessarily 
mutually exclusive, hypotheses stated earlier, i.e., through engaging the pluripotency 
network and/or mainly through engaging the lineage-specific TFs. We first focused on 
transcriptome analysis in LNCaP cells upon NANOG1 or NP8 induction for various 
intervals of time under either AD (serum-containing) and AI (in CDSS medium) 
conditions (Figure 4-1). Unsupervised hierarchal clustering showed that the overall 
DEG profile of NANOG1 induced cells was very similar to that in NP8-induced cells in 
AD condition. Dendrogram of hierarchical clustering of DEGs revealed that the overall 
transcriptional responses to NANOG induction were more similar in AD or AI 
conditions than between AD and AI conditions. Of interest, total DEGs were clustered 
into 11 groups (data not shown) with 6 clusters identified that could potentially be 
involved in mediating distinct transcriptional responses involved in NANOG-induced 
LNCaP cell reprogramming (Figure 4-2). Genes in clusters 1, 3, and 4 appeared to be 
only regulated by NANOG induction independently from androgen context and time 
course of induction, but genes in clusters 2, 5, and 6 showed time and androgen 
dependence coincident with the effect by NANOG induction (Figure 4-2).  
 The DEGs in clusters 1 (95 genes) and 3 (163 genes) exhibited an overall 
similar expression pattern, which was persistently suppressed by NP8 (Figure 4-2). 
The Oncomine concept analysis revealed that 42 of the total 258 genes in clusters 1 
and 3 were downregulated in primary prostate tumors compared to normal tissues and 
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58 genes downregulated in metastases compared to primary tumors (Figure 4-3A). 
Also, 20 genes, including AHNAK and AZGP1, were commonly downregulated in both 
comparisons (Figure 4-3B). Both AHNAK and AZGP1 have been reported to be tumor 
suppressors (214, 215), and downregulation of these genes in primary tumors and 
metastases imply potential tumor-suppressive functions for, at least, some of these 
genes. Consistent with this idea, GSEA revealed that NANOG-repressed genes in 
cluster 1 were associated with the gene expression profiles present in normal 
differentiated (mature) prostate luminal epitheilal, differentiated PSA+ PCa, low-grade 
tumor, and AD PCa cells, as well as in patient tumors before ADT (Figure 4-3C). Thus, 
genes in cluster 1 are generally associated with more differentiated, low-grade, and 
androgen-sensitive tumor phenotypes. A similar association was also observed with 
the NANOG-repressed genes in cluster 3 (Figure 4-3D) and in the analysis of DEGs in 
both cluster 1 and cluster 3 (Figure 4-3E). Significantly, the cluster 1 DEGs repressed 
by NANOG contained classical AR downstream targets involved in cell differentiation, 
such as KLK3 (PSA), KLK2, NKX3.1, TMPRSS2, LRIG1, and ELL2. To determine the 
potential clinical significance of the NANOG-repressed genes in clusters 1 and 3, we 
derived a 33-gene signature using the clinical information in Oncomine applying 
comparison of differentially expressed genes in primary and metastatic tumor, which 
successfully classified patients into high- and low-risk groups in a training cohort 
(Figure 4-3). Cox proportional hazards model computing survivor function and Kaplan-
Meier survival analysis successfully predicted clinical outcome in an independent 
testing cohort, with low expression of these genes associated with poor outcome 
(Figure 4-3F). These results suggest that the genes in cluster 1 and 3 are not only 
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associated with differentiated and low-grade tumor phenotypes but also are 
candidates of gene signatures to predict the clinical outcome. 
 DEGs in clusters 2 and 6 (136 and 73 genes, respectively) shared somewhat 
similar dynamic expression patterns, first upregulated by NP8 in AD conditions at day 
5 and then moderately downregulated at day 12. Cluster 2 genes were significantly 
downregulated in AI conditions at both time points (Figure 4-2). Of interest, genes in 
these two clusters included AKR1C1, AKR1C3, UGT2B4, UGT2B15, UGT2B17, 
CREB5, BMP6, ID1 and ID3, many of which are well known to be involved in 
androgen metabolism and catabolism (see Discussion). In sharp contrast to cluster 1 
and 3 DEGs comprising predominantly downregulated genes, the genes in cluster 4 
(139 genes) were persistently activated by NP8 (Figure 4-2). Many of the genes in this 
cluster, exemplified by ABCG2, LMO2, TERT, NEDD9, and RDX, are known to be 
expressed in, and functionally regulate, SCs and CSCs. Indeed, GSEA correlated this 
DEG cluster with CSC and castration-resistant phenotypes (Figure 4-4). We also 
examined the mRNA levels of iPSC reprogramming factors including OCT4, SOX2, 
KLF4, and MYC, in our RNA-Seq data. As shown in Table 4-1, none of these factors 
except MYC were significantly upregulated. We previously showed that NANOG 
induction in LNCaP cells led to increased MYC protein levels in vitro and in vivo (93). 
The current RNA-Seq results indicated that NANOG induced MYC mRNA levels in AI 
d7 (2.14X p-value < 0.001) and AI d22 (1.63X p-value < 0.001), suggesting that 
NANOG upregulates MYC in androgen deprivation conditions. 
 Genes in cluster 5 were upregulated by NP8 in the absence of androgen but 
more prominently induced in long-term AI conditions (Figure 4-2). Of the total 240 
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DEGs in cluster 5, the Oncomine concept analysis showed that 59 genes were 
significantly upregulated in patient tumors compared to normal prostate tissues and 
122 in metastases compared to primary tumors (Figure 4-5A). Also, 40 genes were 
commonly upregulated in both comparisons (Figure 4-5B). Annotation of the DEGs in 
cluster 5 unveiled that, strikingly, more than half of the genes were involved in DNA 
replication, cell cycle, and mitosis, highlighted by CDK1, CKS2, UBE2C, BUB1, 
AURKB, and MCM5/7. In support, GSEA demonstrated that the cluster 5 DEGs were 
associated with more aggressive, metastatic, and castration-resistant tumor 
phenotypes (Figure 4-5C). A 58-gene signature was derived from cluster 5, including 
all the genes significantly upregulated in metastasis versus primary comparison by 
Oncomine Concept analysis, which successfully predicted patients’ survival outcome 
in a training set and independent testing dataset by Cox proportional hazards model 
and Kaplan-Meier analysis (Figure 4-5D). 
 The above time-related RNA-Seq analysis in both AD and AI conditions has 
revealed changes in AR transcriptome and in genes associated with SC/CSC 
regulation, DNA replication, cell-cycle control, and cell motility but not in genes 
associated with OCT4/SOX2 signaling. These results seem to suggest that NANOG-
induced LNCaP cell reprogramming may primarily engage prostate/PCa-specific 
lineage factors such as AR rather than the endogenous reprogramming and 
pluripotency factors such as OCT4 and SOX2. To test this possibility, we examined 
NANOG genomic occupancy in LNCaP cells by performing NANOG1 and NP8 ChIP-
Seq experiments (Figure 4-1). A total 14,449 NP8 and 14,331 NANOG1 peaks were 
identified, respectively. MEME motif analysis followed by TOMTOM analysis revealed 
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that, to our surprise, the FOXA1 motifs were the top and most highly enriched motifs, 
identified in 583 peaks of the top 800 NP8-binding sites (Figure 4-6A). FOXA1 is a 
well-established ‘pioneer’ factor for AR. A meta analysis of center of distribution (+/- 
10 Kb) heatmaps using published data confirmed that, remarkably, AR and FOXA1 
co-occupied more than 50% of NP8-binding sites, and AR or FOXA1 separately co-
occupied another 40% of NP8-binding sites with each occupying 20% of the sites 
(Figure 4-6B) among all the 14,449 NP8 peaks. Examination of NANOG binding to the 
genomic loci of OSKM revealed only slightly increased Nanog binding to Myc at -10 kb 
(151). These analyses support the scenario that NANOG reprograms LNCaP PCa 
cells by physically binding to the AR and FOXA1 genomic loci and primarily 
‘interfacing’ with the AR/FOXA1 signaling axis.  
 Integrated analysis of the ChIP-Seq and RNA-Seq data provides further 
support to this interpretation. For instance, the DEGs in clusters 1 and 3 were mostly 
(61%) co-occupied by NP8, AR, and FOXA1 simultaneously (Figure 4-6C). In cluster 
4, two genomic binding patterns were enriched, NP8/AR/FOXA1 co-occupation or 
NP8-only (Figure 4-6C). On the other hand, the DEGs in clusters 2 and 6 were co-
occupied by NP8/AR/FOXA1, NP8/AR, or NP8/FOXA1 (Figure 4-6C). These results, 
collectively, indicate that NANOG reprograms LNCaP cells to the castration-resistant 
‘stemness’ state (93) via, primarily and dynamically, engaging the AR/FOX1 
transcription factors in a dynamic manner. Surprisingly, however, none of these three 
transcription factors bound to the genomic regions of DEGs in cluster 5 (Figure 4-6C). 
When we performed IPA Upstream Regulator analysis in attempt to decipher the 
potential transcription factors involved in regulating the cluster 5 genes, we found that 
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MYC was the common upstream transcription factor of a cohort of mitosis genes 
upregulated by NP8 induction (Figure 4-6D). Reciprocally, these DEGs were also 
enriched in a MYC oncogenic signature (Figure 4-6E). Therefore, during NANOG-
induced reprogramming of AD LNCaP cells, MYC might be the pivotal downstream 
transcriptional regulator of the mitosis and cell cycle-related genes. 
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Figure 4-2. Unsupervised hierarchical clustering and heatmap for differentially 
expressed genes (adapted from (151) Jeter, C. R., B. Liu, Y. Lu, H. P. Chao, D. Zhang, X. 
Liu, X. Chen, Q. Li, K. Rycaj, T. Calhoun-Davis, L. Yan, Q. Hu, J. Wang, J. Shen, S. Liu, and 
D. G. Tang. 2016. NANOG reprograms prostate cancer cells to castration resistance via 
dynamically repressing and engaging the AR/FOXA1 signaling axis. Cell discovery 2: 16041).  
DEGs were defined as the gene expression that passed the cutoffs, FC ≥ 1.5 or ≤ 0.67 and p-
value < 0.05. In total, there were 1,154 DEGs, including 215, 262, 420, and 605 DEGs, for 
NP8 induction in AD condition collected at day 5 and 12, and in AI condition collected at day 7 
and 22, respectively. 
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Figure 4-3. Deciphering transcriptome profiles of cluster 1 and 3 DEGs (adapted from 
(151) Jeter, C. R., B. Liu, Y. Lu, H. P. Chao, D. Zhang, X. Liu, X. Chen, Q. Li, K. Rycaj, T. 
Calhoun-Davis, L. Yan, Q. Hu, J. Wang, J. Shen, S. Liu, and D. G. Tang. 2016. NANOG 
reprograms prostate cancer cells to castration resistance via dynamically repressing and 
engaging the AR/FOXA1 signaling axis. Cell discovery 2: 16041). 
A. Heatmaps of genes (in clusters 1 and 3) downregulated in prostate tumors compared to 
normal/benign tissues and metastases compared to primary tumors by Concept Analysis 
in Oncomine database. Only the genes with significant downregulation (p-value < 0.05) 
were presented in the heatmaps. 
B. Venn diagram of the commonly downregulated genes in both comparisons. In total, 42 
genes were significantly downregulated in normal vs. cancer comparisons, 58 genes in 
primary tumor vs. metastases comparisons, and 20 genes in both comparisons. 
C-E. GSEA showing gene signature enrichment in cluster 1 (C), cluster 3 (D), and cluster 1 
and 3 (E) of DEGs. The DEGs classified into cluster 1 were associated with more 
differentiated tumor type or cell type, AD tumor, and before ADT. 
F. A 33-gene expression signature derived from clusters 1 and 3 as a predictor of survival in 
PCa patients. Thirty-three genes were selected from comparison of primary vs. metastatic 
tumors based on Concept Analysis from Oncomine. The Setlur dataset served as training 
set and the Taylor dataset as the testing set. 
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Figure 4-4.  Gene signatures uncovered in the cluster 2 and cluster 6 DEGs (adapted 
from (151) Jeter, C. R., B. Liu, Y. Lu, H. P. Chao, D. Zhang, X. Liu, X. Chen, Q. Li, K. Rycaj, 
T. Calhoun-Davis, L. Yan, Q. Hu, J. Wang, J. Shen, S. Liu, and D. G. Tang. 2016. NANOG 
reprograms prostate cancer cells to castration resistance via dynamically repressing and 
engaging the AR/FOXA1 signaling axis. Cell discovery 2: 16041). 
The DEGs classified into cluster 2 were associated with biological phenotypes, such as PSA-, 
AI condition, and after ADT. On the other hand, the DEGs clustered into cluster 6 tend to 
associated with transcriptome profiles of PSA+ cell, AD patient, and patient tumor before ADT. 
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Figure 4-5. Deciphering the transcriptome profile of cluster 5 DEGs (adapted from (151) 
Jeter, C. R., B. Liu, Y. Lu, H. P. Chao, D. Zhang, X. Liu, X. Chen, Q. Li, K. Rycaj, T. Calhoun-
Davis, L. Yan, Q. Hu, J. Wang, J. Shen, S. Liu, and D. G. Tang. 2016. NANOG reprograms 
prostate cancer cells to castration resistance via dynamically repressing and engaging the 
AR/FOXA1 signaling axis. Cell discovery 2: 16041). 
A. Heatmaps showing the genes in cluster 5 that were upregulated in prostate tumor vs. 
normal/benign tissue (left) and metastases vs. primary tumor (right) comparisons. 
Heatmaps presented the genes in cluster 5 with significant upregulation (median rank < 
6000 and p-value < 0.05) in Oncomine by Concept Analysis.  
B. Venn diagram of the common DEGs in both comparisons of prostate tumor vs. 
normal/benign tissue and metastases vs. primary tumor in (A). In total, 40 genes were 
significantly upregulated in both comparisons. Also, there were 19 genes uniquely 
upregulated in normal/benign vs. cancer and 82 genes in primary vs. metastatic tumor. 
C. The gene signatures uncovered in the cluster 5. All the DEGs classified into cluster 5 were 
ranked and analyzed. The DEGs in cluster 5 were associated with tumor development, 
metastasis, and AI phenotype by GSEA. 
F. A 58-gene expression signature derived from cluster 5 as a predictor of survival in PCa 
patients. The 58 genes were selected by comparisons of primary vs. metastatic tumors 
based on Oncomine Concept Analysis. The Setlur dataset was used as the training set 
and Taylor dataset was testing set. 
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Figure 4-6. NANOG reprograms LNCaP cells via engaging FOXA1 and AR (adapted from 
(151) Jeter, C. R., B. Liu, Y. Lu, H. P. Chao, D. Zhang, X. Liu, X. Chen, Q. Li, K. Rycaj, T. 
Calhoun-Davis, L. Yan, Q. Hu, J. Wang, J. Shen, S. Liu, and D. G. Tang. 2016. NANOG 
reprograms prostate cancer cells to castration resistance via dynamically repressing and 
engaging the AR/FOXA1 signaling axis. Cell discovery 2: 16041). 
A. The FOXA1 motif was identified as the most highly enriched in the top 800 peaks from 
NP8 ChIP-Seq, as analyzed by MEME followed by TOMTOM. The left is FOXA1 motif and 
the right is the frequency of FOXA1 motif bound by NP8 with the significant occurrence (E-
value = 1.3e-310). 
B. Intensity distribution heatmap of ChIP-Seq signal centered by NP8 peaks with a range of 
±10 kb. The peaks were sorted by intensity of NP8 signal. 
C. Inspection of NP8, AR, and FOXA1 co-occupancy on the DEGs in each cluster. The co-
occupancy was examined by Fisher’s exact test with range of ± 50kb from the center of 
the peak and y-axis was the p-values of NP8/AR/FOXA1, NP8/AR, NP8/FOXA1, or NP8 
occupancy on the DEGs in each cluster. 
D. The Upstream Regulator Analysis of gene expression reveals MYC and FOXM1 as the 
two major NP8 downstream transcription factors in regulating cluster 5 genes. The 
Upstream Regulator analysis was performed for a cohort of genes lack of binding by any 
of NP8, AR or FOXA1 to find the potential downstream mediators of Nanog signaling. 
MYC (Z-score = 4.262 and p-value = 6e-7) and FOXM1 (Z-score = 4.578 and p-value = 1e-
23) were predicted as two major NP8 downstream transcription factor mediating its 
transcriptional network. 
E. MYC oncogenic signature was enriched in NP8 induced transcriptome, under both AD and 
AI conditions. 
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4.5 Discussion   
 The main goal of this project was to understand how, at the molecular level, a 
single stemness factor, NANOG, could reprogram a largely differentiated somatic PCa 
cell line, LNCaP, to the castration-resistant and stem-like state. Bioinformatics 
analyses of the integrated RNA-Seq and ChIP-Seq results suggest that NANOG 
accomplishes this feat, primarily, by dynamically repressing and engaging the 
AR/FOXA1 signaling axis, although NANOG also engages MYC to regulate cell 
cycle/mitosis related genes, especially during late stages of reprogramming under AR-
blocked conditions (Figure 4-7). Importantly, integrated analyses of RNA-Seq and 
ChIP-Seq data reveals an intricate portrait of NANOG genomic binding and its 
transcriptional output in the course of LNCaP cell reprogramming (Figure 4-7). Many 
DEGs in clusters 1 and 3 are conventional AR downstream genes, which are 
repressed by NP8 and co-occupied by NP8/AR/FOXA1. These genes include KLK3, 
which encodes PSA and represents the best know AR target and a clinically used 
diagnostic and prognostic biomarker for PCa, NKX3.1, an androgen-regulated 
homeobox TF, and ELL2, a transcriptional elongation factor. Both NKX3.1 and ELL 
are direct downstream target genes of AR contributing to prostate differentiation (216, 
217). Reduced KLK3 mRNA expression is consistent with earlier findings that 
overexpression of NANOG1 or NP8 reduces PSA protein levels (151). Altogether, 
these results suggest that early during, and throughout the process of, NANOG-
induced LNCaP cell reprogramming, NANOG impedes AR/FOXA1 transcription 
machinery to suppresses ‘conventional’ AR target genes and genes associated with 
cell differentiation and tumor suppression (Figure 4-7).  
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 Other interesting genes in clusters 1 and 3 that also possess tumor-
suppressive functions include AHANK (214) and AZGP1 (215). Both genes function 
as tumor suppressors through TGFβ signaling. TGFβ is well known to function as a 
tumor suppressor via SMAD in early stages of tumorigenesis and as a tumor promoter 
in advanced and metastatic tumors via non-SMAD pathways (218). AHANK directly 
interacts with Smad2/3 and the complex translocates into the nucleus, resulting in 
downregulation of c-MYC, inhibition of cyclin D/CDK4 and subsequent cell-cycle arrest 
(214). The AHANK-MYC connection through Smad2/3 could indirectly contribute to 
NANOG-induced MYC expression and transcriptome. AZGP1, on the other hand, 
functions as gatekeeper for TGFβ1-mediated ERK2 phosphorylation, which blocks 
cross talk between TGFβ/ERK signaling and epithelial-mesenchymal transition (215). 
Although the biological functions of AHNAK and AZGP1 have been investigated in 
other cancers, our current findings also implicate both molecules, and, potentially, 
TGFβ, in NANOG-induced pro-differentiation and tumor suppression during the 
reprogramming process.  
 The DEGs in cluster 2 and, in particular, cluster 6, are upregulated at the early 
stage of NP8 induction in AD conditions but then downregulated by NP8 in AI 
conditions (Figure 4-2). Several members (e.g., AKR1C1, AKR1C3, UGT2B4, 
UGT2B15, and UGT2B17) of the two steroid hormone metabolic enzyme families, 
uridine diphosphate-glucuronosyltransferase (UGT) and aldo-keto reductase (AKR), 
are in the DEGs in these 2 clusters. AKR1Cs are known for catalyzing the reduction 
and inactivation of DHT (219). The glucuronidation activities of UGT2B15 and 
UGT2B17 locally inactivate androgens. Suppressing UGT2B15 and UGT2B17 leads 
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to increased bioactive DHT and stimulates the expression of AR dependent genes 
(220). Thus, NANOG-induced upregulation of AKR1C1, AKR1C3, UGT2B4, 
UGT2B15, and UGT2B17 genes in AD conditions might cooperate with repression of 
AR downstream pro-differentiation genes (in clusters 1 and 3) to dampen AR-
mediated differentiation signaling at early time (day 5) (Figure 4-7). On the other hand, 
under AI conditions and especially at a later time point (day 22) when LNCaP cells are 
partially or even completely reprogramed (Figure 4-7), these gene are downregulated, 
which, theoretically, might lead to decreased androgen catabolism and increased 
androgen levels in the cells. This phenomenon, called intracrine androgen synthesis 
(221, 222), has been reported in PCa cell cultures in vitro and prostate tumors in vivo.   
 The DEGs in cluster 4 are very interesting and include many involved in SC 
and CSC genes, which are persistently co-occupied by NP8/AR/FOXA1 and 
upregulated by NANOG in both AD and AI conditions. For example, ABCG2, similar to 
CD133 and integrin α2β1 (223),  is one of the PCa stem/progenitor cell markers and 
the ABCG2+, CD133+ and α2β1+ cell populations overlap with one another (103). 
ABCG2 is an ABC transporter and functions as an energy-dependent efflux pump that 
has been implicated in multi-drug resistance (224). Upregulated ABCG2 might 
contribute to NANOG-induced castration resistance in LNCaP cells by pumping out 
steroid hormones, as reported by Huss et al (225). LMO2, a regulator of yolk sac 
erythropoiesis (226), has been implicated in PCa progression, and LMO2 mRNA 
expression correlates with Gleason score and metastasis in clinical samples and is 
high in androgen-independent cell and tumor lines (227). TERT, encoding the catalytic 
subunit of telomerase, is responsible for maintaining telomere length and promotes 
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cell immortality. TERT is highly expressed in ESC (228) and CSC (229, 230) and 
potentially contributes to indefinite self-renewal capacity of stem-like cells. In support, 
PCa cells with high TERT expression possess SC gene signatures, long-term tumor-
propagating capacity, and ability of symmetric self-renewal of CSCs (231).  
 Contrasting with genes coordinately regulated by NP8/AR/FOXA1, roughly 20% 
cluster 4 genes are bound by NP8 alone. GO analysis implicates most of these genes 
in potentially regulating cell motility, invasion, and metastasis. For example, NEDD9 is 
a crucial mediator of TGFβ regulated EMT and invasion via upregulating EMT TFs 
and effectors including BCAR1, Snail, Slug, and MMP14, as well as activating ERK 
signaling (232). Another example is RDX, which is required for PCa cell migration by 
regulating epithelial polarity via Rac1 and forming adherens junctions via VavGEF 
(233). Of note, the androgen-context independent nature of these 20% NANOG-
upregulated cluster 4 genes may relate to the absence of AR binding to cis-elements. 
 Genes in cluster 5 are strongly upregulated in the absence of androgen, 
especially at the later time point (AI d22), implying that the development and growth of 
AI tumors promoted by NANOG may rely, greatly, on these genes. Strikingly, more 
than half of the cluster 5 DEGs are involved in cell cycle progression and cell division, 
especially M-phase cell-cycle genes highlighted by UBE2C. Previous studies have 
shown that AR promotes G1/S transition in androgen-dependent PCa cells in 
presence of androgen (234), whereas AR selectively upregulates M-phase genes and 
accelerates M-phase transition in AI PCa cells (140). Furthermore, histone H3K4 
methylation and FOXA1 are recruited to UBE2C and CDK1 enhancers in AI PCa cells. 
UBE2C is an E2 ubiquitin-conjugating enzyme that works with ubiquitin ligases, 
	 111	
APC/C, to degrade cyclin B and terminate the M phase (235). CDK1 is a kinase that 
partners with cyclin A and cyclin B during the G2/M stage of cell cycle (236). Both 
CDK1 and UBE2C are in cluster 5, significantly upregulated in the absence of 
androgen and co-occupied by NANOG/FOXA1/AR on their enhancers. Other M-phase 
and cell cycle genes such as Bub1 and AURKB are also upregulated in cluster 5. 
BUB1 function as a scaffold kinase to stabilize kinetochore during spindle assembly, 
and BUB1 coordinates spindle checkpoint signaling and response (237). AURKB 
participates in multiple functions during cytokinesis and in mitotic control during G2/M 
transition, via regulation of chromatin posttranslational modifications, and microtubule-
kinetochore attachment and separation (238).  
 Surprisingly, the majority of the cluster 5 genes are not bound by any 
combination of NP8, AR, or FOXA1. MEME analysis infers that MYC might be a 
potential upstream regulator of these genes. Indeed, NANOG occupies a site -10 Kb 
from the TSS of c-MYC and induces c-MYC expression in PCa cells (93). Additionally, 
the DEGs in cluster 5 are highly associated with a MYC oncogenic signature (Figure 
4-6E). MYC represents a common response hub downstream of many growth and 
proliferation promoting signaling pathways, including WNT/b-catenin, PI3K/AKT, 
ERK/MAPK, and SMAD (239). In PCa, MYC expression not only promotes PIN 
(Prostate Intraepithelial Neoplasia) precursor lesions, but MYC amplification and 
overexpression are also associated with CRPC development (240-242). Therefore, 
NP8 may take advantage of MYC and its downstream target genes to reprogram the 
PCa transcriptome in the absence of androgen, both directly and indirectly. In this 
regard, the NANOG-induced LNCaP cell reprogramming, compared with iPSC 
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reprogramming by OSKM factors from somatic cells such as fibroblasts, seems to 
involve a ‘hybrid’ mode of mechanism involving one of the OSKM quartet, i.e., MYC, 
and prostate/PCa-specific lineage factors, i.e., AR and FOXA1. Hence, both of our 
initial hypotheses seem to be operational in NANOG-mediated reprogramming of PCa 
cells.  
 It is striking and also informative that NANOG mediates PCa cell 
reprogramming via converging on the AR/FOXA1 signaling axis. FOXA1 is a pioneer 
TF crucial to endoderm development, prostatic cell differentiation, prostate glandular 
morphogenesis, and CRPC development (243). Previous studies have demonstrated 
FOXA1 to be an AR co-regulator co-occupying the majority of the AR binding sites 
(244) and physically interacting with AR (245) to coordinately activate gene 
expression required for prostatic differentiation. For example, FOXA1 occupies PSA 
enhancers and interacts with DNA-binding domain/hinge region of AR via its forkhead 
domain (245). In addition to direct interactions between FOXA1 and AR, FOXA1 also 
promotes chromatin accessibility via its winged helix domain, leading to increased AR 
accessibility to the nucleosomes (246). FOXA1 has been shown to work with AR in 
three different ways: independent from AR, as a pioneering factor for AR (i.e., FOXA1 
required for AR recruitment), and competing with AR (FOXA1 depletion is required for 
AR recruitment) (247). Interestingly, the stoichiometric ratio of AR and FOXA1 seems 
to dictate the mode of AR functions. Thus, a relatively higher level of AR results in AR 
binding dominantly and enforces AR target gene transcription even without androgen; 
equilibrium of AR and FOXA1 results in cooperation between the two factors with 
FOXA1 opening up FKHD regions to interact with AR; and a relatively higher level of 
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FOXA1 leads to opening up of the genome broadly and decreased specific AR-
chromatin binding (93). In our system, the expression levels of FOXA1 and AR are not 
significantly different between NP8 versus control or between AD versus AI conditions 
(data not shown). Hence, NANOG reprograms LNCaP cells not by simply changing 
the expression levels and ratios of AR and FOXA1. 
 FOXA1/AR signaling is also associated with specific histone modifications and 
DNA methylation patterns. FOXA1 preferentially occupy H3K4me1 and H3K4me2 
(248, 249) and we found that NANOG is enriched at H3K4me1 and H3K4me2 
enhancer sites (151). H3K4me2 distribution on enhancers is cell-type specific and 
defines lineage-specific FOXA1 recruitment on chromatin (250). Thus, FOXA1 and 
NANOG may converge on H3K4me2 marks in a cell-type specific manner ultimately 
regulating and altering the prostate lineage-specific AR cistrome. Furthermore, the 
enhancer regions bound by FOXA1 appears to have lower methylated DNA content 
than juxtaposing genomic regions (251). These mechanisms suggest that NANOG 
may reprogram the AR cistrome not only by functioning as a master TF but also by 
partnering with FOXA1 to broadly affect the chromatin and epigenetic environment. 
 In conclusion, our current study indicates that NANOG redirects PCa cell fate 
towards undifferentiated and castration-resistant CSCs via multiple mechanisms: 
hijacking the pre-existent prostate lineage TFs AR and FOXA1 to reprogram the AR 
transcirptome, engaging one of the iPSC reprogramming factors MYC to confer cell-
cycle autonomy, and, likely, modulating chromatin structure to permit dynamic gene 
expression changes required for full reprogramming.   
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Figure 4-7. Overview of Nanog induced reprogramming model in AR+PSA+ LNCaP cells 
(adapted from (151) Jeter, C. R., B. Liu, Y. Lu, H. P. Chao, D. Zhang, X. Liu, X. Chen, Q. Li, 
K. Rycaj, T. Calhoun-Davis, L. Yan, Q. Hu, J. Wang, J. Shen, S. Liu, and D. G. Tang. 2016. 
NANOG reprograms prostate cancer cells to castration resistance via dynamically repressing 
and engaging the AR/FOXA1 signaling axis. Cell discovery 2: 16041).  
A hypothetical model showing that Nanog may interact with FOXA1 and/or AR and their 
responsive elements, forkhead responsive elements (FKHRE) or androgen responsive 
elements (ARE), respectively, to regulate downstream gene expression leading to 
reprogramming of PCa cells. 
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CHAPTER FIVE 
Bioinformatics analyses uncover novel molecular 
mechanisms of castration resistance 
5.1 Background and Preliminary Data 
 Due to the essential role of AR signaling in PCa development, progression, and 
therapy response, ADT (i.e., chemical castration) is the standard-of-care treatment for 
advanced and metastatic PCa as well as for recurrent tumors after radical 
prostatectomy and radiation therapy. The first-line ADT using gonadotropin-releasing 
hormone analogs (or antagonists) suppresses gonadal production of testosterone. 
The recurrent tumor after this initial ADT is referred to as primary CRPC. Further 
treatment of primary CRPC via enzalutamide (a high affinity AR antagonist, also called 
anti-androgen) and abiraterone aims to inhibit continued AR signaling and adrenal 
androgen biosynthesis, respectively. The inevitable emergence of recurrent tumor 
post enzalutamide and abiraterone treatment is termed secondary CRPC.  
 Current treatments for PCa mainly target the AR signaling pathway. However, 
AR heterogeneity has been observed in human PCa and is accentuated in advanced, 
metastatic, and relapsed PCa (25, 123, 252-254). How the heterogeneity in AR 
expression levels impacts PCa biology and PCa cell response to ADT and 
antiandrogens remains unclear. Indeed, when our laboratory analyzed AR expression 
by IHC (immunohistochemistry) in CRPC sections from 195 tissue microarray (TMA) 
cores (Figure 5-1A) and 8 whole-mount slides (Figure 5-1B) obtained from 89 patients, 
we observed three distinct AR expression patterns - overexpression, loss, and 
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subcellular redistribution. Also, when 4 AR+ human PCa xenograft lines (i.e., LNCaP, 
VCaP, LAPC4, and LAPC9) are serially propagated in castrated NOD/SCID or NSG 
mice, we observed distinct ‘evolutionary’ changes in AR expression levels/patterns. 
Thus, castration-resistant LNCaP tumors are characterized by prominent nuclear AR 
(AR+/hi CRPC), VCaP and LAPC4-derived castration-resistant tumors display both 
nuclear and cytoplasmic distribution of AR (nuc/cyto-AR CRPC), and LAPC9 CRPC 
show marked reduction in AR levels (AR-/lo CRPC) (Figure 5-1C). Strikingly, the 
distinct AR expression in the 4 CRPC models has been liked to their different 
responses to second-line ADT therapeutics, enzalutamide: the AR-/lo LAPC9 CRPC is 
enzalutamide-resistant de novo, whereas the three AR+ CRPCs are transiently 
sensitive to enzalutamide followed by emergence of enzalutamide-resistant secondary 
CRPC (Figure 5-1D).  
 As these xenograft models have different genetic backgrounds, my colleague, 
Dr. Qu Deng, employed a zinc finger nuclease mediated integration strategy to 
generate RFP-tagged homogeneously AR-positive (AR+) LNCaP cell clones and 
utilized the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-
cas9 system to generate AR knockout (KO) LNCaP clones (152). Using the 
genetically matched LNCaP cell clones, they performed side-by-side comparisons of 
(RFP+)AR+ and AR-KO cells with respect to their tumorigenic potential and responses 
to enzalutamide. The results showed that AR-KO LNCaP clones manifest high 
tumorigenicity and enzalutamide resistance upon transplantation in castrated mice, 
when compared to AR+ LNCaP cells (Figure 5-1E). Interestingly, AR+ LNCaP cells 
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possess competitive advantages in androgen-containing conditions in vitro in the 
presence of dihydrotestosterone (DHT) (Figure 5-1F).  
5.2 Hypothesis  
 Undoubtedly, AR is a very critical therapeutic target for primary PCa in general. 
Nevertheless, AR expression is highly heterogeneous in primary tumors as well as in 
CRPC and there exists AR-/lo PCa cell population that is inherently insensitive to 
castration and antiandrogens(152). Of note, during progression of androgen-
dependent into androgen-independent tumors, decreased PSA protein levels are 
observed in all 4 CRPC models regardless of changes in AR expression (Figure 5-1G), 
indicating decreased differentiation status and increased PSA-/lo PCa cells and 
‘stemness’ in the experimental CRPC models. 
 These preliminary observations led to my overarching hypothesis that ADT and 
enzalutamide treatment represent a reprogramming process that results in enrichment 
of PSA-/lo PCSCs and increased stemness in CRPC regardless of evolution of the AR 
status. I further hypothesize that ADT (castration) induced reprogramming of 
androgen-dependent AR+ PCa to the castration-resistant state, in both AR+/hi (e.g., the 
LNCaP type) and AR-/lo (e.g., the LAPC9 type) CRPCs, involves common enrichment 
of gene expression profiles known to be associated with, for example, castration, 
stemness, and neurogenesis. On the other hand, I also hypothesize that the AR+/hi or 
AR-/lo CRPCs induced by ADT may possess unique transcriptomes that facilitate their 
individual evolutionary trajectories. In order to dissect the overlapping and distinct 
molecular circuitry of AR+/hi vs. AR-/lo CRPC development, I interrogated the RNA-Seq 
transcriptional profiles of xenografts in intact hosts (AD), and primary CRPC and 
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secondary CRPC in castrated hosts, which recapitulate PCa development and 
disease progression in patients. Analysis of these clinically relevant AR+/hi vs. AR-/lo 
CRPC models sheds light on the possible mechanisms by which these tumors 
progress to castration resistance, and provides potentially novel therapeutic targets. 
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Figure 5-1. AR expression heterogeneity in CRPC and its impact on enzalutamide 
response (adapted from (152) Li Q, D. Q., Chao HP, Liu X, Lu Y, Lin K, Liu B, Tang GW, 
Zhang D, Tracz A, Jeter C, Rycaj K, Calhoun-Davis T, Huang J, Rubin MA, Beltran H, Shen J, 
Chatta G, Puzanov I, Mohler J, Wang J, Zhao R, Kirk J, Chen X, and Tang DG. 2018. Linking 
prostate cancer cell AR heterogeneity to distinct castration and Enzalutamide responses. 
Nature communications.) (performed by Dr. Qiuhui Li and Dr. Xin Chen) 
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A. IHC images of AR protein expression, representative of a total of 195 CRPC cores 
analyzed from three TMAs. 
B. Representative IHC images of AR protein expression in whole-mount sections from two 
CRPC patients. The * indicates the AR-/lo areas. 
C. Representative IHC images of AR protein expression in four xenograft models, LNCaP, 
VCaP, LAPC4, and LAPC9. 
D. Therapeutic responses of CRPC to enzalutamide in four xenograft models. The green 
arrows indicate the enzalutamide treatment starting time and the * indicates the statistical 
significance with p-value < 0.01.  
E. AR+ LNCaP cells are sensitive whereas AR-KO LNCaP cells are resistant to enzalutamide. 
Shown are endpoint tumor images with tumor weight, incidence and p-values (determined 
using unpaired Student’s t-test and Chi-squared test for tumor weight and incidence, 
respectively) indicated. 
F. Competitive advantages of AR+ and AR-KO LNCaP cells in DHT vs. enzalutamide 
containing media. Shown is the ratio of RFP+ (AR+) over GFP+ (KO, AR knockout) LNCaP 
cells. 
G. Decreased PSA protein levels in CRPC models. Shown is the WB analysis of AR, AR-V7 
and its targets in androgen-dependent (AD), castration-resistant prostate cancer (CRPC), 
and enzalutamide-resistant LNCaP and LAPC9 models. P1 - P5 refer to passage numbers. 
The numbers in other panels refer to individual tumors. The * indicates the potential AR 
variants. Note that in the LNCaP AD è primary CRPC, PSA protein levels did not 
significantly change on WB (left). However, since PSA is a secreted protein, we examined 
PSA expression in tumor cells in immunofluorescence and confocal microscopy and results 
showed reduced intra-tumor cell PSA and increased PSA-/lo LNCaP cells in primary CRPC 
(123). 
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5.3 Materials and Methods 
 
Biological models 
 Xenograft models of AD tumors were maintained by injecting purified single 
cells into immunodeficient NSG and NOD/SCID mice for LNCaP and LAPC9, 
respectively. Primary CRPCs were established by subcutaneous (s.c.) injection of 
purified single parental AD cells mixed with Matrigel and serially passaged in 
surgically castrated immunodeficient mice. Secondary CRPCs were generated by s.c. 
injection of primary CRPC cells into castrated immunodeficient mice concurrent with 
enzalutamide treatment (Figure 5-2). In total, four biological replicates of LNCaP (AD, 
primary, and secondary) tumors and five of LAPC9 (AD and CRPC) tumors were 
harvested and utilized in RNA-Seq analysis. Note that since the AR-/lo LAPC9 CRPC 
did not respond to enzalutamide treatment (Figure 5-1D), we did not harvest any 
enzalutamide-treated tumors for RNA-Seq analysis. 
 
Tumor harvest and RNA-Seq 
 After tumors were harvested, total RNA was extracted by RNeasy mini kit 
(Qiagen) and genomic DNA was depleted by on-column DNA digestion. RNA quality 
was checked by bioRobot and 1  g of total RNA was used to prepare cDNA libraries 
by Illumina TruSeq Stranded Total RNA LT Sample Prep kit following the 
manufacturer’s guidelines.  The libraries were ligated with adaptors and then 
sequenced by 2x75 bases paired-end on HiSeq 2000 instrument (Illumina, San Diego, 
CA). 75-98 and 47-70 million pairs of read were produced per sample in LNCaP and 
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LAPC9 samples, respectively. Each pair of reads represents a cDNA fragment from 
the library. 
 
Bioinformatics analysis 
 All reads were quality checked by FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The reads were mapped 
to the reference human genome sequence (hg38) by TopHat (version 2.0.10) (209), 
which implements Bowtie (version 2.1.0) (210) with parameters “-r 50 --mate-std-dev 
50 --library-type fr-unstranded –G”, as mentioned in Chapter 2. More than 80% 
fragments were uniquely mapped to the human genome. The number of fragments 
located on all 60,119 known genes from GENCODE Release 21 (255) was 
enumerated by htseq-count from HTSeq package (version 0.6.1) (155) with 
parameters “-f bam -m union -s reverse”. Genes with fewer than 10 fragments in all 
the samples were removed for differential expression analysis, resulting in a total of 
23,933 genes for LNCaP and 20,842 genes for LAPC9 models. DEseq (version 1.14.0) 
(157) was applied for calling Differentially Expressed Genes (DEGs). 
 The DEGs were the genes passing statistical cutoff of fold change (FC) ≥ 2 and 
the FDR < 0.05. In LNCaP, there were 2,451 DEGs in primary CRPC over AD and 
3,254 in secondary over AD. Also, there were 601 DEGs in secondary over primary 
LNCaP CRPCs by setting cutoff at FC ≥ 1.5 and FDR < 0.05. In LAPC9, there were 
3,929 DEGs in (primary) CRPC over AD. The Venn diagram, heatmaps, and 
landscape profiles were generated as discussed in Chapter 2. For IPA, the DEGs with 
FC ≥ 2 and FDR < 0.05 were run for the Core Analysis. For GSEA, the normalized 
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read count of all genes was included to compare to the gene list enriched in multiple 
clinical and experimental datasets, including those in PCa patient tumors before 
versus after ADT (referred to as before ADT vs. after ADT, (175)), AD versus AI 
LNCaP cells (181), non-recurrent versus recurrent PCa (Rec vs. non-Rec, (256)), in-
house PSA+ versus PSA-/lo (also see Chapter 3), normal prostate basal/stem cells 
versus luminal cells (112), and CRPC adenocarcinoma versus neuroendocrine-like 
CRPC (i.e., CRPC-Adeno vs. CRPC-NE, (257)). The curated gene set C2 of MSigDB 
was used for GO term enrichment. 
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Figure 5-2. Experimental scheme of RNA-Seq in the xenograft models (adapted from 
(152) Li Q, D. Q., Chao HP, Liu X, Lu Y, Lin K, Liu B, Tang GW, Zhang D, Tracz A, Jeter C, 
Rycaj K, Calhoun-Davis T, Huang J, Rubin MA, Beltran H, Shen J, Chatta G, Puzanov I, 
Mohler J, Wang J, Zhao R, Kirk J, Chen X, and Tang DG. 2018. Linking prostate cancer cell 
AR heterogeneity to distinct castration and Enzalutamide responses. Nature 
communications.). 
A. Scheme of generating AR+/hi LNCaP CRPC model. The xenograft tumor line generated in 
intact NSG mice with purified parent LNCaP cells is designated AD tumors and, in 
castrated mice, primary AI tumors. The primary AI tumors treated with, and subsequently 
became resistant to, enzalutamide are designated secondary AI tumors. 
B. Scheme of generating AR-/lo LAPC9 CRPC.  The xenograft tumor line generated in intact 
NOD/SCID mice with parent LAPC9 cells is designated AD tumors and, in castrated mice, 
AI tumors (i.e., CRPC). Note that primary AR-/lo AI LAPC9 tumors did not respond to 
enzalutamide treatment (see Figure 5-1D). 
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5.4 Results 
 To dissect the transcriptomes of different LNCaP tumors at various stages of 
CRPC reprogramming, I performed several types of analysis including: characterizing 
the global transcriptome features, annotating biological functions or pathways of gene 
expression profiles, and conducting more detailed analysis of target genes. First, I 
applied the pair correlation analysis to examine the correlation between samples and 
performed unsupervised clustering to investigate the similarity of the samples. The 
correlation coefficients between samples within the same condition were higher than 
0.90, indicating consistency of the biological replicates (Figure 5-3A). Interestingly, the 
correlation coefficients of primary LNCaP CRPC over AD (0.89-0.91) were higher than 
those in secondary LNCaP CRPC over AD (0.84-0.89), suggesting that the global 
transcriptome profiles gradually diverged along the course of castration and 
enzalutamide treatment (Figure 5-3A). Strikingly, the correlation coefficients of 
secondary LNCaP CRPC over primary CRPC were very high (0.92-0.97), suggesting 
relatively minor changes in transcriptomes during transition from ADT (castration) 
resistance to enzalutamide resistance (Figure 5-3A). Both unsupervised clustering and 
the pair correlation analyses revealed a concordance among biological replicates. 
Furthermore, the global transcriptome features of AD tumors were distinct from those 
in CRPC, but transcriptome features of primary CRPC and secondary CRPC were 
very similar (Figure 5-3A and B).  
 To further analyze transcriptome variations in our biological samples, I 
performed PCA, which applies linear transformation to distinguish datasets according 
to variance. The first principal component successfully separated the AD and CRPC 
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groups and accounted for more than 30% variance of the total, whereas the second 
principal component separated the primary and secondary CRPC and underlie 18% of 
the variance (Figure 5-3C). PCA indicated that the consistency of biological replicates 
and transcriptome profiles gradually changed from AD to primary CRPC and 
secondary CRPC. Specifically, there were 2,451 DEGs in primary LNCaP CRPC over 
AD and 3,254 DEGs in secondary CRPC over AD, when using a cutoff at FC ≥ 2 and 
FDR < 0.05. When using the same cutoff parameters, we only observed slightly >100 
DEGs between secondary vs. primary CRPC (data not shown), again suggesting that 
differences in transcriptomes are rather subtle when comparing enzalutamide-
resistant (secondary) vs. ADT-resistant (primary) LNCaP CRPC. This is not 
particularly surprising as both ADT and enzalutamide target the AR signaling. On the 
other hand, we did observe 601 DEGs in secondary over primary LNCaP CRPCs 
when using the cutoff of FC ≥ 1.5 and FDR < 0.05. In total, 2,033 genes were shared 
between primary CRPC over AD and secondary CRPC over AD, including 1,437 
upregulated and 596 downregulated genes (Figure 5-3D).  
 To help interpret the biological meaning of the transcriptomic changes during 
AD castration è resistance              è resistance transitions, 
functional annotations and comparisons were performed. GSEA, by comparing our 
xenograft CRPC transcriptomes with published datasets, suggests that the overall 
gene expression profiles of both primary and secondary LNCaP CRPCs are enriched 
in genes associated with ADT resistance and neuroendocrine PCa (i.e., CRPC-NE) 
phenotype in patients (Figure 5-4A). CRPC-NE is an aggressive form of CRPC with 
high epithelial plasticity, heterogeneous clinical features and poor prognosis. The 
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canonical pathway analysis of IPA revealed that the DEGs preferentially expressed in 
both primary and secondary LNCaP CRPC over AD were involved in Stem Cell 
Signaling, Lipid Signaling and Neurogenesis (Figure 5-4B left and middle panel). Stem 
cell signaling is enriched in not only secondary CRPC over AD but also in secondary 
over primary CRPC, highlighted by many genes in the STAT3, IGF-1, Wnt/β-catenin, 
TGFβ, and Notch signaling pathways (Figure 5-4B middle and right panel). 
Consistently, the DEGs of both primary CRPC over AD and secondary CRPC over AD 
are highly associated with the gene signatures in PSA-/lo PCSCs as well as normal 
human prostate basal/stem cells (Figure 5-4C).  
 In the LAPC9 model, the overall gene expression profiles in CRPC compared 
with the AD tumors were also enriched in genes that have been associated with ADT 
resistance and recurrence in clinical CRPC (Figure 5-5A). In common with the LNCaP 
CRPC gene expression profiles, the 3,929 DEGs in the LAPC9 CRPC over AD (FC ≥ 
2; FDR < 0.05) were also enriched in lipid signaling and neurogenesis pathways 
(Figure 5-5B). Of note, the axonal guidance signaling, serotonin degradation pathway, 
phospholipase signaling, eicosanoid signaling, and FXR/RXR signaling were all 
enriched in both LNCaP and LAPC9 CRPC models.  
 Paralleling IHC results, AR mRNA expression was progressively upregulated 
along the course of castration and enzalutamide treatment in the LNCaP progression 
model, but much reduced AR mRNA levels were observed in LAPC9 CRPC (Figure 5-
6A and E). Strikingly, though, the two AR downstream target genes, KLK3 and 
FKBP5, were decreased at the mRNA levels in both LNCaP and LAPC9 CRPC with 
KLK3 barely detectable in LAPC9 CRPC (Figure 5-6B and E). This latter observation 
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again indicates that the CRPC, regardless of the AR status, loses differentiation and 
becomes enriched in phenotypically undifferentiated PSA-/lo CSCs.  In support, among 
the CSC genes examined including ALDH7A, BCL-2, CDH2, ITGA2, MYC, and 
STAT3, BCL-2 was prominently and significantly upregulated in both primary and, 
particularly, secondary LNCaP CRPC, as well as in LAPC9 CRPC (Figure 5-6C and 
D). These results suggest that BCL-2 may be a pivotal factor that mediates castration 
and/or enzalutamide resistance in both AR+/hi and AR-/lo CRPC. In addition, BCL-2 was 
the only BCL family member found to be selectively upregulated in clinical CRPC 
(258). Thus, BCL-2 may be a common and critical therapeutic target for enzalutamide-
resistant CRPC. 
 Among the CSC related target genes, BCL-2 is upregulated in both AR+/hi and 
AR-/lo CRPC, particularly associated with enzalutamide treatment (Figure 5-6C and D). 
BCL-2 is a pro-survival molecule regulating apoptosis. However, in both normal and 
transformed cells BCL-2 maintains viability by preventing cell death but does not affect 
proliferation. BCL-2-mediated premalignant cell survival benefit permits acquisition of 
additional oncogenic lesions such as MYC overexpression leading to tumorigeneisis 
(259). Furthermore, BCL-2 mRNA levels have been shown to increase in CRPC 
patients (175). These important findings lead my colleagues to perform combinatorial 
therapeutic experiments by treating mice harboring either AR+/hi or AR-/lo CRPC 
tumors with combination treatment of BCL-2 specific inhibitor, ABT-199, and other 
regimens. We found that combination of enzalutamide with ABT-199, but not GR 
(Glucocorticoid Receptor) antagonist, RU486, dramatically and significantly (P< 0.05) 
inhibited the AR+/hi CRPC tumor incidence (Figure 5-7A). ABT-199 alone inhibited AR-
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/lo CRPC growth and organoid expansion, and enzalutamide did not affect AR-/lo CRPC 
(Figure 5-7B and C). However, combination of ABT-199 with JQ1, BET (Bromodomain 
and Extra-Terminal motif) inhibitor, further suppressed the tumor growth (Figure 5-7B). 
JQ1 is known to transcriptionally downregulate Myc and its target genes and 
significantly attenuate MYC transcriptional program (260). Thus, AR-/lo CRPC might 
undergo MYC-assisted reprogramming (somewhat like NANOG-mediated LNCaP cell 
reprogramming; Chapter 4). In short, the results obtained with our xenograft models 
demonstrate that combination regimens with enzalutamide and inhibitors that target 
CSC signaling may be critical for the prevention and treatment of CRPC.   
 Of note, the AR-/lo LAPC9 CRPC is resistant to AR antagonist de novo, and, in 
fact, treating AR-/lo CRPC with ADT may do more harm than good (261). Interesting, 
however, the AR-/lo CRPC is sensitive to ABT-199 with JQ1 combination regime, 
whereas the GR inhibitors might be efficacious for AR+ CRPC because GR has been 
suggested to play a role in enzalutamide and docetaxel resistance (262). Thus, it is 
vital to tailor the combinatorial treatment strategies for CRPC patients to fit the precise 
tumor phenotype. 
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Figure 5-3. Global transcriptome changes in LNCaP CRPC model (adapted from (152) Li 
Q, D. Q., Chao HP, Liu X, Lu Y, Lin K, Liu B, Tang GW, Zhang D, Tracz A, Jeter C, Rycaj K, 
Calhoun-Davis T, Huang J, Rubin MA, Beltran H, Shen J, Chatta G, Puzanov I, Mohler J, 
Wang J, Zhao R, Kirk J, Chen X, and Tang DG. 2018. Linking prostate cancer cell AR 
heterogeneity to distinct castration and Enzalutamide responses. Nature communications.). 
A. Pair correlation plots for all biological samples. The red line marks the biological replicates. 
B. Unsupervised clustering of all experimental conditions. The results show good separation 
of AD tumors from AI tumors, and primary and secondary AI tumors are closer to each 
other transcriptomically. The cpm values with the top 5% most abundant genes across all 
the samples were removed, and unsupervised clustering was performed with Euclidean 
distance and complete clustering method. 
C. PCA plots presentation of relatedness of all biological samples. The upper was the main 
PCA plots and the bottom bar chart was the eigenvalues of each component over sum that 
means the percentage of variance explained by each component. 
D. Venn diagram showing the overlapping DEGs between primary and second CRPCs over 
AD (using the statistic cutoff of FC ≥ 2 and FDR < 0.05). 
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Figure 5-4. Functional annotation of the AR+/hi LNCaP CRPC transcriptome (adapted 
from (152) Li Q, D. Q., Chao HP, Liu X, Lu Y, Lin K, Liu B, Tang GW, Zhang D, Tracz A, Jeter 
C, Rycaj K, Calhoun-Davis T, Huang J, Rubin MA, Beltran H, Shen J, Chatta G, Puzanov I, 
Mohler J, Wang J, Zhao R, Kirk J, Chen X, and Tang DG. 2018. Linking prostate cancer cell 
AR heterogeneity to distinct castration and Enzalutamide responses. Nature 
communications.)). 
A. The gene expression profile in LNCaP CRPC positively associates with gene sets in ADT-
resistant patient CRPC and patient CRPC-NE. All the DEGs were used in GSEA against 
the gene set of Rajan dataset (175) (left) and Beltran dataset (263) (right). 
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B. Functional annotation of the transcriptome profiles of LNCaP AD tumors and CRPC. 
Presented are the top pathways enriched in primary CRPC over AD (left), and in 
secondary CRPC over AD (middle panel), in secondary over primary CRPC (right panel). 
The statistical cutoff of DEGs was FC ≥ 2 and FDR < 0.05. The right panel was the DEGs 
in secondary CRPC over primary CRPC with the cutoff at FC ≥ 1.5 and FDR < 0.05. 
C. GSEA plots showing that the LNCaP CRPC is enriched in stem cell-associated gene 
signatures. The left two figures were comparison between the top 700 DEGs from primary 
CRPC over AD and secondary CRPC over AD to PSA-/lo stem cell gene signatures 
(manuscript in preparation). The right panel was comparison to the neurogenesis gene 
profile derived from normal prostate basal/stem cells (112). 
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Figure 5-5. Functional annotation of the transcriptome of AR-/lo LAPC9 CRPC (adapted 
from (152) Li Q, D. Q., Chao HP, Liu X, Lu Y, Lin K, Liu B, Tang GW, Zhang D, Tracz A, Jeter 
C, Rycaj K, Calhoun-Davis T, Huang J, Rubin MA, Beltran H, Shen J, Chatta G, Puzanov I, 
Mohler J, Wang J, Zhao R, Kirk J, Chen X, and Tang DG. 2018. Linking prostate cancer cell 
AR heterogeneity to distinct castration and Enzalutamide responses. Nature 
communications.). 
A. The LAPC9 gene expression profiles are enriched in castration-resistant patient tumors in 
the Rajan (175) (left) and Sun (256) (right) datasets. 
B. IPA biological function profiles of the DEGs (using the statistic cutoff FC ≥ 2 and FDR < 
0.05) in the AR-/lo LAPC9 CRPC. 
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Figure 5-6. Examples of DEGs in AR+/hi LNCaP and AR-/lo LAPC9 CRPC models (adapted 
from (152) Li Q, D. Q., Chao HP, Liu X, Lu Y, Lin K, Liu B, Tang GW, Zhang D, Tracz A, Jeter 
C, Rycaj K, Calhoun-Davis T, Huang J, Rubin MA, Beltran H, Shen J, Chatta G, Puzanov I, 
Mohler J, Wang J, Zhao R, Kirk J, Chen X, and Tang DG. 2018. Linking prostate cancer cell 
AR heterogeneity to distinct castration and Enzalutamide responses. Nature 
communications.). 
A-D. Box plots showing the mRNA expression levels of AR (A), several AR target genes (B), 
and representative CSC associated genes (C and D). Statistically significant FDR values 
were indicated in the figures. The y-axis of the box plots was normalized counts 
estimated by DESeq.  
E. RNA-Seq tracks of AR, KLK3, and BCL-2 genes in AR+/hi and AR-/lo CRPC models. The 
tracks were displayed in UCSC genome browser and the maximum height was adjusted 
by the highest expression of each gene in each tumor type. 
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Figure 5-7. The combination treatment for AR+ and AR-/lo CRPC (adapted from (152) Li Q, 
D. Q., Chao HP, Liu X, Lu Y, Lin K, Liu B, Tang GW, Zhang D, Tracz A, Jeter C, Rycaj K, 
Calhoun-Davis T, Huang J, Rubin MA, Beltran H, Shen J, Chatta G, Puzanov I, Mohler J, 
Wang J, Zhao R, Kirk J, Chen X, and Tang DG. 2018. Linking prostate cancer cell AR 
heterogeneity to distinct castration and Enzalutamide responses. Nature communications.). 
A. Treatment schema and results in AR+ CRPC. The top panel shows the experimental time 
line of LNCaP CRPC in NSG mice. The bottom panel presents the tumor incidence and 
weight and χ2 test for tumor incidence at end point. 
B. Treatment schema and results of AR-/lo CRPC. The top panel shows the experimental time 
line of LAPC9 CRPC in NOD/SCID mice. The bottom panel presents the tumor incidence 
and weight and Student’s t-test for weight at end point.  The right panel is the growth curve 
of tumor. 
C. The growth curve of LAPC9 organoid in response to BCL-2 inhibitor, ABT-199, 
enzalutamide (Enza), or both. 
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Discussion  
 AR heterogeneity pre-exists in untreated prostate tumors such that there are 
both AR+ and AR-/lo PCa cells. These two subpopulations of PCa cells seem to co-
evolve under the pressure from ADT/antiandrogens, resulting in the AR+/hi and AR-/lo 
PCa cell subpopulations in patient CRPC. Strikingly, our LNCaP and LAPC9 xenograft 
models, during AD è primary CRPC (ADT resistance) è secondary CRPC 
(enzalutamide resistance) progression, recapitulate this AR heterogeneity. Thus, 
castration gradually reprograms AR+ LNCaP AD tumors to the AR+/hi CRPC phenotype 
whereas castration in AR+ LAPC9 leads to the AR-/lo CRPC phenotype. Significantly, 
the distinct AR phenotypes in the two CRPC models are directly linked to their 
contrasting enzalutamide responses: while the AR+/hi LNCaP primary CRPC remains 
transiently sensitive to enzalutamide, the AR-/lo LAPC9 CRPC is enzalutamide 
resistant de novo. I took advantage of these two unique xenograft CRPC models and 
interrogated the transcriptomes during their progression to castration and/or 
enzalutamide resistance. My analysis overall corroborated my hypothesis and shows 
that castration-induced reprogramming of androgen-dependent AR+ PCa to the 
castration-resistant state, in both AR+/hi and AR-/lo CRPCs, involves common 
enrichment of gene expression profiles known to be associated with castration, 
stemness, and neurogenesis. On the other hand, castration-induced AR+/hi or AR-/lo 
CRPCs are also characterized with unique transcriptomes that facilitate their individual 
evolutionary trajectories. 
 GSEA reveals that gene signatures enriched in LNCaP primary AR+/hi, LNCaP 
secondary AR+/hi, and LAPC9 AR-/lo CRPCs are associated with those enriched in 
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patient CRPC that failed castration and antiandrogen treatment (175). Considering 
that both AR+/hi and AR-/lo xenograft CRPC gene expression profiles correlate similarly 
(NES are 1.76 and 1.67 and FDRs are 0.014 and 0.028, respectively) with the patient 
CRPC gene signatures, these data further demonstrates that both CRPC subtypes are 
present in patient CRPC, as validated by IHC analysis (Figure 5-1). Overall, 
bioinformatics analysis indicates that our experimental CRPC models, regardless of 
the AR expression status, preferentially and commonly express genes known to be 
involved in mediating castration resistance. 
 The second gene category commonly enriched in both AR+/hi LNCaP and AR-/lo 
LAPC9 CRPC is the “Stem Cell Signaling”, including terms such as ‘Human ESC 
Pluripotency’ and ‘STAT3 Signaling’ pathways. Some of these stem cell signaling 
pathways are particularly enriched in enzalutamide-resistant AR+/hi secondary LNCaP 
and AR-/lo LAPC9 CRPC. Included in ‘stemness genes’ are, among many others, BCL-
2, SMAD6, TDGF1, WNT8B, BMP5, FGFR3, BMP6, WNT5A, PDGFRB, and SALL4. 
For example, the secondary (enzalutamide-resistant) AR+/hi CRPC express high levels 
of SALL4 mRNA. Sall4 is a ‘pluripotency’ transcription factor that directly interacts with 
NANOG, and, knocking down SALL4 or NANOG has been shown to alter ES cell 
morphology accompanied by reduced expression of SC genes and increased 
expression of differentiation-associated genes. (264). Although the functions of SALL4 
in cancer are just emerging, its expression has been proposed as a biomarker for 
germ cell tumors such as embryonic carcinoma, sex cord stromal tumors, and yolk sac 
tumors (265). SALL4 is not abundantly expressed in PCa (266) but inhibition of SALL4 
has been reported to reduce proliferation and promotes apoptosis in PCa cells via 
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modulating BCL-2 and BAX expression (267). SALL4 inhibition has also been shown 
to promote apoptosis and reduce proliferation, migration, clonogenicity, and 
tumorigenicity in esophageal squamous cell carcinoma cells (268). In theory, 
enzalutamide and other ADT drugs might reprogram PCa cells by inducing 
pluripotency factors such as SALL4 to mediate resistance. 
 Consistent with a common enrichment of stemness genes in both AR+/hi and 
AR-/lo CRPC, both types of CRPC have significantly reduced mRNA levels of KLK3, 
which encodes PSA, suggesting that both types of CRPC would be enriched in PSA-/lo 
PCa cells, which we had reported in IHC studies (123). We have previously 
demonstrated that the PSA-/lo cell population is enriched in PCSCs and intrinsically 
resistant to castration and antiandrogens (25). It remains obscure whether progression 
of CRPC reprograms the tumor cells to PSA-/lo and/or enriches the pre-existent 
refractory PSA-/lo cells. Regardless, the PSA expression level is markedly and 
progressively decreased and even undetectable in some CRPC patient samples. The 
heterogeneous expression and distribution of AR and discordant expression between 
AR and PSA in CRPC indicates that restored AR may reprogram castration resistant 
gene expression profiling. In AR+ CRPC, the androgen downstream signaling may be 
activated by other epigenetic or transcription factors hijacking the AR signaling 
pathway in the absence of androgen ligand. For example, FOXA1/H3K4 methyl marks 
(269), FOXA1/HOXB1/AR (270), and NANOG/FOXA1/AR (151) have all been shown 
to, independently or cooperatively, occupy regulatory element of AR target genes and 
reprogramming AR cistromes. In the AR-/lo CRPC, the androgen downstream signaling 
will be reactivated by alternative ways and bypassing AR. The possible mechanisms 
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include alternative androgen synthesis, modified AR or associated proteins, and 
unconventional initiation or regulation of downstream signaling cascades. The first 
resistance mechanism in enzalutamide-resistant CRPC is the “glucocorticoid receptor 
take-over”, in which glucocorticoid receptor binds to AR regulated genes owing to 
similarity of DNA binding domain of two nuclear receptors (271). The other resistance 
mechanism is unbalanced force on cell death, like deregulating autophagic cascade 
via activation of AMP-dependent protein kinase (AMPK) and the suppression of 
mammalian target of rapamycin (mTOR) (272). Also, there are enzalutamide 
resistance specific point mutations in AR such as the F876L mutation (273). Therefore, 
combination regimens may enhance efficacy by targeting key pathways in a 
synergistic or an additive manner (274) to prevent or tackle CRPC efficiently. 
 Neural/neuronal gene signatures are also highly enriched in both PSA-/lo CSC 
(see Chapter 3, manuscript in preparation) and PSA- basal/stem cells (112). Perhaps 
that’s one of the reasons that the overall gene expression profiles of our xenograft 
CRPC (which have the PSA-/lo phenotype) correlate with the NE-cancer phenotype 
revealed by GSEA (Fig 5-4A). These proneural genes functionally regulate the 
stem/progenitor cell activities and the proneural differentiation in vitro in freshly 
purified human prostate basal cells (112). Particularly notable in the neurogenesis 
gene signature are some genes involved in regulating axonal guidance, which 
represents a neural development process that promotes axon growth and helps 
establish neuronal connections. In CRPC, several neurogenesis-associated 
morphogens are upregulated including WNT5A, WNT8B, BMP5, and BMP6. 
Interestingly, noncanonical Wnt ligand Wnt5a has been shown to be essential for 
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multiple processes of normal prostate gland development, including bud outgrowth, 
ductal elongation, branching, cell polarity, and lumenization in the mouse prostate 
(275). Expression of BMP6 is induced by WNT5A via PKC/NF-kB pathway, and then 
BMP6 activates BMP-RII and ALK2 leading to SMAD5 phosphorylation and interaction 
with β-catenin. This signaling pathway has been shown to facilitate CRPC 
development (276, 277). Semaphorin (SEMA) genes were also upregulated broadly in 
our CRPC models, including SEMA3A, SEMA3D, SEMA3E, and SEMA5A. SEMA3 
proteins are in the extended family of VEGF molecules and function to compete for 
binding to neuropilin with VEGF family members. SEMA3A cleavage by MMP7 is 
involved in PCa metastasis by disrupting stability of SEMA3A and neuropilin-1-plexin 
complex and trigger downstream FAK signaling (278). SEMA3C activates multiple 
RTKs, EGFR, ERBB2, and MET via Plexin B1 and promotes CRPC growth and 
progression (279). Expression of SEMA3 family members is associated with 
angiogenesis in metastatic CRPC (280).  
 AR-mediated lipid biosynthesis has been shown to be reactivated in 
progression of clinical CRPC (281). Our RNA-Seq data shows that eicosanoid 
signaling pathway is commonly affected during the CRPC progression regardless of 
AR status and stage of progression. Eicosanoids are bioactive hormone-like lipid 
signaling molecules derived from arachidonic acid and released by phospholipase A2 
(PLA2) and metabolized by cyclooxygenases (COXs) and lipoxygenases (LOXs). 
AKR1C3, PLA2G7, and PTGS1 are the common eicosanoid pathway genes 
upregulated in both AR+/hi and AR-/lo CRPC. AKR1C3 is known as Aldo-keto reductase 
family 1 member C3 and plays pivotal roles in steroidogenesis, especially for 
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androgen biosynthesis in the human prostate (282). More importantly, AKR1C3 is 
overexpressed in response to ADT and contributes to CRPC (283, 284). PLA2G7 is 
known as phospholipase 2 group VII in PLA2 family and mediates arachidonic acid 
release from the plasma membrane (285). PLA2G7 suppresses apoptosis and 
induces tumorigenesis, cell adhesion, migration, and invasion, especially in ERG-
positive PCa (285, 286). PTGS1 encodes COX-1, which catalyzes the conversion of 
arachidonate to prostaglandins. COX-1 expression and functions have been 
associated with several cancer types including cancers in the colon (287), ovary (288) 
and prostate (289). PTGS1 may cooperate with PTGS2, as knockdown of both 
molecules synergistically inhibited PCa cell growth in vitro (289).  
 In addition to the above-discussed signaling pathways commonly altered in the 
two subtypes of CRPC, AR+/hi CRPC seems to uniquely rely on steroid signaling 
whereas AR-/lo CRPC uniquely impacts immune/inflammation pathways (152). 
Although the detailed mechanisms are under investigation, these results suggest that 
AR+/hi CRPC remain responsive to steroid hormones that may impart a competitive 
advantage in surviving ADT (Figure 5-4). The AR-/lo as well as AR-NE- (290) CRPCs, 
on the other hand, are enriched in immune/inflammation gene signatures such as 
antigen presentation pathway, adaptive immune cells, and interferon signaling (Figure 
5-5). The exact meaning and significance of the enrichment of such immune and 
inflammation related signatures in AR-/lo CRPC remain to be elucidated. Interestingly, 
however, clinical bone metastatic CRPC appears to display a negative association 
between AR signaling and expression of some immune responses genes such as 
HLA-A (291). In our system, the AR-/lo LAPC9 CRPC expresses high levels of HLA-A 
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(7749 times higher than corresponding AD tumors) whereas AR+ LNCaP CRPC hardly 
expresses any HLA-A (FDR > 0.05).  
 In summary, by interrogating and annotating the RNA-Seq data related to two 
distinct CRPC models that recapitulate the evolution of AD tumors to either AR+/hi or 
AR-/lo CRPC phenotype, my bioinformatics analysis has helped to uncover 
transcriptomic changes both common to the two subtypes of CRPC and unique to 
each subtype. Thus, both AR+/hi LNCaP CRPC and AR-/lo LAPC9 CRPC are enriched 
in genes involved in Stemness, Neurogenesis, and Lipid Signaling. On the other hand, 
AR+/hi LNCaP CRPC preferentially expresses genes associated with Steroidogenesis 
(hormone biosynthesis and metabolism) whereas AR-/lo LAPC9 CRPC is enriched in 
genes that participate in Immune and Inflammation Signaling. These results have, 
overall, tested my starting hypothesis and suggest that, not surprisingly, ADT and 
enzalutamide treatment cause reprogramming of AD PCa cells through inducing 
widespread gene expression changes. There is little doubt that many of these altered 
genes and signaling pathways likely play causative roles in CRPC reprogramming and 
thus represent important regulators of CRPC development. Importantly, my 
bioinformatics analysis has also helped to pinpoint potential therapeutic target(s) and 
strategies for tackling the two subtypes of CRPC, as best illustrated by identification of 
BCL-2 upregulation in both enzalutamide-resistant AR+/hi LNCaP and AR-/lo LAPC9 
CRPC and our therapeutic experiments using the BCL-2 inhibitor ABT-199. 
Consequently, ABT-199 alone inhibits the growth of LAPC9 CRPC while ABT-199 in 
combination with enzalutamide greatly suppresses the emergence of enzalutamide-
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resistant secondary CRPC (152). These preclinical data, originated from 
bioinformatics-based discoveries, have set the stage for novel clinical trials.    
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CHAPTER SIX 
Conclusions and perspectives 
6.1 Conclusions 
 My Ph.D. thesis research has been centered on employing bioinformatics 
approaches and tools to help elucidate intrinsic PCa cell heterogeneity and induced 
PCa cell plasticity. For the former, we interrogated both the RNA-Seq transcriptomes 
and the histone modifications (H3K4me3 and H3K27me3) based ChIP-Seq data sets 
obtained in the CSC-enriched PSA-/lo LNCaP cells and the less tumorigenic PSA+ 
counterparts (Chapter 3). For the latter, I helped analyze and interpret the NGS data in 
PCa cell reprogramming caused by inducible NANOG overexpression in vitro (Chapter 
4) or by chronic castration treatment in vivo (Chapter 5). The results from the 3 
experimental systems have converged on several common findings and also revealed 
some novel insights on each unique model. For example, both unperturbed PSA-/lo 
cells and NANOG- and treatment-reprogrammed PCa cells are enriched in SC and, 
surprisingly, neurogenesis genes. The PSA-/lo and PSA+ subpopulations of LNCaP 
cells, though lineage-related, possess distinct histone modification patterns. NANOG-
induced reprogramming of bulk LNCaP cells to the castration-resistant, stem-like 
state, surprisingly, appears to involve a ‘hybrid’ mode of action, i.e., engaging both 
prostate lineage master factors AR and FOXA1 at early phases and one of the OSKM 
factors, c-MYC, at a late stage. Finally, long-term castration in vivo led to two distinct, 
AR+/hi (LNCaP) or AR-/lo (LAPC9) CRPC models, both of which are enriched in 
SC/CSC as well as neurogenesis gene signatures.  
  Interestingly, although GO analysis reveals “Stem Cell Signaling” as a common 
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term to be enriched in PSA-/lo and the ‘reprogrammed’ PCa cells/tumor, these models 
seem to preferentially express different SC/development genes. For example, 
unperturbed (naïve) PSA-/lo LNCaP cells preferentially express genes such as TGFβ3, 
FZD2, and KLF5, and NANOG-reprogrammed LNCaP cells highly express ABCG2, 
WNT5A, and IGFBP5, whereas treatment-enriched CRPC cells express high levels of 
BCL-2, WNT5A, BMP5, and SALL4. Presumably, these SC genes, in a model-
dependent manner, help sustain cell identity and stemness properties. As targeting 
CSCs has been proposed as an important strategy for cancer therapy (60-66), these 
stemness genes may represent potential therapeutic targets. This is best illustrated by 
the upregulation of BCL-2, a critical CSC gene, in both AR+ and AR-/lo CRPC cells. 
Thus, treatment of AR+/hi LNCaP CRPC with the BCL-2 inhibitor ABT-199 and AR-
targeting enzalutamide significantly prevents the emergence of secondary CRPC, 
whereas treatment of AR-/lo LAPC9 CRPC with ABT-199 alone inhibits CRPC growth. 
In short, CSCs possess stemness properties that are supported by expression of SC 
genes, which can serve as effective therapeutic targets. 
 Our earlier studies have demonstrated that the PSA-/lo cell population is 
enriched in heterogeneous CSC subpopulations, which contribute to CRPC (20, 25). 
Our current studies indicate that naïve (i.e., untreated) PSA-/lo cells possess SC gene 
signatures (Chapter 3). NANOG-reprogramed CSCs and castration-selected PCa cells 
also displayed low cellular PSA expression. Also, cellular PSA expression is 
consistently low in CRPC regardless of the AR status (123, 152). In the Rajan dataset, 
log2 fold change of PSA is -2.68 with FDR 1.12e-09 (CRPCs over primary tumors), and 
log2 fold change of AR is 0.11 with FDR 0.96. These findings in patient ADT-failed 
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tumors support our xenograft studies and imply that cells with low PSA expression 
(i.e., losing differentiation) may play key roles in the evolution of PCa to CRPC. This 
emerging idea has been observed in other investigations that link PSA-/lo cells to 
aggressive PCa variants, such as neuroendocrine prostate cancer (NEPC), which is 
markedly increased in CRPC patients (292, 293). In short, PSA-/lo cells are enriched in 
CRPC, and are linked to advanced PCa phenotypes such as CSC properties and 
NEPC features. 
 Castration-induced NEPC (sometimes called CRPC-NE) is a hormone-
refractory type of PCa with poor prognosis and represents about 25% of late-stage 
treatment-failed disease (294). CRPC-NE, like NEPC de novo (i.e., the primary tumor 
diagnosed as NEPC), frequently expresses mature NE markers such as CHA 
(chromogrannin A) and SYN (synaptophysin). The molecular underpinning of 
treatment-induced NEPC manifestation is not clear, but it may arise from 
transdifferentiation of PCa adenocarcinoma cells (292, 293). Molecularly, CRPC-NE 
generally lacks PSA expression and shows elevated BCL-2 expression, which echo 
our experimental systems. Nevertheless, PSA-/lo PCa cells, NANOG-reprogrammed 
cells, and castration-selected tumors all lack the expression of CHA and SYN. 
Strikingly, however, both naïve PSA-/lo and reprogrammed PCa cells, like the AR-PSA- 
normal prostate basal/stem cells (112), are enriched in neurogenesis genes, which 
normally regulate the neural progenitor cell activities and neural cell development. It is 
tempting to speculate that these neurogenesis genes may promote PSA-/lo and 
treatment-reprogrammed PCa cells to undergo potential differentiation along neural 
lineages and differentiation into neuron-like or neural progenitor-like cells but without 
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pushing them to full NE differentiation. Of interest, NEPC cells are often found to have 
overexpression of cell cycle genes (292) such as UBE2C, cyclin D1, and AURKA, and 
these genes are also upregulated in NANOG-reprogrammed CSCs (151).  
 Enrichment of a neurogenesis gene signature appears to be a common 
phenomenon in PSA- normal basal/stem epithelial cells, PSA-/lo PCa cells, and both 
AR+ and AR-/lo CRPC cells. Although the precise role of these genes in normal 
prostate development, prostate tumorigenesis, regulation of PCSCs, and CRPC 
emergence and evolution into NEPC remains to be elucidated, two pertinent points 
may be worth considering. First, at least some of the neurogensis genes seem to be 
functionally important in regulating the stem/progenitor activities of PCSCs and tumor 
aggressiveness. Thus, quite a few neurogenesis genes preferentially expressed in 
PSA-/lo PCa cells are inversely associated with poor patient survival. Moreover, 
knocking down expression of some of these genes, e.g., NRXN1 and CHRM3, 
attenuates CSC properties and tumorigenicity of PSA-/lo cells. Second, nerves are 
present throughout the prostate stroma, and various types of neural cells and 
neurotransmitters exist in the tumor microenvironment, which may regulate PCSC 
survival and functions through the expression of certain neurogenesis genes such as 
receptors. A recent study demonstrated that adrenergic fibers from the sympathetic 
nervous system had a major impact on tumor initiation via β2- and β3- adrenergic 
receptors, whereas cholinergic fibers from the parasympathetic nervous system were 
found to regulate PCa cell invasion, migration, and metastasis via Chrm1 signals 
(295). Therefore, the role of the neurogenesis program and neurogenesis genes in 
regulating PCSCs and development of CRPC and NEPC will be a fertile ground for 
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future investigation. 
 Lineage related PSA-/lo and PSA+ cells have quite different transcriptome 
profiles and epigenetic landscapes. For instance, many epigenetic factors (e.g., 
ARID2, JMJDIC, KDM5A, KDM6A, KDM6B, SETD2, SETD5, TET1, and TET3) are 
upregulated in PSA-/lo cells compared to PSA+ cells. Epigenetic modifications 
contribute to dynamic plasticity of cancer cells and heterogeneity of cell populations 
that advance tumor progression and treatment resistance (182). Our data suggest that 
various epigenetic regulators involved in multiple epigenetic mechanisms may play an 
important role in regulating the CSC properties of PSA-/lo cells. In PCa, KDMs are 
considered prognostic factors and therapeutic targets (296). For example, both 
KDM6B mRNA and protein expression levels are upregulated in human PCa samples, 
especially in metastatic tumors (297). KDM5A has been suggested as an oncogene 
and potential prognostic factor to predict disease recurrence (296). KDMs, which 
mediate histone lysine demethylation, together with other epigenetic machinery, have 
been implicated in maintaining tumor-initiating cell plasticity and metastatic potential 
(296). Thus, although it is unknown whether epigenetic changes are the cause or 
effect of transcriptomic differences, our data suggest that epigenetic and 
transcriptomic heterogeneity may likely support phenotypic and functional differences 
of lineage-related subpopulations of PCa cells and sustain the inherent CSC features 
of PSA-/lo cells.  
 Transcriptional networks are another critical regulatory mechanism contributing 
to CSC features. For example, NANOG, as a TF, re-directs PCa cell fate towards 
undifferentiated and castration-resistant CSCs via multiple mechanisms. First, 
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NANOG ‘hijacks’ the lineage TF, AR, and pioneer factor, FOXA1, to reprogram the AR 
transcriptome. Late in the reprogramming process, NANOG also engages one of the 
iPSC reprogramming factors MYC to re-establish cell-cycle autonomy. Moreover, 
NANOG may modulate chromatin structure to coordinate dynamic gene expression 
changes required for full reprogramming. It is interesting to note that reprogramming of 
differentiated somatic cells to pluripotent stage generally requires at least 3-4 TFs; 
intriguingly, however, NANOG alone can gradually (in ~2-3 weeks) push LNCaP PCa 
cells back to a more undifferentiated state through activation of transcriptomic 
reprogramming of multiple TF networks. These results indicate that somatic cancer 
cells most likely possess a more permissive epigenetic and transcriptomic 
environment compared with normal cells. 
 Therapeutic reprograming also reshapes a whole transcriptome and triggers 
cells to regain plasticity during the development of CRPC. Interestingly, though, long-
term castration leads to two subtypes, i.e., AR+/hi and AR-/lo, of CRPC, both of which 
are enriched in the expression of, commonly or uniquely, some SC/CSC genes. For 
example, SALL4 is only upregulated in AR+ CRPC. Knocking down SALL4 and/or its 
interacting protein, NANOG, has been shown to alter SC properties in ES cells by 
reducing expression of SC genes and increasing expression of differentiation-
associated genes (264). Also, inhibition of SALL4 expression has been reported to 
reduce proliferation and promote apoptosis in PCa cells via modulation of BCL-2 and 
BAX expression (267). However, the AR+/hi LNCaP CRPC only express high levels of 
SALL4 (152) but not NANOG (151), again suggesting fundamental differences 
between normal ES cells and reprogrammed CSCs. On the other hand, some SC 
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genes (e.g., BCL-2) are commonly overexpressed in AR+ and AR-/lo CRPC subtypes, 
rendering both sensitive to the BCL-2 inhibitor, ABT-199. 
 
6.2 Perspectives 
 My bioinformatics analysis of our cell and xenograft models has raised new 
questions pertinent to understanding PCa cell heterogeneity and plasticity and helped 
open new areas of research. For example, what is the real role of the neurogenesis 
program in regulating intrinsic and induced stemness and invasiveness in PCa cells? 
What is the master regulator(s) of the neurogenesis program? In NANOG-induced 
PCa cell reprogramming, how do epigenetic mechanisms contribute to the 
reprogramming process in addition to NANOG-induced transcriptomic changes? In 
castration-induced xenograft reprogramming, how can we dissect out the (murine) 
host contribution to the transcriptomic changes caused by ADT? Although RNA-Seq 
can identify global gene expression profiles that represent many molecular features of 
tumors (298), there are still some biological and computational confounding factors 
that complicate the translation of transcriptomic profiles into clinical diagnosis (299). 
For instance, untreated tumors may harbor only a small population of CSCs with 
various features and CSC subpopulations may dynamically change during tumor 
progression. Therefore, attempt to distinguish key features of such small subsets of 
CSCs from the random noise of bulk-processed tumors is one of the greatest 
challenges in the RNA-Seq field (300). The fast evolving single-cell RNA sequencing 
may provide high-resolution information of cancer heterogeneity and partially cancel 
the inherent noise from bulky tumor RNA-Seq. Integration of refined histological 
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examination of tumor morphology with various -omics tools and tailored bioinformatic 
and statistic analysis may also help mitigate the issue of tumor heterogeneity. 
 Cancer has been classically defined as an abnormal, uncontrolled, growth of 
transformed cells, so conventional chemotherapies (e.g., paclitaxel) mainly target 
rapidly proliferating cells. Recent appreciation and intensive studies of tumor cell 
heterogeneity have opened a new era in cancer research, leading to the development 
of precision oncology, which aims to personalize accurate and effective treatment 
strategies for each individual cancer patient based on integrative evidence from a 
tumor’s molecular (-omics) profile (e.g., genomics, transcriptomics, proteomics, 
metabolomics, and epigenomics), disease theranostics (e.g., disease diagnosis and 
prognosis), and pharmacogenomics (301). Additionally, precision oncology may also 
aim to redirect evolving cancers from a devastating lethal disease to a manageable 
chronic disease (302). Due to the heterogeneous and dynamic nature of cancer cell 
subpopulations, emergence of treatment-resistant tumors is, theoretically, inevitable, 
and, for most tumor types, the response rate, progression-free survival, and overall 
survival of single-agent treatments has likely plateaued. Therefore, more and more 
investigations have been dedicated to identifying rationally designed combination and 
sequential therapy strategies. In metastatic breast cancer, patients treated with 
paclitaxel (targeting cell cycle) and trastuzumab (targeting HER2 overexpressing cells) 
have better overall survival compared to paclitaxel alone (303). In PCa, two recent 
clinical trials, the CHAARTED trial (304, 305) and the STAMPEDE trial (306), have 
demonstrated the benefit of ADT plus docetaxel in treating advanced or metastatic 
CRPC over ADT alone. ADT plus abiraterone/glucocorticoid combination therapy has 
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also demonstrated improved clinical outcomes compared to ADT alone (307, 308). In 
such new combinatorial treatment, transcriptomics and other -omics approaches, 
especially single cell RNA-Seq, should help map out the responsive and resistant 
cancer cell populations and delineate the evolutionary trajectory of the tumors during 
treatment. 
 In the context of tumor cell heterogeneity, preclinical and clinical observations 
have implicated CSCs as the potential driving force for tumor relapse and CSC-
targeted therapeutic approaches can improve patient survival (309). Various CSC-
targeting therapeutic strategies are being attempted, including targeting critical surface 
and adhesion molecules, altering the intrinsic epigenetic landscape, redirecting CSC 
signaling pathways, manipulating microenvironment signaling, suppressing drug-efflux 
pumps, and inducing CSC apoptosis and differentiation (310). Some efforts are also 
being made to target CSC in PCa, especially CRPC. Examples include developing 
inhibitors of Wnt and Shh signaling, which has been implicated in regulating PCSC 
stemness (63, 64).  
 Is targeting of CSCs alone sufficient to cure cancer? The answer is yes and no, 
based on our xenograft studies (124, 152). Theoretically, combinatorial targeting of 
multiple CSC regulators such as BCL-2, integrin α2, MYC, and N-cadherin could 
eliminate the AR-/lo LAPC9-subtype of CRPC. However, for the AR+/hi LNCaP-subtype 
of CRPC, anti-CSC strategies must be combined with AR-blocking agents such as 
enzalutamide (152). Because PCa patient primary (prostate) tumors harbor both AR+ 
and AR-/lo cells/clones and their metastases may be AR+ or AR-/lo (252), a 
combinatorial approach is entailed to co-target AR+ PCa cells/metastases with 
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enzalutamide and AR-/lo PCa cells with CSC inhibitors. By dissecting various CSC 
transcriptomic profiles, our results (152) lead to a proof-of-principle study combining a 
CSC-targeting drug (ABT-199, BCL-2 inhibitor) with ADT (enzalutamide), which 
showed beneficial effect over single-agent alone in mouse CRPC xenograft models. 
Importantly, these pre-clinical studies have supported the launch of a new Phase Ib/II 
clinical trial of treating metastatic CRPC with a combination of enzalutamide and ABT-
199. RNA-Seq informing the design of combination therapeutic strategies and 
precision medicine is an effective strategy in cancer therapeutics and may lay the solid 
foundations for curing cancer. 
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